Oneview / the connected care experience company

Annual Report &
Financial Statements 2025



For personal use only



Unifying the care experience.

For personal use only

About Us

Oneview is the connected care experience company - a global leader in patient, clinical and hospital experience solutions. Our intuitive platform is thoughtfully designed to integrate with electronic health record ("EHR") systems for fully automated, consistent and personalised user experiences for all. Oneview's digital tools are fully customizable, and can be deployed across tablets, televisions and mobile devices to optimise clinical workflows while enhancing communication and engagement for all users.

Founded in 2008 in Dublin, Ireland

Commercial success on four continents

Proudly partners with 3 top 25 U.S. hospitals*

* US Hospital Rankings from Newsweek's world's best hospitals review 2025

Contents

Strategic Report

Our Principles	04
Chair's statement	05
Message from the CEO	06
About Oneview	08
2025 Performance Review	12
Innovation	17
Business Outlook	19
Environmental, Social and Governance	22

Governance

Risk Management	25
Board of Directors	32
Leadership team	34
Corporate Governance Overview	36
Remuneration & Nomination Committee Report	39
Directors' report	44

Financial Statements

Independent auditors' report	47
Consolidated statement of total comprehensive income	51
Consolidated statement of financial position	52
Company statement of financial position	53
Consolidated statement of changes in equity	54
Company statement of changes in equity	56
Consolidated statement of cash flows	58
Notes to the consolidated and company financial statements	59
Additional ASX Info	93
Corporate Information	96

Performance & Position Snapshot

14,880 live endpoints
at 31 December 2025
11% growth during 2025

€12.0 million revenue
for the year ended 31 December 2025
€9.9 million for the year ended 31 December 2024
21% growth during 2025

64% gross margin
for the year ended 31 December 2025
67% for the year ended 31 December 2024

€4.6 million cash
at 31 December 2025
€13.8 million at 31 December 2024

€10.1 million cash[1]
following the settlement of the first tranche of the Placement

For personal use only

Performance Highlights

Expanded our customer base in the U.S. with four new customer logos including Willis-Knighton Health System, White Plains Hospital, Kennedy Krieger Institute and Peterson Health.

Added to the **Group Purchasing Organisation ("GPO") of a Top 10 health system** (in January 2026)

Developed a new user interface which will be delivered during the second half of 2026.

Advancing the **Ovie AI-powered ecosystem, an intelligence engine powering personalization, anticipation, orchestration, and context-awareness** across the Oneview platform.

Leveraging AI to deliver enhanced quality and efficiency across software development life cycle ("SDLC"), product development and general business ops.

Announced commitments for a two-tranche **placement to raise approximately A$19 million and launched a security purchase plan to raise up to A$2 million** in March 2026.

1. Cash balance of €10.1 million following the settlement of the first tranche of the Placement only (net proceeds of approximately A$11.4 million / approximately €7.0 million). The Company will have additional gross proceeds inflows of $9 million (approximately €5.5 million) assuming the Company gains shareholder approval for the second tranche of the placement involving the Company's largest shareholder and if the Company raises A$2 million (approximately €1.2 million) from the SPP.

Oneview's Mission, Vision and Values

Our mission, vision, and values represent the very foundation of Oneview—acting as both guide and compass. They drive internal alignment and fuel decision-making.

Mission / Our why

To improve connected care experiences, every day.

Vision / Our future

Reimagining the digital environment of care to make it accessible, seamless and reliable for all.

For personal use only



Values / Who we are

Integrity
We always act in our Customers' best interest and deliver on what we have promised, because to us, trust is everything.

Intention
We are thoughtful and deliberate to understand and solve real Customer needs.

Compassion
We approach every Customer, every person, every challenge with empathy and understanding.

Together, these elements serve as the heart of Oneview's identity.

For personal use only



Our Principles

The Oneview Principles are the behaviours that are unique to Oneview, that help us articulate who we are, what we believe in, what we aspire to, how we see ourselves and what we expect from each other. They're ultimately the things we do and say every day with our customers, partners and each other.

Accountability

We rely on each other. We understand that together we make our customers – and their patients and staff – happy and solve problems quickly. We don't let each other down.

- We pitch in
- We go the extra mile
- We have each other's backs
- We execute with urgency
- We find the solution and make it happen

Attitude

We overcome obstacles because we have the right attitude. We focus on the long game and we never give up on each other, our customers, or our goals.

- We are passionate
- We are inclusive
- We are welcoming
- We are approachable
- We are loyal
- We are determined

Connection

We understand that we are what makes Oneview unique. It's why we joined and it's why we stay. We appreciate each other and understand the strengths and value we all bring to our teams, customers, partners and shareholders.

- Be yourself
- We are one team
- We are considerate
- We celebrate the wins
- We value each other's time

Communication

We are always striving to improve how we communicate with others. From 1:1 conversations to team meetings, from interns to leaders, from Slack to PowerPoint, we turn up for each other.

- We keep each other in the loop
- We say it as it is
- We ask for help
- We think before we type
- We listen to each other

Learning

In a world where change is constant, we are always learning, always improving, always innovating. We aren't afraid of failure – we know it makes us stronger.

- We share knowledge
- We think creatively
- Mistakes happen – we learn from them

Legacy

This is what you leave behind for your colleagues, customers, partners, and shareholders.

- Legacy is how we are remembered.
- It's not one single act
- It's built every day
- We make it better
- We do right by the customer and patients
- We win with dignity and humility

For personal use only

Chair's Statement

On a positive trajectory



For personal use only

Dear Shareholders,

On behalf of the Board, I am pleased to present the Oneview Healthcare plc Annual Report for the year ended 31 December 2025.

2025 marked a year of excellent progress for Oneview, underpinned by strong financial performance and continued operational momentum. A key highlight was the company's 21% growth in total revenue, reflecting successful deployments at recently signed customers and the strengthening commercial traction across both our direct and Baxter-led sales channels. This growth demonstrates the increasing relevance of Oneview's solutions as hospitals seek partners capable of enabling more efficient, digitally supported models of care and an enhanced patient experience.

We were encouraged by the acceleration of deployment activity during the year, supported by improvements in process design, configuration tooling, and greater operational standardisation. These actions continue to enhance the predictability and scalability of our delivery model as the company efficiently converts contracted demand into live endpoints.

The Board also recognises the significant advances made in product innovation. The development of Oneview's new user interface, which will be delivered during the second half of 2026, and the advancement of the Ovie AI-powered ecosystem demonstrate Oneview's commitment to delivering intelligent, context-aware tools that serve patients, care teams, and hospital leaders.

The Board is pleased with the strong emphasis the management team is placing on AI-powered solutions to drive meaningful improvements in quality, velocity, and efficiency across the software development life cycle, product development, and general business operations. This focus is strengthening the company's long-term capabilities, efficiency and differentiation, whilst enhancing the foundations required to scale effectively.

Although the broader US hospital market continues to navigate budgetary constraints and regulatory uncertainty, the Board has great confidence in Oneview's competitive position and strategic trajectory. We saw a significant proof point of the value of the Baxter partnership, as we were added, through Baxter, to the Group Purchasing Operation of a Top 10 U.S. Health System, with over 85 hospitals and 15,000 beds. This lays a tremendous foundation for continued growth. The combination of revenue growth, operational discipline, and a clearly differentiated product roadmap positions the Company well as it continues its progress toward cashflow breakeven.

During the year, we were delighted to welcome Michael Dowling to the Board as an Independent Non-Executive Director. Michael is CEO Emeritus of Northwell Health, having served as CEO for the past 23 years. Northwell Health is the largest health system in New York and one of the most respected systems in the United States. Michael's extensive leadership experience and network in the US health sector provides invaluable insight as Oneview continues to scale in its largest market.

On behalf of the Board, I would like to thank our CEO, James Fitter, and the entire Oneview team for their ongoing dedication and resilience. We are also grateful to our customers, partners, and shareholders for their continued trust and support. Finally, I would like to thank my fellow directors for all their support to the Company and to me personally in 2025. I look forward to working with all of them in 2026. The foundations laid and momentum built during 2025 give the Board strong confidence in Oneview's trajectory, and we look forward to a year of continued execution, growth, and strategic advancement in 2026.

Barbara Nelson
Chair
25 March 2026

Message from the CEO

Building on strong foundations



For personal use only

Dear Shareholders,

It gives me pleasure to share our annual report for the financial year 2025. Throughout this annual report, you will find detailed information regarding the financial and operating highlights of Oneview for 2025 and our outlook. I would like to add some of my own personal reflections.

Capitalising on the Market Opportunity

The hospital environment continues to evolve rapidly as care delivery models shift and the expectations of patients and care teams increase. The macroeconomic drivers of an ageing population and a global nursing shortage continue to demand that hospitals turn to technology to drive operational efficiency. Hospitals are seeking ways to streamline operations, improve efficiency, and deliver more personalised care at the bedside. A key enabler for the market is the wider adoption of virtual care solutions, which is accentuating the value of bedside technology like ours and accelerating the need for interoperable digital platforms that can support hybrid models of care and integrate seamlessly into existing clinical and operational workflows.

Within this changing landscape, Oneview's role is becoming increasingly strategic. Our Connected Care Experience platform sits at the centre of the smart patient room, empowering patients, reducing clinical burden, and enabling more coordinated, digitally supported models of care. In 2025, we continued to advance our platform to meet the needs of the smart patient room of the future, further differentiating our offering through our new user interface, which will deliver a simple, intuitive, accessible and personalised experience for all users and enable the advancement of Ovie, our digital care assistant that helps patients help themselves while allowing care teams to prioritise tasks.

2025 Financial Performance and Capital Position

2025 was a year of strong financial performance for Oneview. Total revenue increased by 21% to €12.0 million, driven by successful deployments at newly signed customers. Recurring revenue grew by 7% to €7.7 million. Our operating EBITDA loss improved by 8% to €8.1 million, reflecting both revenue momentum and the continued benefits of enhanced internal efficiency. Importantly, cash operating expenditure declined by 9% during the second half of the year compared to the first half, supported by a global restructuring executed in May 2025 and the continued focus on efficiency across the organisation. We ended the year with a cash balance of €4.6 million.

Subsequent to year-end, in March 2026, the Company announced commitments for a two-tranche placement to raise A$19 million (approximately €11.6 million) in gross proceeds. Tranche 1 settled on 24 March 2026, raising A$12 million (€7.3 million). Tranche 2, raising A$7 million (approximately €4.3 million) and involving the Company's largest shareholder, Manderrah Pty Ltd (as trustee of the GJJ Family Trust), is subject to shareholder approval at an extraordinary general meeting expected to take place in May 2026. The Company has also launched a security purchase plan (SPP) to raise up to A$2 million (approximately €1.2 million), which will close in April 2026.

Proceeds from the Placement and SPP will strengthen the balance sheet as deployments scale, supporting conversion of the contracted pipeline into revenue-generating endpoints. Funds will also advance Ovie, the AI-powered virtual patient assistant, and enhance AI development, automation, and operational efficiency. Balance sheet strength remains a key competitive factor as major US health systems increasingly prioritise financially robust vendors. We are grateful to both new and existing shareholders for their continued support and confidence in Oneview's market opportunity and strategic direction.

AI as an Enabler of Quality, Efficiency and Differentiation

On 12 May 2025, Oneview became the first company on the ASX, and the first in the connected care sector, to achieve ISO 42001 certification, the global standard for excellence in AI governance. This milestone assures our customers and shareholders that our AI-powered solutions are developed and deployed within a rigorously managed Artificial Intelligence Management System (AIMS), emphasising ethical practice, transparency, patient safety, and robust risk management. ISO 42001 certification provides independently validated evidence of responsible AI, strengthening trust, reducing compliance risk, and reinforcing our leadership in secure, innovative digital healthcare.

For personal use only

We are leveraging AI to deliver enhanced quality and efficiency across our software development life cycle, product development, and broader business operations. Our new Ovie ecosystem uses AI-powered tools to connect Oneview's products with other hospital systems, enabling self-service and helping focus patients and care teams on what matters most to help orchestrate care. At the same time, the depth of our workflow and vertical integrations across hospital technologies, the physical infrastructure required for smart patient rooms, and the tightly regulated environment of hospitals mean that our platform is deeply embedded within hospital operations in ways generic AI solutions cannot replicate.

In 2025, we redesigned our software development lifecycle to leverage AI with the goal of velocity, with quality, and this transformation is already accelerating the pace, quality and scale of what our teams can deliver. Across the organisation, we are increasing our focus on automation and AI-powered tools to drive greater efficiency, consistency and scale in the way we operate. These improvements are strengthening the foundations of the business and enhancing our ability to deliver high-impact innovation to customers with greater speed and reliability.

Our Operational and Commercial Activity

2025 was a year of meaningful commercial and operational progress for Oneview. We added four new customer logos, bringing the total to 18 new logos over the past three years, each representing a substantial opportunity to execute our land-and-expand strategy, through upselling additional products such as our Digital Whiteboard and Digital Door Sign, or through broader expansion across the enterprise into additional beds and facilities.

A major milestone in early 2026 was our addition by Baxter to the Group Purchasing Organization of a Top 10 US Health System, a system with over 85 hospitals and more than 15,000 beds. Any hospital within this network can now procure Oneview's products in a streamlined and efficient way, creating a highly scalable pathway for expansion across the enterprise.

We ended 2025 with 14,880 live endpoints, representing 11% year-on-year growth as we continued to scale delivery across newly contracted customers. This 11% growth is net of the 894 endpoints which were decommissioned from an Australian customer due to budgetary constraints. The annual revenue added by new endpoints added during 2025 is more than double the annual revenue that had been earned from the decommissioned endpoints. Operationally, our deployment execution continued to strengthen. Deployment activity increased by 31% during the second half of 2025 compared to the first half of 2025, supported by improvements in configuration tooling, workflow standardisation, and delivery processes. Importantly, we are now capable of deploying our platform within 90 days of contract signing, significantly reducing customer time-to-value and enhancing our ability to scale efficiently as contracted demand grows. Looking ahead to 2026, we expect to further benefit from our increasingly efficient deployment process as deployments across our recent customer wins progress.

Our partnership with Baxter

Our partnership with Baxter continued to strengthen during 2025 and remains an important pillar of our commercial strategy. Baxter's extensive presence in the US and Canadian hospital market and their established relationships with health system leadership have significantly expanded our reach and visibility. I believe the Baxter-led addition of Oneview to the Group Purchasing Organization of a Top 10 US Health System in January 2026 is a major milestone for Oneview and can be a major catalyst for our partnership with Baxter. It illustrates how this partnership provides a scalable and efficient pathway for Oneview to win business within large, complex enterprises. Baxter's sales organisation continues to generate strong engagement, with a deep pipeline of qualified opportunities and active collaboration across sales, marketing, product integration, and co-innovation initiatives.

Our Outlook

As I noted above, the completion of the share placement and SPP that we announced in March 2026, strengthens our balance sheet at a time when we have strong commercial momentum, an expanding base of enterprise customers, and a clear pathway to further growth through our land-and-expand strategy. In parallel, our operating costs are declining having focused on the delivery of significant new products and features over the past few years. We are extensively leveraging AI across the SDLC, product development and the wider business, and we have advanced our deployment process to consistently deploy within 90 days. Furthermore, the advancement of Ovie represents a meaningful shift in the value Oneview delivers to hospitals, moving our platform into an integral smart-room capability with deep system integration that tangibly relieves the burden on care teams, improves the efficiency and quality of care, and elevates the patient experience. With these foundations in place, we believe Oneview is well positioned to capitalise on the enormous opportunity to enhance operational efficiency in healthcare. The trend towards the virtualization of care will drive continued growth, operational efficiency, and meaningful progress on our trajectory toward profitability.

As we look ahead, I want to express my deepest gratitude to our extraordinary team. Their dedication, resilience, and belief in what we are building continue to be the driving force behind our progress. Every milestone we have achieved, and those still to come, is rooted in their commitment to improving the lives of patients, empowering care teams, and advancing our mission to transform the care experience. To our shareholders, thank you for your continued trust and support. Together, we remain focused on the profound purpose that guides us: delivering technology that truly makes a difference where it matters most.

James Fitter
Chief Executive Officer
25 March 2026

About Oneview

Oneview is a global leader in connected care experience technology, offering a trusted software platform that integrates hospital systems, care teams, and patients into a seamless digital environment. Founded in Dublin in 2008, our cloud-native and on-premises solutions are deployed across hospitals and healthcare systems, academic medical centres and paediatric hospitals worldwide, including 3 of the top 25 U.S. hospitals. Our mission is to improve connected care experiences every day, empowering patients and streamlining clinical workflows.

Our Care Experience Platform connects bedside devices, digital signage, and patients' own mobile devices to unify data, automate tasks, and enhance engagement. Through deep integrations with EHRs, nurse call systems, and other hospital technologies, we help hospitals improve efficiency, reduce costs, and deliver a more personalised, empowering experience for patients and families.

The Challenge

- Severe global nursing shortages and workforce burnout
- Rising healthcare costs and funding constraints
- Increasing patient expectations for digital empowerment
- Fragmented hospital IT systems and inefficient workflows
- Long sales and deployment cycles in hospital environments

For personal use only

The Connected Care Experience

Connected Patients & Families

Oneview brings your patients calm and control

- Self-service meal ordering, clinical requests and room controls
- Personalised information and educational content
- Multi-lingual support of 50 languages
- Hotel-like entertainment experience

Optimised Care Teams


Oneview streamlines your clinical team's experience by automating tasks and unifying data

- Automated manual processes like meal ordering and educational write-back
- Direct routing of non-clinical requests to care team wireless devices
- Virtual care platform integration for hybrid care models

Synchronised Hospital Systems

Oneview scales and integrates across the enterprise

- Cloud-native or on-prem deployment
- Reduced upfront and ongoing costs
- Potential HCAHPS improvement
- Increased focus on Patient & Care Team safety



For personal use only

The Connected Care Experience Room

Oneview's Care Experience Platform is deployed on interactive patient bedside TVs, bedside tablets, digital whiteboards, and digital door signs, as well as on patients' own devices via MyStay Mobile. Through deep integrations with hospital systems (over 50 out-of-the-box integrations including EHR, nurse call, and room controls), Oneview unifies real-time data at the bedside and automates workflows for staff. This means that critical patient information, educational content, and services are synchronised across all devices in the room, creating a truly integrated environment of care where patients can engage in their care plan and self-service needs, while clinicians save time and effort.

Oneview continued to improve Oneview's Care Experience Platform during 2025, strengthening its position as a core component of the smart patient room, through the development of a new user interface and by advancing the Ovie AI-powered ecosystem, an intelligent digital care assistant that streamlines patient self-service and automates hospital workflows through deep real-time context.



The New User Interface – A Modern, Accessible, Patient-Centric Experience

During 2025, Oneview redesigned its MyStay TV and MyStay Tablet experience, delivering a modern, intuitive, and accessible interface built specifically for hospital environments. It features a widget-based home screen and incorporates Ovie's capabilities (via an Ovie Engage widget) to surface context-aware prompts and information for patients at just the right moment. By combining familiar consumer UX patterns with hospital-specific functionality, Oneview's updated design promotes patient comfort and engagement in ways that support healing.

The new user interface provides:

- **A simple, consistent, and highly intuitive design** across TV and tablet
- **Accessibility features** such as adjustable text size and multilingual support for up to 50 languages
- **Personalised layouts** tailored to patient demographics and clinical context
- **A unified home screen** with widgets that surface timely, context-aware information
- **A familiar, consumer-grade experience** that supports comfort and engagement.

The redesigned interface enhances the patient experience by combining on-demand services, entertainment, and care information in a way that is effortless to navigate, while maintaining enterprise-grade security, scalability, and interoperability for hospital IT teams. It also provides the foundation for the next evolution of Ovie. This new user experience will be delivered during the second half of 2026.

The Ovie Ecosystem

Ovie is an intelligent digital care assistant that transforms how hospitals run. It gives patients an effortless, guided way to get what they need and frees care teams to focus on delivering exceptional care rather than managing interruptions. Powered by deep context from Oneview, the EHR, and real-time hospital systems, Ovie acts as a smart orchestration engine, understanding what's happening with the patient, identifying what matters most, and automatically driving the right workflows. It handles common questions, routes non-clinical requests, surfaces insights, and keeps staff informed and ahead of bottlenecks — all in real time.

The Ovie AI-powered ecosystem is made up of 4 products.

- **Ovie Engage** is a context-aware widget on the patient's home screen – ensuring they are aware of what they need to know or do, towards a safe and timely discharge. It is built-into the new user interface, and launched at the ViVE trade show in February 2026. It will be live with customers over the coming months.
- **Ovie Voice** is the natural language voice assistant. Building on the prototype the Company launched in 2025, Ovie Voice is now integrated with MyStay TV enabling patients to engage with and control the system, as well as ask questions and make requests. Ovie Voice will go into pilot in 2026.
- **Ovie Console** is a new staff facing product – it provides staff visibility into operations and experience. Customers wanted real-time data to support operations, and Ovie Console will provide it. Ovie Console is in development, a first iteration was unveiled at the ViVE trade show in February 2026, and it will be piloted in the coming months.
- **Ovie Rounds** is a smart rounding tool that shifts leader rounding from reactive to proactive, to ensure satisfaction issues are dealt with quickly and efficiently. Like all the Ovie products, it will use context to ensure staff focus on the right patients, with the right information, to recover service. Ovie Rounds is still in prototype stage, and will be delivered in 2027 subject to customer validation.

About Oneview
(continued)

The Ovie Ecosystem

Ovie Engage
Context-aware patient prompts
Launched:February 2026

Ovie Voice
Natural-language interaction
Pilot in 2026



Ovie Console
Real-time operational visibility
Pilot in 2026

Ovie Rounds
Guided experience rounding
Future product

Oneview's solutions, including Ovie, enhance experiences for everyone

	Patients & Family	Care Team	Operations & Leadership
The Problem	Patients feel uninformed, anxious, and disconnected during their stay	Clinicians waste time on coordination, communication, and chasing information	Leaders lack real-time visibility into patient experience, satisfaction, and operational performance
What We Enable	Self-service meals, room controls, service requests, care information, and entertainment	Faster escalation, clearer handoffs, and more time at the bedside	Continuous operational intelligence with less administrative overhead
Our Solutions	 • MyStay TV/Tablet • MyStay Mobile • Digital Whiteboard • Ovie Voice	 • Digital Door Sign • Digital Whiteboard • Ovie Voice • Ovie Console	 • Ovie Console • Ovie Rounds • Data Analytics
The Outcome	Higher satisfaction scores and stronger patient loyalty	Better care quality, safer escalation, greater clinical capacity	Lower costs, stronger quality performance, faster throughput

For personal use only

For personal use only

Commercial Strategy

"Land and Expand"


Oneview's commercial strategy centres on growing annual recurring revenue through software subscriptions, supported by non-recurring revenue generated from deployment projects. Its "land and expand" approach is built on developing deep, trusted partnerships with large healthcare enterprises and reinforced by Oneview's proven ability to scale across entire hospital systems.

Contracts typically span three to five years, and customer churn has historically been very low due to the value delivered, high service levels, and the deep system and workflow integrations of the Connected Care Experience, which enable information flow and workflow automation.

Oneview's land and expand strategy aims to broaden both the range of products adopted by each customer and the deployment of the Care Experience Room across whole hospital enterprises. Oneview's modular product suite enables significant expansion potential, with add-on solutions generating up to a 92% uplift in per-day, per-bed revenue compared with the core platform alone.

The company leverages strong relationships to expand system-wide and introduce additional products, an opportunity strengthened by high upsell potential and consistently low churn. In parallel, securing new customer logos remains a priority, and Oneview has already seen strong success in winning new customer logos, supported by a robust late-stage pipeline and its combined direct and Baxter-led sales presence in the U.S.

% Per Bed Per Day Uplift



A Global Footprint

Oneview has customers in Australia, Thailand, Ireland and the US. 75% of live endpoints at 31 December 2025 were in the U.S., and the U.S. continues to be the primary engine of growth in the near-term.

The Company has an established customer base in Australia, including highly reputable health systems, but challenging conditions in the private hospital market have made growth more difficult in recent years.

Expansions in other regions will be pursued selectively based on the market opportunity and conditions over the coming years.

US Market

Oneview maintains its own U.S. sales team, and this presence is further amplified by a value-added-reseller agreement with Baxter, originally signed in June 2023 and extended in October 2024 for an additional two years through mid-2027. This extension also broadened the partnership to include the Canadian market.

Oneview and Baxter are collaborating on a joint product roadmap to enhance patient experience and quality of care for Baxter customers, including efforts to streamline integration between the two platforms. The first integration from this roadmap was completed in 2024, enabling service-request delivery through Baxter's Voalte Nurse Call system, and further integration initiatives are being evaluated.

Beyond product development, the partnership leverages Baxter's nationwide network of experienced technicians and installation contractors, helping to streamline deployment of the Oneview Care Experience Platform (CXP) at scale and strengthen Oneview's commercial reach across its largest market.

2025 Performance Review

Financial

For personal use only

€12.0m
Total Revenue
(2024: €9.9 million): 21% increase

€7.7m
Recurring Revenue
(2024: €7.2 million): 7% increase

14,880
Live Endpoints
(2024: 13,411): 11% increase

€4.6m
Cash at 31 December 2025
(€13.8m at 31 December 2024)

€10.1m
Cash following the settlement of the first tranche of the placement

2025 Financial Performance

	Year ended 31 December 2025	Year ended 31 December 2024	Variance
	€'m	€'m	%
Recurring revenue	7.7	7.2	7%
Non-recurring revenue	4.3	2.7	60%
Total Revenue	**12.0**	**9.9**	**21%**
Cost of sales	(4.3)	(3.2)	(34%)
Gross Profit	**7.7**	**6.7**	**15%**
Cash operating Expenses	(15.8)	(15.5)	(2%)
Operating EBITDA loss	**(8.1)**	**(8.8)**	**8%**
Non-cash expenses:			
Share based payment expense	(2.4)	(2.0)	(23%)
Depreciation & amortisation	(0.5)	(0.5)	-
Net finance income / (costs)	(1.5)	0.6	-
Loss before tax	**(12.5)**	**(10.8)**	**(16%)**
Income tax expense	(0.1)	(0.1)	-
Loss after tax	**(12.6)**	**(10.8)**	**(16%)**

Total revenue increased by 21% in 2025 compared with 2024, driven by a 7% increase in recurring revenue to €7.7 million and a 60% increase in non-recurring revenue to €4.3 million. This growth was underpinned by our addition of 18 new customer logos over the past three years, including four new customers wins during 2025. Total revenue for 2025 was negatively impacted by the weakening U.S. Dollar and Australian Dollar during 2025. Gross margin of 64% (2024; 67%) was negatively impacted by the overall mix of revenues, including a larger portion of the lower-margin non-recurring revenue in 2025 compared to 2024. Cash operating expenses were marginally higher in 2025 compared to 2024, but the 2025 expense includes €168k restructuring charges related to the organisational restructuring completed in May 2025 and which has contributed to the reduction in cash operating expenses by 9% during the second half of 2025 compared to the first half of the year.

Oneview's Operating EBITDA loss decreased to €8.1 million in 2025 from €8.8 million in 2024. The lower loss in 2025 is largely attributable to the 15% increase in gross profit, partially offset by the marginally higher cash operating expenses, including restructuring charges.

The net finance cost of €1.5 million (2024: €0.6 million net income) is comprised of an intercompany foreign currency loss of approximately €1.0 million on the translation of a US dollar-denominated intercompany loan, with the balance largely attributable to realised foreign currency losses.

For personal use only

2025 Balance Sheet and Cash Flow Position at 31 December 2025

Balance Sheet Position	As at 31 December 2025 €'m	As at 31 December 2024 €'m	Variance %
Cash and cash equivalents	4.6	13.8	(67%)
Trade & other receivables	4.7	5.3	(11%)
Inventory	2.9	3.1	(6%)
Property, plant & equipment	1.1	1.1	-
Intangible assets	0.7	0.7	-
Other assets	1.5	2.0	(25%)
Total Assets	**15.5**	**26.0**	**(40%)**
Trade and other payables	1.2	1.3	(8%)
Lease liabilities	1.1	1.2	(8%)
Deferred income	5.4	5.0	8%
Pandemic Support: Warehoused Debt	1.4	1.9	(26%)
Accruals and other liabilities	2.7	3.3	(18%)
Total Liabilities	**11.8**	**12.7**	**(7%)**
Net Assets / Total Equity	**3.7**	**13.3**	**(72%)**

Cash Flow Statement Summary	As at 31 December 2025 €'m	As at 31 December 2024 €'m	Variance %
Net cash used in operating activities	(8.3)	(10.5)	21%
Net cash used in investing activities	(0.1)	(0.5)	80%
Net cash generated by / (used in) financing activities	(0.3)	13.1	-
Net (decrease) / increase in cash held	(8.7)	2.2	-
Cash at 1 January	13.8	11.5	20%
Foreign exchange impact on cash	(0.5)	0.1	-
Cash at 31 December 2025	**4.6**	**13.8**	**(67%)**

Cash at 31 December 2025 was €4.6 million compared to €13.8 million at 31 December 2024. The decrease in cash is driven by the Operating EBITDA loss of €8.1 million, balance sheet outflows of €0.6 million and a foreign currency loss of €0.5 million.

Strengthening the capital base

Subsequent to year-end, in March 2026, the Company announced commitments for a two-tranche placement to raise approximately A$19 million (approximately €11.6 million) in gross proceeds through the issuance of 100 million New CDIs at A$0.19 per CDI. Tranche 1 settled on 24 March 2026, raising A$12 million (approximately €7.3 million). Tranche 2, raising A$7 million (approximately €4.3 million) and involving the Company's largest shareholder, Manderrah Pty Ltd as trustee of the GJJ Family Trust, is subject to shareholder approval at an extraordinary general meeting expected to take place in May 2026. The Company has also launched a SPP to raise up to A$2 million (approximately €1.2 million), which will close in April 2026.

Proceeds from the Placement and SPP will strengthen the balance sheet as deployments scale, supporting conversion of the contracted pipeline into revenue-generating endpoints. Funds will also advance Ovie, the AI-powered virtual patient assistant, and enhance AI development, automation, and operational efficiency.

The settlement of the first tranche of the placement (net proceeds of approximately $11.4 million / €7.0 million) increases the Company's cash position to approximately €10.1 million. The Company will have additional inflows of $9 million (approximately €5.5 million) assuming the Company gains shareholder approval for the second tranche of the placement involving the Company's largest shareholder and if the Company raises A$2 million (approximately €1.2 million) from the SPP.

2025 Performance Review
(continued)

Commercial

Oneview added 4 new logos during 2025 and was added to the Group Purchasing Organisation of a Top 10 US Health System in January 2026.

Willis Knighton Health is an 800- bed health system based in Louisiana. This customer was added via the Baxter channel.

White Plains is a 300-bed facility in Westchester, New York. This customer was a direct sale by the Oneview sales team.

Kennedy Krieger is a leading Baltimore-based paediatric hospital and research centre affiliated with Johns Hopkins, specialising in neurological, developmental, and rehabilitative care, operating a 70-bed inpatient facility serving children and adolescents nationally. This customer was a direct sale by the Oneview sales team.

Peterson Health has a 161-room facility in Kerrville, Texas. This customer was a direct sale by the Oneview sales team.

GPO of a Top 10 US Health System

In January 2026, Oneview was added to the Group Purchasing Organisation of a Top 10 US Health System, a network comprising more than 85 hospitals and over 15,000 beds. This provides a scalable and efficient pathway for hospitals across the system to procure Oneview's solutions.



Baxter completing a demo at the Association of California Nurse Leaders (ACNL) Annual Nursing Leadership Conference.

For personal use only

For personal use only

Sales Opportunity Cycle

Oneview operates within a dynamic and challenging healthcare environment, where the adoption of new technologies is shaped by evolving industry demands and complex stakeholder requirements. Healthcare organizations, particularly hospitals, continue to face significant margin pressures, rising operational costs, and persistent workforce challenges. These factors contribute to a cautious approach to technology investment, with decision-makers prioritizing solutions that deliver measurable value, enhance productivity, and support financial sustainability.

The sales landscape in healthcare is characterised by extended decision cycles, rigorous governance structures, and a heightened focus on compliance and data security. Buyers seek scalable, cost-effective platforms that integrate seamlessly with existing infrastructure and align with strategic objectives. The emphasis on interoperability, reliability, and a clear technology roadmap is paramount, as organizations strive to future-proof their operations while maintaining high standards of patient care.

Oneview's engagement with healthcare providers is informed by these realities. The Company's value proposition centers on delivering robust, integrated solutions that address the sector's operational and clinical needs. By fostering long-term partnerships and demonstrating a commitment to innovation, Oneview supports healthcare organizations in navigating industry complexities and achieving sustainable transformation.

Execution of our Commercial Strategy

Oneview continues to demonstrate strong commercial traction and success with its land-and-expand approach. Over the past three years, the Company has added 18 new customer logos, including large and complex US health systems that collectively manage over 11,600 licensed beds. These organisations present substantial long-term revenue potential for Oneview because each initial deployment becomes a strategic foothold within the enterprise. Once the platform is live, customers experience firsthand the operational efficiencies and patient-experience improvements enabled by Oneview, creating a natural pathway for expansion across additional sites, units, and facilities as well as through broadening the platform adoption into complementary products including the Digital Door Sign, Digital Whiteboard, MyStay Tablet, and MyStay Mobile.

The depth of opportunity within our newest customers is particularly notable. Across the 18 new logos added over the past three years, the Company estimates that the expansion potential is approximately 46,000 potential endpoints based on the potential of deploying four endpoints per room but even with an average of 2 endpoints per room, the potential is over 1.5 times the total number of live endpoints the Company had at 31 December 2025.

Baxter Partnership is delivering

The partnership with Baxter is delivering a meaningful commercial impact for Oneview and is an important part of our growth strategy in the United States and Canada. Baxter's scale, brand presence, and deep relationships with hospital executives have significantly amplified Oneview's market reach, enabling the Company to engage directly with large enterprise health systems that align closely with our strategic focus. Baxter's ability to open doors within complex organisations has accelerated our visibility, expanded our funnel, and shortened early-stage engagement cycles, positioning Oneview to compete for and win major enterprise opportunities. Through the end of 2025, Baxter had delivered five new customer logos for Oneview including Sharp Healthcare in San Diego, Citizens Health in Kansas, Willis Knighton Health in Louisiana, Nicklaus Children's Health System in Miami and Summit Pacific Medical Center in Washington state.

A major milestone for the partnership was achieved in January 2026 when a Baxter-led sales process had Oneview added to the Group Purchasing Organization (GPO) of a Top 10 US Health System, a network comprising more than 85 hospitals and over 15,000 beds. Being added to a health system's GPO is strategically significant: it removes procurement friction, accelerates contracting timelines, and enables any hospital within the system to purchase Oneview's platform efficiently. This creates a scalable pathway for expansion across one of the largest and most prestigious health systems in the country, providing Oneview and Baxter with a powerful proof point for engaging other large enterprises. The GPO milestone demonstrates the effectiveness of Baxter's advocacy and validates the alignment between Oneview's Connected Care Experience platform and the strategic priorities of major health systems.

Beyond contracted wins, Baxter's sales organisation continues to build a robust, qualified opportunity pipeline. As of year-end, the partnership had 156 qualified opportunities across the United States and Canada, reflecting both the breadth of Baxter's reach and the growing market appetite for integrated smart-room solutions.

Taken together, the logos won through Baxter, the GPO addition, and the depth of the current pipeline demonstrate that the partnership is not only working but accelerating. Baxter's scale, relationships, and complementary portfolio continue to enhance Oneview's commercial momentum and position the Company for substantial growth within some of the largest health systems in North America.

What is a Group Purchasing Organisation?

GPOs aggregate hospitals' buying power to streamline procurement. Being added to a health system's GPO contract allows any member hospital to procure Oneview solutions more easily, creating a scalable pathway for system-wide adoption and faster sales cycles.

2025 Performance Review
(continued)

For personal use only

Operations

14,880
Live endpoints
(2024:13,411): 11% increase

With the development of new products over the past few years, Oneview has evolved from a single platform solution to a suite of revenue-generating products and delivery channels. An endpoint is any Oneview-enabled device that runs our platform and generates recurring revenue. This includes the My Stay Patient devices, the bedside TV and the tablet, as well as the digital whiteboard and the digital door sign. Management is now tracking and reporting on endpoints rather than beds to give a more accurate and wholesome view of deployment progress and revenue-generating potential.


Deployment performance strengthened significantly in 2025, reflecting the progress Oneview has made in standardising, automating, and scaling its delivery processes. The Company had 14,880 live endpoints at 31 December 2025, representing a net 11% year-on-year increase and demonstrating strong operational execution across both new and existing customers. This growth was underpinned by the introduction of enhanced configuration tooling, improved workflow standardisation, and more mature delivery operating rhythms that collectively enabled faster and more predictable execution.

This 11% growth is net of the 894 endpoints which were decommissioned from an Australian customer due to the budgetary constraints. This customer had been only utilising a basic version of the Oneview Solution and total annual revenue from this customer was approximately €230k.

A key achievement in 2025 was the establishment of a 90-day deployment cycle, which now enables Oneview to move from contract signing to go-live within a three-month window. This represents a material improvement in customer time-to-value. The impact of these improvements became increasingly evident as the year progressed. Deployment activity accelerated sharply in the second half of 2025, increasing by 31% compared to the first half of the year. The faster cadence also supports the Company's land-and-expand strategy by enabling customers to see value earlier, creating stronger momentum for follow-on deployments and enterprise-level expansion.


Looking ahead to 2026, Oneview expects deployment volumes to increase further as recent customer wins progress through their implementation cycles and as the Company continues to benefit from its more efficient and repeatable deployment framework.

Deployments: Outlook



Targeting ~20% growth in live endpoints by the end of 2026

Live endpoints as at 31 December 2025



31% acceleration in deployment activity in H2 vs H1

Note:
894 endpoints decommissioned in June 2025 with Australian customer due to budgetary constraints offset by materially higher margin deployments in the US.

AI: An enabler, not a competitor

How AI is enabling Oneview

AI is a powerful enabler for Oneview, helping the Company operate more efficiently, innovate more rapidly, and expand the value delivered through its platform. Across the business, AI is being leveraged to improve productivity, streamline processes, and strengthen product velocity, making the organisation more scalable and responsive to customer needs.

A key achievement in 2025 was the redesign of Oneview's software development lifecycle to deeply integrate AI and multi-agent workflows. This transformation has already increased engineering productivity, accelerated requirement generation, improved testing quality, and enabled faster delivery of new features. The Company's AI-enabled SDLC helps teams achieve "velocity with quality", allowing Oneview to innovate more rapidly and consistently than in previous cycles. These gains compound as adoption broadens, meaning future releases can be delivered with greater speed, accuracy, and cost-efficiency. In May 2025 Oneview also became the first company on the ASX, and the first in the connected care sector, to achieve ISO 42001 certification, the global standard for excellence in AI governance.

These efficiency improvements extend beyond engineering, with AI-enabled tools increasingly used across the organisation to automate routine tasks, reduce manual effort, and support more data-driven decision-making.

AI also enhances Oneview's product offering across the smart patient room. Ovie is powered by AI to deliver personalised, context-aware support. Ovie connects Oneview's products and hospital systems to guide patients through common tasks, answer routine questions, route non-clinical requests to the right teams, and surface real-time operational insights that help care teams focus on what matters. By embedding this orchestration layer directly into the TV and tablet experience, AI amplifies Oneview's ability to relieve clinical burden, enhance patient autonomy, and support smoother unit operations. These capabilities increase the measurable operational efficiency that hospitals achieve from the platform and are expected to deliver tangible financial benefits as adoption grows.



For personal use only

AI: An enabler, not a competitor
(continued)

ONE's Connected Care Experience is a deeply entrenched vertical platform in a tightly regulated hospital environment.

1. Oneview manages deep and complex system integrations
The platform is vertically integrated with various hospital technologies including EHRs, nurse-call systems, dietary, building management systems, virtual-care platforms and more than 50 other Smart Hospital systems. These integrations automate information flow, enable context-aware functionality and streamline clinical and operational workflows, creating a unified environment that is highly challenging for new entrants to replicate.

2. Oneview is deeply embedded in clinical and operational workflows
The platform sits at the intersection of patient experience, care-team coordination and non-clinical workflow automation. This level of workflow integration is difficult to replicate and creates strong stickiness once deployed at scale across hospitals and health systems.

3. Oneview operates within strict healthcare and patient-privacy regulations
Hospitals require technologies that comply with robust governance frameworks, clinical-safety requirements and data-protection standards. Oneview's adherence to these requirements, supported by its security, privacy and AI governance practices, creates a trusted foundation that generic AI or consumer-focused products cannot easily match.


4. Smart patient rooms require physical infrastructure with variable operating systems
Oneview orchestrates experiences across TVs, tablets, digital whiteboards, door signs and patient mobile devices. Supporting this multi-device ecosystem, each with different hardware, firmware, update cycles and environmental constraints, creates a significant operational and technical moat that AI-only or software-only solutions cannot overcome.

5. Oneview benefits from strong brand trust and high switching costs
Hospitals rely on the platform as a mission-critical component of care-delivery and patient-experience workflows. The tangible switching costs from infrastructure and integrations to training and workflow adoption combined with intangible factors such as trust, reliability and partnership depth, make Oneview difficult to replace once embedded.

For personal use only

Simplicity on the surface, power beneath

Visible
- Consistent user experience
- Guest and personalised (patient) modes
- Multi-lingual support
- Customer branding
- Oneview apps and workflows
- Third-party apps and workflows
- Content and information
- Data analytics



Hidden

Reliability & Security
- Device and system security
- Device management and monitoring
- TV infrastructure
- Digital wipe

Automation & Integration
- EHR integration
- Personalization
- System integrations & workflow automation
- Virtual care integration

Infrastructure & Support
- Hardware provisioning and support
- Device pairing
- Offline/maintenance mode
- Fully managed service

Business Outlook

The outlook for Oneview Healthcare is underpinned by powerful macro trends reshaping healthcare delivery. Hospitals globally continue to face persistent workforce shortages, rising demand for virtual and hybrid models of care, intensifying financial pressures, and heightened expectations from patients for digital, personalised experiences. These structural forces are accelerating hospital investment in connected smart-room platforms capable of improving operational efficiency, reducing clinical burden, and supporting new models of care. Oneview's Connected Care Experience Platform, together with the Ovie AI-powered ecosystem and the Company's redesigned user interface is uniquely positioned to benefit from these shifts due to its interoperability, deep workflow integration, multi-endpoint reach and intelligence-enabled care coordination.

For personal use only

1. Nursing Shortages & Burnout

The nursing workforce crisis continues to intensify, with surveys showing that a large majority of nurses are considering leaving or reducing their clinical hours. A projected shortfall of ~350,000 registered nurses in the U.S. by 2026 underscores how critical this issue is. Hospitals are struggling to maintain staffing levels, and the nurses who remain face heavier workloads and stress. This has pushed hospitals to prioritise technologies that help reduce avoidable nurse interruptions, automate routine tasks, and provide real-time visibility into the needs of patients.

Oneview directly helps mitigate nursing workload pressures by offloading tasks and improving efficiency. The platform routes non-clinical tasks (like meal requests, room comfort adjustments, entertainment questions) away from nurses to other team members or self-service, which frees nurses to focus on clinical care. Additionally, the Ovie AI-powered ecosystem, will further augment the ability of the Care Experience Platform to address the workflow inefficiencies caused by routine, non-clinical demands on nursing staff. Ovie streamlines patient interaction by providing guided, context-aware ways for patients to complete common tasks, request services, ask questions, and manage their environment independently. It also intelligently routes non-clinical tasks to the appropriate service teams, ensuring nurses remain focused on clinical priorities. For care leaders, Ovie provides real-time operational insight into education completion, pending requests and emerging workflow bottlenecks, strengthening the ability to maintain smooth, consistent operations across units. As hospitals increasingly look for solutions that reduce workforce pressure without compromising quality of care, Oneview's ability to alleviate non-clinical burden places it in a favourable competitive position.



Oneview's Business Outlook
(continued)

For personal use only

2. Virtual Care & Hybrid Models

Another major trend is the expansion of virtual care within the hospital setting, creating hybrid models of care delivery. This ranges from virtual patient observation (tele-sitters) and telehealth consultations for inpatients, to the emergence of virtual nursing programs where off-site or centralised nurses handle certain patient interactions via camera. The American Nurses Association notes that virtual nursing is increasingly seen as a way to extend care capacity – in fact, around 66% of Chief Nursing Officers say virtual nursing will be integral to acute care models going forward. Hospitals are investing in telehealth infrastructure and rethinking care workflows to blend in-person and virtual elements (partly to cope with staff shortages, and partly to enhance patient monitoring and convenience).

The Oneview platform was built with virtual care integration in mind. Oneview provides a vendor-agnostic Virtual Care API that allows hospitals to plug in their telehealth solution of choice (e.g., Caregility, care.ai, Teladoc) into the patient's bedside screen. This is used for virtual rounding and interpreter services as well as for virtual nursing programs, Oneview served as the in-room interface for virtual nurses. A virtual nurse can appear on the Oneview tablet to teach a patient about a new medication, or check in on pain levels, without needing a physical presence. Oneview's Ovie AI-powered assistant will augment this capability through its ability to escalate certain requests to a virtual nurse if needed (for instance, if a patient asks a complex medical question, Ovie could route that to a tele-nurse hub). By doing so, Oneview knits together floor nurses, virtual nurses, and AI into a cohesive hybrid care team. Additionally, Oneview's integration with devices like digital whiteboards means that when a virtual clinician updates something (say, adds a care note or precaution), it can instantly reflect on the patient's door sign or whiteboard, keeping on-site staff informed. We foresee virtual care becoming standard in inpatient settings, and Oneview is fully prepared for that future.

3. Financial Pressures & Value Focus

Hospitals remain under intense financial pressure as operating costs continue to climb faster than reimbursement rates. This squeeze has pushed many hospitals into thin or negative margins, prompting cost-cutting, layoffs, or even closures in some cases. Additionally, healthcare providers are looking harder at the value of every technology investment: ROI and outcomes are scrutinised more than ever. There's also a trend of consolidation: systems merging and aiming to rationalise vendors to reduce costs.

Oneview's value proposition is inherently about efficiency and cost avoidance by helping hospitals achieve cost savings and improve nurse time efficiency. By improving patient experience and potentially impacting HCAHPS scores, Oneview can also indirectly help hospitals secure full reimbursement and avoid penalties tied to patient satisfaction.

Ovie will further augment the value Oneview brings to hospitals by adding an intelligent, digitally integrated layer that materially amplifies the operational benefits of our platform. Building on the strong foundation of the Connected Care Experience, Ovie enhances patient autonomy through guided self-service, streamlines non-clinical tasks through intelligent routing, and provides real-time operational insight that supports smoother unit operations. These capabilities strengthen the efficiency gains hospitals already achieve with Oneview and are expected to deliver tangible and measurable financial benefits through reduced non-clinical workload, improved workflow coordination, and more effective utilisation of care-team resources. By embedding intelligent orchestration directly into the smart patient room, Ovie expands the impact of the Oneview platform and further supports hospitals' goals of improving both operational performance and the patient experience.


For personal use only

4. Consumerised Patient Expectations

People increasingly expect the same level of convenience, control and digital simplicity in hospital that they experience in daily life, from using voice assistants at home to managing services on their smartphones. Patients want on-demand information, easy navigation, personalised content, and autonomy over routine tasks, while families expect clear communication and real-time updates. Hospitals are therefore prioritising technologies that deliver a modern, user-friendly, patient-centred experience.

Oneview is naturally aligned with this shift. The platform puts meaningful control in the hands of patients, enabling them to manage daily needs, access care information, adjust their environment, and stay informed through an intuitive, consumer-grade interface. In 2025, Oneview strengthened this alignment further with its redesigned user interface, built with contemporary UX patterns, accessible design, and personalisation features that support comfort, engagement and ease of use across TV, tablet and mobile.

Ovie further enhances this value by providing guided, context-aware support that helps patients help themselves. Through simple interactions, Ovie offers timely information, personalised prompts and seamless access to tasks and services, creating a more supportive and interactive experience at the bedside. Together, the redesigned interface and Ovie's intelligent assistance help hospitals meet rising digital expectations, improve patient satisfaction, and support better engagement—key contributors to stronger outcomes and reputation.



Environmental, Social and Governance (ESG) Report

For personal use only

ESG principles remain deeply embedded in Oneview Healthcare's strategy, guiding decision-making across environmental stewardship, social responsibility, governance excellence, and innovation. Throughout 2025, Oneview continued to strengthen its ESG foundations, treating ESG not as a compliance requirement, but as a strategic driver of resilience, trust, and long-term value creation for our stakeholders.

We maintained transparency and accountability through regular ESG dashboards and quarterly reporting, providing insight into our performance and progress. By integrating ESG considerations into our operations and product innovation, we ensure that growth aligns with ethical principles and contributes positively to society and the planet.

Environmental Stewardship

Oneview operates with an inherently low environmental footprint due to its digital-first business model. Our environmental impacts are primarily associated with office energy use, employee commuting, and cloud infrastructure. Our product innovation further supports sustainability: the transition to cloud-based solutions and the launch of MyStay Mobile significantly reduced the need for in-room hardware, lowering energy consumption and minimizing electronic waste. By enabling hospitals to leverage patients' own devices, we help our customers reduce their carbon footprint and operational costs, reinforcing our shared commitment to sustainable healthcare delivery.

Social Responsibility

The Social pillar reflects Oneview's dedication to supporting dignity, equality, well-being, and continuous development. In 2025, we strengthened diversity and inclusion policies to ensure fair representation and equitable practices across the organization. Initiatives promoting pay equity and health and safety standards were reinforced, while investments in skills development programs equipped employees with the evolving demands of the healthcare technology sector.

We maintain a zero-tolerance approach to child labour, forced labour, and modern slavery, with no cases reported in 2025. We also remain focused on embedding diversity and equal opportunity across the organization.

Our Connected Patient Room vision exemplifies this commitment, empowering patients and families, improving clinical outcomes, and reducing the burden on care teams. The introduction of Ovie, our GenAI-powered voice assistant, further demonstrates our dedication to enhancing the care experience through responsible innovation. To support our AI-first transformation, we launched an AI Community of Practice, fostering collaboration and knowledge-sharing across departments. This initiative lowers barriers for non-technical teams to engage with AI, driving efficiency and creativity while ensuring ethical and compliant adoption.

Central to these efforts is Oneview's AI Software Development Life Cycle (SDLC), which embeds responsible AI principles into every stage of product development. Our AI SDLC ensures that all AI-driven features are designed, tested, and deployed within strict ethical and regulatory guardrails. It incorporates bias detection, fairness assessments, and explainability reviews, alongside rigorous security and privacy checks aligned with ISO 42001 standards for AI Management Systems. By integrating these controls into our development process, we safeguard patient trust, protect sensitive health data, and ensure that AI solutions deliver equitable outcomes for all stakeholders. This structured approach reflects our belief that innovation must be both transformative and responsible, reinforcing our commitment to social responsibility in the age of AI.



For personal use only

Governance Excellence

Governance remains central to Oneview's ESG strategy. The company is led by an independent Board of Directors supported by a formal Audit & Risk Management Committee responsible for oversight of compliance, internal controls, and risk management. Our governance framework includes a Code of Conduct, a Whistleblower Policy, anti-corruption standards, and mandatory compliance training. No incidents of corruption or bribery were reported during the year. Our commitment to data privacy and security was underscored by ISO 27001 and ISO 27701 certifications, while the AI Governance Group ensured responsible AI adoption aligned with global standards and ethical principles. We measure our ESG progress against the World Economic Forum's universal ESG framework and report quarterly on achievements, maintaining transparency and accountability at every level.

Strategic Context and Looking Forward

Oneview's ESG strategy is deeply integrated with our broader business transformation and AI-first vision. We are focused on embedding responsible AI practices, driving operational efficiency, and supporting our customers' sustainability and social responsibility goals. Looking ahead, we will continue to uphold ESG-driven innovation, working closely with hospitals and partners to deliver solutions that create lasting value for patients, care teams, and communities worldwide.

Our Approach to Employee Engagement and Retention

We foster a culture of collaboration, innovation, and inclusion, creating an environment where employees can thrive. Our investment in career development includes comprehensive onboarding programs, mandatory compliance and security training, and leadership development initiatives. Employees are encouraged to dedicate time each week to learning and upskilling, supported by access to both internal and external resources. This commitment to growth enhances individual capability and drives organizational resilience.



Flexibility and wellbeing remain core priorities. We offer adaptable work arrangements and maintain a strong focus on diversity and inclusion across all levels of the organization. Progress is tracked quarterly, and our latest engagement survey revealed that 78% of employees feel highly valued, with turnover at 12.8% in 2025 well below industry benchmarks.

To reinforce retention and align employee interests with long-term success, we provide competitive remuneration packages complemented by equity-based incentives such as Restricted Stock Units (RSUs). These programs reward performance and foster a sense of shared ownership in Oneview's future

Finally, we measure engagement through annual surveys and continuous feedback loops, ensuring that employee voices guide our actions. By combining a strong cultural foundation with meaningful development opportunities and competitive rewards, Oneview remains committed to attracting, engaging, and retaining exceptional talent as part of our ESG-driven strategy.

Prosperity and Community Contribution

Oneview's Prosperity pillar encompasses economic contribution, innovation, and community support. Throughout the year, Oneview advanced product innovation in areas such as mobile patient engagement and digital hospital infrastructure. The company participated in community initiatives, including donations to healthcare organisations and fundraising activities supporting children's health and well-being. These actions reflect our broader commitment to social impact and leadership within the healthcare technology sector.

78%
of employees state they "feel highly valued" in the 2025 employee sentiment survey

12.8%
employee turnover rate in 2025.

Corporate Governance Introduction

For personal use only

At Oneview, corporate governance is the cornerstone of our commitment to integrity, transparency, and sustainable growth. Our governance framework is designed to uphold the highest standards of accountability while fostering a culture of ethical decision-making and innovation. We believe that strong governance is essential to delivering long-term value for our shareholders and stakeholders, and it underpins every aspect of our operations. This approach reflects our core values—trust, collaboration, and excellence—which guide how we conduct business and engage with our global community.

Our governance culture is supported by robust policies and charters that define clear roles and responsibilities across the organization. These include our Board Charter, Code of Conduct, and risk management policies, which collectively ensure compliance with regulatory requirements and alignment with best practices. We emphasise transparency and fairness in all dealings, and our governance framework is regularly reviewed to adapt to evolving market conditions and stakeholder expectations. This proactive approach enables us to maintain resilience and agility while safeguarding the interests of all parties.

The Board of Directors plays a pivotal role in overseeing management and setting the strategic direction of the Company. Acting as stewards of shareholder value, the Board ensures that Oneview's strategy aligns with our mission and long-term objectives.

Their responsibilities include monitoring performance, assessing risk, and ensuring that management operates within the parameters of sound governance. Through rigorous oversight and constructive engagement, the Board provides guidance that balances innovation with prudent risk management, ensuring sustainable growth.

Management, led by the CEO, is responsible for executing the strategic plan approved by the Board and driving operational excellence. The CEO provides leadership across the organisation, ensuring alignment with our vision and values, while the CFO oversees financial stewardship and transparency. Together, they work closely with the Board to maintain accountability and deliver on our commitments to shareholders. This collaborative relationship between governance and management ensures that decisions are made in the best interests of the Company and its stakeholders.

Ultimately, our governance framework reflects our responsibility to shareholders and our dedication to creating long-term value. We recognise that trust is earned through consistent performance, ethical conduct, and transparent reporting. By embedding governance principles into our culture and operations, Oneview strives to maintain the confidence of investors, employees, and partners alike. Our approach is not static—it evolves to meet the challenges of a dynamic business environment while staying true to our core values and purpose.

Risk Management	25
Board of Directors	31
Leadership team	33
Corporate Governance Overview	34
Remuneration & Nomination Committee Report	37
Directors' report	43



Risk Management

The Company takes a proactive and structured approach to risk management. The Board is responsible for ensuring that risks are identified on a timely basis and that the Company's objectives and activities are aligned with identified risks and opportunities. The Board has established an Audit & Risk Management Committee which plays a guiding role in the development and evolution of the risk management framework.

Risk oversight is delegated to the Audit & Risk Management Committee, comprising independent Non-Executive Directors. Details of the Committee's charter, membership and meeting attendance during the year ended 31 December 2025 are set out in the Corporate Governance section and the Directors' Report of this Annual Report.

The Audit & Risk Management Committee's primary responsibility is to monitor and review the Company's risk management framework at least annually to assess whether it is sound and operating in accordance with the nature and extent of risk acceptable to the Board. The Committee reports the results of those assessments to the Board and oversees management's implementation of appropriate risk mitigation strategies.

During the year ended 31 December 2025, the Board, through the Audit & Risk Management Committee, completed its annual review of Oneview's risk management framework. Following this review, the Board was satisfied that the framework continues to be sound and that the Group is operating with due regard to the risk appetite set by the Board.

Oneview does not currently have a formal internal audit function. Management regularly reviews the Group's major business units, organisational structure and control environment and reports the outcomes of these reviews to the Audit & Risk Management Committee and the Board, which are satisfied that these processes appropriately evaluate and continually improve the effectiveness of Oneview's risk management and internal control systems.

This section describes the principal risks and uncertainties facing the Company and the way in which these risks are managed and mitigated and is intended to meet the related disclosure requirements of the Companies Act 2014.

The material strategic, operational, financial and general risks being managed by the Company are outlined below.

Strategic Risks

1. Failure to successfully implement its business strategy

Oneview is reliant on the talent, effort, expertise, industry experience and contacts, and leadership of its management. Whilst Oneview has entered into employment contracts with all management personnel, their retention cannot be guaranteed and the loss of any of Oneview's senior members of management and the inability to recruit suitable replacements represents a material risk to Oneview which may have a material impact on its business, financial performance and operations. Competition for talent in software and technology development is intense, and the loss of key personnel or inability to recruit suitable replacements could constrain growth, reduce service quality and weaken Oneview's competitive position. There is also a risk that, as Oneview grows, it cannot attract and retain personnel with the necessary industry experience, expertise and ability to execute its strategy, such that its future growth may be restricted and the quality of its services and revenues reduced, with a corresponding adverse impact on its business, financial performance and operations.

2. Implementation, installation and hardware risk

Customers frequently require Oneview to contract with third party suppliers to source and install the appropriate hardware to operate the Oneview Connected Care Experience solutions at the customer's locations. There is a risk that Oneview is required to fund the hardware procurement costs where it is unable to negotiate preferential payment terms with its clients or alternatively encourage its clients to enter into direct contracts with third-party hardware providers. A requirement to fund hardware procurement costs has an initial negative cashflow impact and any interruptions in the timing for hardware installation can result in further delayed realisation of cash flows. Oneview's reliance on third parties to deliver and support its products also exposes

For personal use only

Risk Management
(continued)

For personal use only

it to risks where those third-party suppliers may not satisfy their obligations in accordance with their contract with Oneview. For example, where the product delivered and installed by a third-party hardware provider does not match contracted requirements or there are supply chain interruptions, this can lead to disruptions in the implementation process, operational or business delays or problems with the service delivered which may damage Oneview's reputation and may result in claims against Oneview by its clients and potential client disputes, potential breach or termination of contracts and/or may impact the renewal of existing contracts or Oneview's ability to win new contracts. Oneview's third-party technology supplier contracts may also not entitle the Company to recover all of the losses it may suffer. These events may have a material adverse effect on Oneview's business, operating and financial performance and position.

3. Competition and technology risk

Oneview's operating performance is influenced by several competitive factors, including the success and awareness of its brand, its sophisticated technology and its commitment to ongoing product innovation. The industry in which Oneview operates, including in Australia, the U.S., Europe and other markets, is subject to increasing domestic and global competition and any change in the foregoing competitive factors, or others, may impact Oneview's ability to execute its growth strategy. As such there is a risk that:

- Oneview may fail to anticipate and adapt to technology changes or client expectations at the same rate as its competitors, or may not have the available resources to deliver customer needs;
- Existing competitors could increase their competitive position through aggressive marketing, product innovation and/or price discounting (which could result in price reductions, reduced gross margins and loss of market share);
- Existing or new competitors could offer software at a more competitive price, which may affect Oneview's ability to sustain or increase prices (even where the Oneview solution has better functionality);
- Clients who currently utilise patient engagement solutions offered by existing competitors (including local operators in specific markets or those with a greater market share in certain markets) which have often been in place for a considerable period of time or have onerous termination clauses, may determine that it is prohibitively costly and/or time consuming to adopt the Oneview solution; and
- New competitors, including large global Electronic Health Record corporations or large software vendors operating in adjacent industries, may enter the market. These corporations may have well-recognised brands, longer operating histories or pre-existing contractual relationships, or greater financial and other resources to apply to R&D and sales and marketing, which may enable them to expand in the patient engagement solutions industry more aggressively than Oneview and/or may enable them to better withstand any downturns in the market.

In addition, competitors are broadening their capabilities in patient engagement and smart-room technologies. This trend towards full-stack platforms integrating virtual care and patient engagement could pose challenges to Oneview's differentiation strategy and potential market share, including because it may result in decreased demand for patient engagement platforms or the Company's products becoming redundant. The Company's ability to innovate at pace, deploy efficiently at scale, and maintain strong customer outcomes remains essential in sustaining competitive advantage and ensuring that Oneview's current and future technologies and products do not become obsolete or uncompetitive.

4. Product Development

Cost estimates for product development and improvement are based on assumptions and judgments which may prove inaccurate. There is a risk that significant unforeseen costs or delays may arise due to technical complexities, hardware cost increases or contractual constraints. If new features or products are not adopted by customers, or do not deliver anticipated outcomes, this could negatively impact Oneview's growth and profitability. There is also no certainty that Oneview will be able to develop new products to broaden its revenue channels. Management continues to invest in the product roadmap and has introduced an AI-enabled development lifecycle to drive greater efficiency and quality in product development. AI-enabled functionality within Oneview products may not perform as intended, which could result in customer complaints, remediation costs or reputational harm.

5. Inorganic Growth Ambitions

Oneview's growth ambitions include the evaluation of both organic and inorganic initiatives and opportunities, including potential mergers, acquisitions or strategic investments. Any such transaction carries inherent risks that could adversely impact Oneview's business, financial performance, or the value of its equity.

For personal use only

Potential transactions may not complete on acceptable terms—or at all—and could require significant management time, due-diligence costs, and advisory fees without any corresponding benefit. If completed, acquisitions may fail to deliver anticipated synergies, may integrate more slowly than expected, or may expose Oneview to unforeseen liabilities, operational challenges, or cultural misalignment. Integration risks include diversion of leadership attention, disruption to existing operations, challenges unifying technology platforms, and the potential loss of key employees or customers.

Inorganic growth may also require Oneview to incur debt, issue new equity, or deploy cash reserves. Equity issuance could dilute existing securityholders and exert downward pressure on the CDI price, while leverage may reduce financial flexibility. There can be no assurance that any inorganic initiative will enhance securityholder value. If an acquisition does not meet expectations or introduces unexpected costs, it could have a material adverse effect on Oneview's financial condition, growth trajectory, and returns to securityholders.

There can also be no guarantee that Oneview will identify any future acquisition opportunities or be able to complete future acquisition opportunities on acceptable terms or, if it does do so, that such acquisitions will be effectively integrated into the Company's business.

Operational Risks

6. Failure to retain existing customers and attract new business / contracts

Oneview's business is dependent on its ability to retain its existing clients, secure new clients and contracts and maintain business relationships. Oneview may not be able to attract new clients at the rate it currently expects or has experienced historically and there is a risk that existing Oneview clients terminate their contracts without cause and on short notice and without financial penalty or do not renew their contracts when the initial contract term comes to an end (generally 3 to 5 years after commencement). There is also a risk of delay or cancellation of projects that Oneview successfully tendered for and/or termination of client customer contracts that Oneview has entered into but not yet commenced implementing. There is also a risk that clients may adopt different strategies or priorities (including because they face budgetary constraints) which reduce the need or desire to implement Oneview's solution. This could have a negative impact on Oneview's successful implementation of its business strategy, having an adverse impact on its business, financial performance and operations, particularly if this were to occur in relation to a number of different customer relationships.

7. Contract risk

Oneview's client contract tender processes often take 12-18 months to conclude. As a consequence, there is a timing risk: external factors may change the nature of these contracts and cause them to be cancelled or delayed, which will impact future revenue, earnings and cash flow.

8. Risk that the Oneview solution is disrupted, fails or ceases to function efficiently

Oneview depends on the performance and reliability of its technology platform. There is a risk that the Oneview solution contains defects or errors, which become evident when the software is implemented for new clients or new versions or enhancements are rolled out to existing clients. Internet-based services frequently contain undetected errors when they are introduced or when new versions or enhancements are released. In addition, Oneview may experience excessive downtime or performance issues with its technology platform. Such occurrences could harm Oneview's reputation, its financial position and performance, its ability to generate new business, its customer satisfaction and impact its customer renewals. Further, under its customer agreements, Oneview provides limited software warranties for the applicable statement of work term, with remedies generally confined to repair, replacement or termination of the affected statement of work. Defects in existing or future products may therefore result in warranty claims or remediation obligations, which could have a material adverse effect on Oneview's business, financial performance and operations.

9. Information technology and cyber security

Oneview's business is dependent on the efficient operation of information technology systems to support its operations and to ensure security and privacy of information. Any system failure, virus, malicious codes, breach of data and IT security issues could result in business interruption, the loss of clients or contracts, damaged reputation and a weakening of Oneview's competitive market position, particularly where restorative/substitute technology systems are not available

Risk Management
(continued)

For personal use only

on acceptable terms. Furthermore, there is a risk that the Oneview solution is the subject of a cyber-attack which could compromise or even breach the technology, rendering the Oneview solution unavailable for a period until the software is restored and/or resulting in the theft, loss or corruption of sensitive data (including patient data, client or business data) and damage to Oneview's business prospects and reputation. End-of-life hardware deployed at certain customer sites may continue to be used despite no longer being supported by the hardware vendor, including the unavailability of security patches, which may increase exposure to security vulnerabilities. The effect of any such event could extend to compensation claims from patients, reputational damage, regulatory scrutiny and fines. Such circumstances could negatively impact upon Oneview's business, financial performance and operations.

10. Actual and potential disputes

Due to the contractual nature of Oneview's relationships, Oneview may in the future be subject to claims, disputes or proceedings in its ordinary course of business. Any dispute could be costly and damaging to Oneview's reputation, business relationships, operating and financial performance and position.

11. Significant unanticipated costs or delays might arise in relation to Oneview's business

Cost estimates are made in advance of undertaking a contract and are dependent upon assumptions, estimates and judgments, which may ultimately prove to be inaccurate or unreliable. There is a risk that significant unanticipated costs or delays may arise during the course of implementation due to (i) errors and omissions; (ii) unforeseen technical conditions or increases in hardware costs; or (iii) inadequate contractual arrangements. Significant unanticipated costs could have a material adverse impact on margins and, ultimately, Oneview's business, financial performance and operations. This risk can be amplified in a higher inflationary environment, where supply chain challenges and inflationary pressures may result in Oneview incurring increased material and component prices, labour rates and supplier costs which it is unable to pass through (either at all, or only in part) under its contractual arrangements.

12. Personnel risk

Oneview is reliant on the talent, effort, expertise, industry experience and contacts, and leadership of its management. Whilst Oneview has entered into employment contracts with all management personnel, their retention cannot be guaranteed and the loss of any of Oneview's senior members of management and the inability to recruit suitable replacements represents a material risk to Oneview which may have a material impact on its business, financial performance and operations. Competition for talent in software and technology development is intense, and the loss of key personnel or inability to recruit suitable replacements could constrain growth, reduce service quality and weaken Oneview's competitive position. There is also a risk that, as Oneview grows, it cannot attract and retain personnel with the necessary industry experience, expertise and ability to execute its strategy, such that its future growth may be restricted and the quality of its services and revenues reduced, with a corresponding adverse impact on its business, financial performance and operations.

13. Market adoption of Patient Engagement Solutions

If Oneview's patient engagement solutions are not widely accepted for use by healthcare providers, including as a result of Oneview's failure to prove return on investment, or if the market for patient engagement solutions (or Oneview's other products) in the healthcare industry fails to grow at the expected rate, demand for the Oneview solution could be negatively impacted and Oneview's ability to sustain and grow its business may be adversely affected.

14. Reliance on its core product and failure to develop new products

Oneview derives all of its revenue from the sale and associated installation of the Oneview solution as well as the recurring software license fees. It relies on its ability to develop new products, features and enhancements to the Oneview solution. There is a risk that upgrading the Oneview solution or introducing new products may result in unforeseen costs, may fail to achieve anticipated revenue or may not achieve intended outcomes. A failure by Oneview to develop successful new products, features and enhancements to the Oneview solution may have an adverse impact on its ability to develop client relationships and maintain current relationships.

15. Intellectual Property Risk

Oneview relies on its intellectual property rights and there is a risk that Oneview may fail to protect its rights for a number of reasons. Oneview has historically used a mixture of legal (e.g. confidentiality agreements and code of conduct agreements) and technical (e.g. data encryption) methods to protect its intellectual property. As Oneview grows and diversifies geographically, there is a risk that these actions may not be adequate

For personal use only

and may not prevent the misappropriation of its intellectual property, prevent intellectual property from being subject to challenge or invalidation or deter independent development of similar products by others. There is also a risk that Oneview may be unable to detect the unauthorised use of its intellectual property rights in all instances. If Oneview fails to protect its intellectual property rights adequately, competitors may gain access to its technology, which would in turn harm its business, financial performance and operations.

16. Integration risk

Oneview depends on the performance and integration capability of the Oneview solution with clients' existing systems. The functionality and accessibility of the platform is important to customers and any disruption or issues with the integration could harm Oneview's reputation and its ability to generate revenue from existing customers or to win new business.

17. Foreign operations and sovereign risks

As the Company is incorporated in Ireland, certain provisions of the Australian *Corporations Act 2001* (Cth) (Australian Corporations Act), including in relation to takeovers and substantial holdings do not apply. Similarly, the Company is not bound by the takeover rules under Irish law because they only apply to public companies incorporated in Ireland whose securities are, or have in the previous five years been, traded on certain exchanges (which do not include the ASX (Australian Securities Exchange)). The Company has therefore incorporated into its Constitution security holder protection provisions that are similar to the provisions of the Australian Corporations Act. In these circumstances, any claim against the Company for a breach of its Constitution would need to be brought in Ireland. Any such claim would be contractual in nature and may therefore not have the same level of enforceability as a claim under the Australian Corporations Act. As a result of the Company being incorporated in Ireland, it may also be difficult for investors to effect service of process upon the Company within Australia and/or to enforce any judgments obtained in a court other than the Irish courts against the Company.

18. Dependency on service providers

Oneview conducts a significant amount of its operations through a series of contractual relationships with third-party service providers. Such arrangements carry a risk that the third parties do not adequately or fully comply with their respective contractual rights and obligations. Such failure may lead to contractual termination and/or significant reputational damage to Oneview. Oneview relies on third-party hardware providers to support its products and services. Factors concerning performance of this hardware, the availability of spare parts and maintenance services which can only be completed externally, may affect the ability of Oneview to maintain its software and minimise interruptions to the continuous performance of its systems, which could impact existing customer retention and attraction of new customers and also cause reputational damage to Oneview.

Risk Management
(continued)

For personal use only

Financial Risks

19. Funding requirements, including reduced access to funding
In the future, Oneview could be required to raise capital through public or private financing or other arrangements. Access to capital markets may be impacted by a variety of factors, including general changes in global capital markets. There is no certainty that such financing will be available on acceptable terms, or at all, and a failure to raise capital when required could harm Oneview's business. There is a risk that if Oneview requires additional funding and cannot raise funds on acceptable terms, it may not be able to fund its operations, grow its business or respond to competitive pressures.

20. Working capital risk
Maintaining sufficient working capital is a fundamental requirement for Oneview to meet its financial obligations. Given the timing difference between accounts receivables and accounts payables falling due, Oneview may face temporary cash constraints, in particular, when Oneview has to make large advance payments for hardware procurement. The inability to maintain a strong balance sheet or to secure new capital or credit facilities (in the form of cash advance, overdraft and bonding facilities) could impact Oneview's opportunity to meet its ongoing liquidity needs, tender for new business or deliver under existing client contracts.

21. Inventory management
Oneview holds significant levels of new hardware inventory and any misalignment between inventory levels and customer demand could result in increased costs, write-downs or delayed deliveries. Holding excess hardware inventory or ineffective inventory management may lead to obsolescence or financial loss if significant deployments are not achieved over the coming years.

22. Absence of dividends
The Board has yet to establish a dividend policy and does not expect to pay dividends in the near term. While Oneview continues to expand its business operations, Oneview expects to continue to reinvest in its growth rather than distribute profits in the form of dividends. The ability of Oneview to pay any dividend in the future is dependent on many factors. The Directors do not give any assurance regarding the payment of dividends in the future.

23. Foreign Currency risk
Oneview's financial reports are prepared in Euros. However, revenue, expenditure and cashflows, and assets and liabilities from Oneview's operations are denominated in various other currencies. For example, its Australian, U.S., and Thailand operations are denominated in Australian dollars, U.S. dollars and Thai Baht respectively. Oneview is therefore exposed to the risk of fluctuations in the value of currencies (for example fluctuations of the Euro against those currencies), and adverse fluctuations in exchange rates may negatively impact the translation of account balances and profitability from these offshore operations.

Further quantitative information on the Group's exposure to credit, liquidity and foreign currency risks, together with the Group's objectives, policies and processes for managing those risks, is set out in Note 23 'Financial instruments' to the consolidated financial statements.

24. Public healthcare funding and other changes to laws, regulations and policies
Oneview's business plan and strategy has been formulated based on the prevailing healthcare policy from the time of listing until the present in its focus markets (including the U.S. and Australia). It is possible that governments in Oneview's focus markets could implement healthcare policy changes that have an effect on Oneview's business and, whilst such changes can create opportunities for Oneview, there is also potential for these changes to favour competitor offerings, to require Oneview to re-engineer its products or incur additional cost or otherwise to be unfavourable to Oneview's business.

There is also a risk that government policy changes result in a reduction in healthcare funding, including specific funding for Healthcare Information Technologies "HCIT" initiatives. If funding is reduced or discontinued in the U.S. or in other target jurisdictions, this could influence the extent to which customers purchase the Oneview solution, which would have an unfavourable impact on Oneview's future business, financial performance and operations. Oneview must comply with the laws and governmental regulations in the markets in which it operates. These laws and regulations often provide broad discretion to the administering authorities. Additionally, all of these laws and regulations are subject to change, which may be retrospective. Such changes may cause Oneview to incur increased costs to ensure compliance with new applicable laws or regulations or otherwise negatively impact Oneview's business, financial performance and operations.

For personal use only

General Risks

25. Environmental and social risks

Oneview undergoes a quarterly ESG (Environment, Social and Governance) assessment to identify any material environmental or social risks that could affect the Group's ability to create or preserve value for security holders. No material environmental or social risks were identified during the year ended 31 December 2025. ESG risks continue to be monitored and reported to the Audit & Risk Management Committee on an ongoing basis.

26. Economic and government risks

The future viability of Oneview is also dependent on a number of other factors affecting performance of all industries and not just the technology industry, including, but not limited to, the following:

- general economic conditions in jurisdictions in which Oneview operates;
- changes in government policies, taxation and other laws in jurisdictions in which Oneview and its customers operate;
- movement in, or outlook on, interest rates and inflation rates in jurisdictions in which Oneview and its customers operate; and
- natural disasters, social upheaval or war in jurisdictions in which Oneview and its customers operate.

A prolonged deterioration in general economic conditions, including an increase in interest rates or a decrease in consumer and business demand, could be expected to have a materially adverse impact on Oneview's business or financial condition. Changes to laws and regulations or accounting standards which apply to Oneview from time to time could adversely impact Oneview's earnings and financial performance.

27. International Trade Policies

Changes in trade policies, particularly in the U.S. and other key markets, may affect Oneview or its customers through tariffs, supply chain disruptions or increased regulatory complexity. These developments can raise costs, create uncertainty and impact both customer demand and expansion plans.

28. Global Events and Business Interruption

Geopolitical tensions, pandemics, natural disasters, industrial action, wars and other large-scale events are beyond the Company's control yet may materially affect its operations. Such events may disrupt project implementation, reduce non-recurring revenue opportunities, affect recurring revenue growth, constrain liquidity and impair the Company's ability to meet regulatory and contractual obligations.

There are also other changes in the domestic and global macroeconomic environment associated with disruptions from global events that are beyond the control of Oneview and may be exacerbated in an economic recession or downturn. These include, but are not limited to:

- changes in inflation, interest rates and foreign currency exchange rates;
- changes in employment level and labour costs;
- changes in aggregate investment and economic output; and
- other changes in economic conditions which may affect the revenue or costs of Oneview.

29. AI-related incidents

As Oneview introduces AI-enabled features into its products, new risks emerge relating to potential misbehaviour or unintended responses from AI components, whether through deliberate misuse by users or through unexpected system behaviour. These incidents could lead to complaints or reputational damage. The Company has achieved ISO 42001 AIMS certification for responsible AI development and incorporates AI safety and ethical evaluations into its development processes; however, residual risk remains as AI usage expands.

30. Global conflicts

The war between Ukraine and Russia and Israel and Palestine, as well as the current expanded conflict in the Middle-East and other potential conflicts (together, **Global Conflicts**), have impacted and may continue to impact global economic markets. The nature and extent of the effect of Global Conflicts on the performance of Oneview remains unknown.

Global Conflicts have potential secondary and tertiary macroeconomic impacts, including impacts on pricing of commodity and energy markets, effects on global supply chain and freight movements which would impact the supply of raw materials and delivery of finished goods and the potential of cyber activity impacting governmental or industry measures taken in response to Global Conflicts.

Board of Directors

Board Composition

Oneview has an experienced and balanced Board with diverse skills drawn from industry leaders who bring in-depth industry and business knowledge, financial management and corporate governance expertise.



Barbara Nelson

Nationality: American
Chair and Independent Non-Executive Director
Director since October 2023, Chair since October 2024

Barbara is a public board director and C-level technology leader, who currently serves on three corporate boards: Oneview Healthcare, Backblaze and o8t (Omniscient Neurotechnology). She has been CEO twice and led global P&Ls as large as US$3 billion in companies ranging from Fortune 500 leaders to VC-funded companies. Barbara has scaled from concept to over US$100M – US$200M, four times in three companies, profitably. She brings extensive board, P&L and general management experience in AI, SaaS/cloud services, IaaS, cybersecurity, biotech/healthcare, mobile, video, data management, storage, IT infrastructure, and semiconductors. Barbara holds a B.S. in Electrical Engineering from Stanford University.



Nashina Asaria

Nationality: American
Independent Non-Executive Director
Director since May 2021

Nashina currently serves as a Non-Executive Director at Oneview Healthcare and is a Trustee and Director at Ashinaga Foundation UK. She is also Chief Commercial Officer at Newfire Global Partners where she is focused on developing strategic partnerships and ventures. She is on the Advisory Boards of several HealthTech and FinTech AI-related companies including Cylerity, Symbiosis and Simplici.io. Nashina has held significant roles, including Chief Product Officer at Nanthealth and Chief Product and Marketing Officer at Cloudbreak Health, where she led substantial revenue growth. Her expertise spans product strategy, commercialisation and technology leadership, with a focus on improving health outcomes and financial inclusion. Nashina holds a BSc in Economics from the London School of Economics and Political Science.



Mark Cullen

Nationality: Australian
Independent Non Executive Director
Director since October 2023

Mark was a non-executive Director and Chair of the Audit Committee at Oneview Healthcare from December 2015 until January 2019. Mark rejoined the Board after retiring from a distinguished 30-year career with Deutsche Bank and DWS Asset Management, most recently as CEO of DWS Americas & COO of DWS Group GmbH & Co. Mark is BlackRock's Head of Strategic Ecosystem Partnerships and Head of Index & Data Solutions division based in London and New York.



Michael J Dowling

Nationality: Irish
Independent Non-Executive Director
Director since December 2025

Michael J. Dowling, CEO Emeritus of Northwell Health, is a globally recognised healthcare leader, ranked No. 1 on Modern Healthcare's "100 Most Influential People in Healthcare" and featured in TIME's "100 Most Influential People in Global Health." Over three decades, he has championed patient-focused reforms, public health advocacy, and innovation in medical research and education. Michael is known for a highly visible, principled leadership style—championing innovation, advocating for social issues, and inspiring teams through a commitment to compassion, lifelong learning, and bold action in the face of complex challenges. Michael's career spans academia, government and industry, earning numerous honours for his visionary contributions to healthcare and society.



Joe Rooney

Nationality: Irish
Independent Non-Executive Director
Director since February 2016

Joe joined Oneview in 2016 as an Independent Director. He assumed the role of Interim Chairman on two occasions, first from August 2017 to November 2019, and then again from June 2023 to October 2024. He resigned voluntarily on both occasions and remains on the board as an Independent Director. Joe was Chair of Fundraising for the Clongowes Wood College Foundation until November 2025. Until the end of 2012, Joe was a partner and global strategist at Autonomy Capital Research LLP, a global macro hedge fund. Prior to this, he held a number of senior positions at Lehman Brothers Inc, where, as a Managing Director, he was the Head of Global Equity Strategy and a trustee of their UK pension fund.

For personal use only

For personal use only

Executive Directors



James Fitter (CEO)
Nationality: Australian

James Fitter has served as CEO of Oneview Healthcare since January 2013, leading the company's remarkable transformation from a 10-person startup to a publicly traded entity in just over three years. His leadership has been instrumental in Oneview's growth and success. With over 25 years of experience in global financial markets, including living and working on four continents, James brings a wealth of international business acumen to the role. Prior to Oneview, he founded and managed an independent asset management company and spent over a decade as a professional investor, corporate governance advocate and independent advisor. This extensive financial background provides him with a unique perspective on the healthcare technology sector. He holds a Bachelor of Commerce from the University of New South Wales, Sydney, Australia and an Executive Diploma in Artificial Intelligence for Business at the University of Oxford.



Darragh Lyons (CFO)
Nationality: Irish

Darragh joined Oneview as CFO on 9 September 2024 and was appointed to the Board on the same date. Darragh leads our finance and commercial teams. Prior to joining Oneview, Darragh was CEO of Malin plc, a listed life sciences investment company, where he previously served as CFO from 2015 until his appointment as CEO in 2019. Prior to that, Darragh held senior finance positions in Elan Pharmaceuticals plc and worked with PwC in Dublin, the U.S. and Canada. Darragh holds a BA in Accounting & Finance from Dublin City University and is a Fellow of Chartered Accountants Ireland. Darragh completed a Professional Diploma in Artificial Intelligence at University College Dublin and has completed postgraduate education at Harvard Business School and Cambridge University.

Company Secretary



Toni Pettit
Nationality: Irish
Company Secretary & Chief of Staff

Toni, the Company's Chief of Staff, was appointed as Company Secretary on 9 September 2024. Toni is an accredited coach with the European Mentoring and Coaching Council and also leads the Company's learning & development strategy. Before joining Oneview, Toni held multidisciplinary roles within the Technology, Pharmaceutical, Hospitality and Education sectors spanning multi-nationals, SMEs and early-stage start-ups.

Leadership Team



James Fitter

CEO

James Fitter has served as CEO of Oneview Healthcare since January 2013, leading the company's remarkable transformation from a 10-person startup to a publicly traded entity in just over three years. His leadership has been instrumental in Oneview's growth and success. With over 25 years of experience in global financial markets, including living and working on four continents, James brings a wealth of international business acumen to the role. Prior to Oneview, he founded and managed an independent asset management company and spent over a decade as a professional investor, corporate governance advocate and independent advisor. This extensive financial background provides him with a unique perspective on the healthcare technology sector. He holds a Bachelor of Commerce from the University of New South Wales, Sydney, Australia and an Executive Diploma in Artificial Intelligence for Business at the University of Oxford.



Darragh Lyons

CFO

Darragh joined Oneview as CFO on 9 September 2024 and was appointed to the Board on the same date. Darragh leads our finance and commercial teams. Prior to joining Oneview, Darragh was CEO of Malin plc, a listed life sciences investment company, where he previously served as CFO from 2015 until his appointment as CEO in 2019. Prior to that, Darragh held senior finance positions in Elan Pharmaceuticals plc and worked with PwC in Dublin, the U.S. and Canada. Darragh holds a BA in Accounting & Finance from Dublin City University and is a Fellow of Chartered Accountants Ireland. Darragh completed a Professional Diploma in Artificial Intelligence at University College Dublin and has completed postgraduate education at Harvard Business School and Cambridge University.



Declan Bright

Chief Technology Officer

Declan is our Chief Technology Officer and AI Officer, driving technology strategy and shaping the roadmap to keep our solutions at the forefront of innovation. He leads the design and evolution of our software platform and manages Oneview's Governance, Risk, and Compliance (GRC) programme. With more than 25 years of experience across multiple sectors in the IT industry, Declan brings deep expertise in enterprise technology, security and data privacy. He holds an MSc from Queen's University Belfast.



Aaron Box

VP, Strategy & Innovation

Aaron leads our Sales Team in North America, overseeing sales strategy and pre-sales engineering. With extensive experience in healthcare IT, he previously played a key role at BJC Healthcare, leading IT initiatives for planning, design and construction as part of their billion-dollar campus renewal project. Aaron received a B.S. in Information Systems & Applied Technologies from Southern Illinois University.



JP Howe

Chief Operating Officer

JP is a pivotal leader within Oneview, driving collaboration across all functions to ensure seamless operational excellence. As Chief Operating Officer, JP oversees every facet of the organization's daily operations, guaranteeing efficiency and precision at scale. JP plays an instrumental role in delivering on the company's strategic objectives. He has over two decades of experience delivering complex software solutions in financial services, travel and education industries. JP holds a Master's Degree in Strategic Management from TU Dublin.

For personal use only

For personal use only



Gabi Mitchell

VP of Clinical Innovation

Gabi leads our account management team and supports clinical innovations for our products and their development. She brings deep clinical expertise from her roles as Chief Nursing Officer and VP of Customer Success at one of the early pioneers of patient experience in the United States. With a hands-on nursing background, she has guided bedside technology implementations across diverse care settings and led hospital design, build, and operations. Her experience driving high-profit service lines gives her a keen understanding of healthcare's challenges and opportunities. Gabi received her Bachelor's of Science in Nursing from the University of Florida and a Master's of Business Administration with a focus in Healthcare at the University of Miami in Coral Springs, FL.



Toni Pettit

Company Secretary & Chief of Staff

Toni, the Company's Chief of Staff, was appointed as Company Secretary on 9 September 2024. Toni is an accredited coach with the European Mentoring and Coaching Council and also leads the Company's learning & development strategy. Before joining Oneview, Toni held multidisciplinary roles within the Technology, Pharmaceutical, Hospitality and Education sectors spanning multi-nationals, SMEs and early-stage start-ups.



Niall O'Neill

Chief Product Officer

Niall is Chief Product Officer at Oneview Healthcare, where he leads product innovation. Previously as Chief Customer Officer, Niall has played a pivotal role in shaping Oneview's growth through a blend of customer-centric leadership and technical insight. Before joining Oneview, Niall held consulting roles at Accenture and Deloitte. He holds a BA in English Studies and an MSc in Multimedia Systems from Trinity College Dublin. His leadership continues to guide Oneview's innovation and global impact.



Aoife Meehan

HR Director

Aoife is the HR Director at Oneview, where she leads the People & Culture function, ensuring employees are supported while robust HR policies, procedures, and governance are in place. She is responsible for shaping and embedding a strong, values-driven culture that supports performance and sustainable growth. Aoife has over 16 years' experience across Legal, Financial Services, and Technology, working with organisations on a global scale. She began her career in the UK and returned to Ireland in 2016. Aoife holds a CIPD qualification in HR Management and a Bachelor's degree in Business (Hons) in Accounting.

Corporate Governance Overview

Corporate Governance Statement

The Company has prepared a statement which sets out the corporate governance practices that were in operation throughout the financial year for the Company, identifies any recommendations that have not been followed and provides reasons, if any, for not following such recommendations.

In accordance with ASX listing rules, the Corporate Governance Statement is available for review on the Company's website (https://www.oneviewhealthcare.com/oneview-healthcare/investors/) and has been lodged together with an Appendix 4G at the same time as this report is lodged with ASX.

Board Committees

The Board and management team maintain high standards of corporate governance as part of our commitment to create value for our stakeholders through effective strategic planning, risk management, transparency and corporate responsibility. The Company has an Audit and Risk Committee and a Remuneration and Nomination Committee. Both committees are comprised of Non-Executive Directors. A description of the role of each committee and its composition is set out in the following table.

Committee	Members	Composition	Role
Audit & Risk Committee	Mark Cullen (Chair) Barbara Nelson Joe Rooney Nashina Asaria Michael Dowling (joined January 2026)	The committee includes at least three members, all of whom must be Non-Executive Directors and a majority of whom are independent directors. The chair must be an independent Non-Executive Director, who is not the chair of the Board. The committee comprises members who are financially literate and include at least one member who has accounting and/or related financial management expertise and some members who have an understanding of the industries in which the Company operates.	The Audit and Risk Committee assists the Board in carrying out its oversight of the quality and integrity of the accounting, auditing and financial reporting of the Company. The Committee also reviews the adequacy of Oneview's internal control structure, corporate reporting processes and risk management framework, monitors the effectiveness, objectivity and independence of the external auditor and reviews reports from the external auditor. The Committee also monitors Oneview's compliance with laws and regulations and seeks to safeguard the assets of Oneview.
Remuneration & Nomination Committee	Joe Rooney (Chair) Mark Cullen (resigned 9 February 2026) Barbara Nelson Nashina Asaria Michael Dowling (joined January 2026)	The committee includes at least three members, all of whom must be Non-Executive Directors and a majority of whom are independent directors. The chair must be an independent Non-Executive Director. The committee includes at least one member who has expertise in remuneration.	The Remuneration and Nomination Committee assists the Board by reviewing and recommending matters related to remuneration policies, Board succession planning, appointments, and re-elections. It oversees Director induction and evaluates the remuneration of senior executives, Directors and employees, including equity-based incentives. The Committee addresses retention policies, as well as CEO and senior executive succession plans. It evaluates Board and executive performance annually and ensures shareholder approval for relevant remuneration policies. Additionally, it advises on Board size, composition and diversity strategies, ensuring no gender or other biases in remuneration practices.

For personal use only

For personal use only

Directors' Meetings

The number of meetings of the Company's Board of Directors and of each Board Committee held during the year ended 31 December 2025 and the number of meetings attended by each Director are set out below:

	Full Board		Remuneration & Nomination Committee		Audit and Risk Committee	
	Eligible to attend	Attended	Eligible to attend	Attended	Eligible to attend	Attended
Barbara Nelson	12	12	5	5	4	4
Nashina Asaria	12	8	5	4	4	4
Mark Cullen	12	10	5	3	4	2
James Fitter	12	11	-	-	-	-
Darragh Lyons	12	11	-	-	-	-
Joe Rooney	12	12	5	5	4	4
Michael Dowling	1	1	-	-	-	-

Oneview's Key Policies

Ethics and Transparency

Oneview and its subsidiaries are committed to maintaining the highest ethical standards in all business activities. The Company expects all directors, employees, consultants, secondees, and contractors to act with openness, honesty, fairness, and integrity, always in the best interests of the Company. Business decisions must be made solely on sound commercial grounds, and personal interests must not conflict with those of the Company. Promises or commitments must only be made when they can be honoured.

Transparency is fundamental: compliance with all laws and regulations is required, and the Company's financial books and records must accurately reflect all transactions. Confidential and proprietary information must be protected and only disclosed for valid business reasons. The Company prohibits bribery, improper inducements, and any conduct that may bring discredit upon the Company.

Equal opportunity, dignity, and respect in the workplace are core principles, with zero tolerance for discrimination or harassment. Any suspected breaches of the Code are investigated, with appropriate action taken to uphold these standards.

Communication and Disclosure

Oneview is committed to maintaining full compliance with ASX continuous disclosure requirements. Subject to limited exceptions, we promptly disclose any information that a reasonable person would expect to have a material impact on the price or value of Oneview securities. Our Communication and Continuous Disclosure policies provide clear guidance for Directors and employees, outlining the steps to take when material information arises and specifying the approved channels for disclosure. These policies are regularly reviewed to ensure alignment with regulatory standards and best practices, reinforcing our culture of transparency and accountability.

Oneview remains committed to transparency and ethical conduct through robust governance frameworks. In addition to our Communication and Continuous Disclosure policies, we maintain a comprehensive Whistleblower Policy designed to encourage employees and stakeholders to report concerns about relevant wrongdoing without fear of reprisal. This policy outlines clear reporting channels, investigation procedures, and protections under the Protected Disclosures Act 2014, ensuring that all disclosures are handled confidentially and appropriately. Together, these measures strengthen our compliance with ASX requirements and support a culture of integrity across the organization.

Data protection and cybersecurity

Oneview collects, stores and uses data for a range of purposes associated with its business, including Protected Health Information (PHI). Oneview places a high priority on privacy and data protection, adhering to various global regulations including the EU General Data Protection Regulation (GDPR); the U.S. Health Insurance Portability and Accountability Act of 1996 (HIPAA), and the Australian Privacy Act 1988. The Company's Data Protection policies mandate strict compliance with data collection, access, use and disclosure rules. Data security and privacy is embedded into the Company culture and the Software Development Lifecycle (SDLC). This includes practices such as privacy by design, threat modelling and regular security training for all employees. Data retention policies at Oneview require that records be protected against loss, destruction and falsification, with clear labelling and categorisation for easy retrieval. Records are retained according to legal requirements and business needs, with specific retention periods outlined in the Oneview Asset Register.

Corporate Governance Overview
(continued)

For personal use only

Oneview also ensures that personal data is processed lawfully, with policies and procedures in place to comply with applicable laws and regulations. Confidential information from clients and partners is protected according to Oneview's security policies and any breaches of data protection guidelines by staff may result in disciplinary action.

Oneview's cybersecurity programme is certified to the ISO 27001 & ISO 27701 standards. It applies to all employees, contractors and business partners to ensure robust protection of information assets. It includes a formal Information Security Policy, annual reviews of security policies, and a Risk Management process to identify, quantify and prioritise risks. Employees undergo annual Security Awareness and HIPAA training, including random phishing tests. Cybersecurity incidents are reported through a defined process and customer data is encrypted both at rest and in transit. Third-party penetration tests and internal network assessments are conducted to identify and mitigate vulnerabilities.

Oneview has implemented an Artificial Intelligence Management System (AIMS) which achieved ISO 42001 certification in April 2025. The AIMS includes policies, procedures, risk management and best practices for the responsible and ethical use of Artificial Intelligence (AI) within our Company and products. All users of AI-enabled systems must use those systems in a manner that aligns with the Company's principles, adheres to legal and regulatory standards and promotes the safety and well-being of our employees and customers.

In addition to ongoing audits and certification renewals, Oneview continues to strengthen its Governance, Risk, and Compliance (GRC) program through a risk-based approach, including alignment with the EU NIS2 Directive.

Risk management

Oneview views risk recognition and management as integral to achieving its objectives and maintaining shareholder value. The Board is responsible for overseeing the risk management system, ensuring that all material risks are identified, assessed, and appropriately managed through regular reviews and delegated responsibilities. The company employs a structured risk management framework, including an active Audit & Risk Management Committee, regular risk assessments, and clear assignment of risk management duties. The policy is reviewed annually, with any amendments requiring Board approval and communication to all employees.

Further details of Oneview's risk management framework are contained in Oneview's Corporate Governance Statement and a description of Oneview's material risks can be found on pages 25 to 31 of this report.

Securities Trading Policy

Directors, employees and consultants must comply with the insider trading prohibitions of the Australian Corporations Act and the Market Abuse Regulation (EU) No 596/2014. Oneview's Securities Trading Policy establishes clear standards to ensure Directors, employees, and consultants act with integrity and transparency when trading in Company Securities, strictly prohibiting insider trading and mandating compliance with relevant laws. By fostering a culture of accountability and ethical conduct, Oneview reinforces its commitment to responsible governance and market confidence.

Remuneration and Nomination Committee Report

For personal use only

Dear Shareholders,

On behalf of the Board of Directors, I am pleased to present Oneview's Remuneration & Nomination Committee Report for the financial year ended 31 December 2025.

1. Principles used to determine the nature and amount of remuneration

i. Objectives & framework

The objectives of the Group's executive reward framework are to ensure that reward for performance is competitive and appropriate for the results delivered. The framework aligns reward with achievement of strategic objectives and the creation of value for shareholders and conforms to market practice for delivery of reward. The Board has ensured that executive reward satisfies the following key criteria for good reward governance practices:

- Competitiveness and awareness
- Acceptability to shareholders
- Performance linkage / alignment of executive compensation
- Transparency
- Capital management

The Group has sought independent advice and structured an executive remuneration framework that is market competitive and complementary to the reward strategy of the organisation. The Board is satisfied remuneration recommendations are made free from undue influence by members of key management personnel.

Alignment to shareholders' interests

- Has economic profitability as a core component of the plan
- Focuses on sustained growth in shareholder wealth, comprising growth in share price and dividends (when available)
- Focuses executives on key non-financial drivers of value
- Attracts and retains high calibre executives

Alignment to programme participants' interests

Rewards capability and experience

- Reflects competitive reward for contribution towards achieving cash-flow break-even
- Provides a clear structure for earning rewards
- Provides recognition for contribution

The framework provides a mix of fixed pay and long-term incentives.

ii. Remuneration & Nomination committee

The Board has established a Remuneration and Nomination Committee comprised of Non-Executive Directors: Joe Rooney (Chairman), Nashina Asaria, Barbara Nelson, Michael Dowling (joined January 2026) and Mark Cullen (resigned 9 February 2026).

The purpose of the Committee is to assist the Board by providing advice on remuneration and incentive policies and practices and specific recommendations on remuneration packages and other terms of employment for Executive Directors, other senior executives and Non-Executive Directors. Specifically:

- the Company's remuneration policy, including as it applies to Directors and the process by which any pool of Directors' fees approved by shareholders is allocated to Directors;
- Board succession issues and planning;
- the appointment and re-election of members of the Board and its committees;
- induction of Directors and continuing professional development programmes for Directors where required;
- remuneration packages of senior executives, Non-Executive Directors and Executive Directors, equity-based incentive plans and other employee benefit programmes;
- the Company's superannuation arrangements;
- the Company's recruitment, retention and termination policies;
- succession plans of the CEO, senior executives and Executive Directors;
- the process for the evaluation of the performance of the Board, its Board Committees and individual Directors;
- the review of the performance of senior executives and members of the Board;
- those aspects of the Company's remuneration policies and packages, including equity-based incentives, which should be subject to shareholder approval; and
- the size and composition of the Board and strategies to address Board diversity and the Company's performance in respect of the Company's Diversity Policy, including whether there is any gender or other inappropriate bias in remuneration for Directors, senior executives or other employees.

iii. Non-Executive Directors

Fees and payments to Non-Executive Directors reflect the demands which are made on, and the responsibilities of, the Directors. Non-Executive Directors' fees and payments are reviewed annually by the Board. The Chair's fees are determined independently to the fees of Non-Executive Directors based on comparative roles in the external market. The Chair is not present at any discussions relating to determination of her own remuneration. Non-Executive Directors have also received Restricted Stock Units under the Oneview Healthcare PLC NED & Consultant RSU Plan which was approved by shareholders at the AGM on 1 December 2025.

Non-Executive Directors' fees are determined within an aggregate Directors' fee pool limit, which is periodically recommended for approval by shareholders. The maximum currently stands €750,000 total pool per annum, as set out in the Company's prospectus issued on 19 February 2016.

Remuneration and Nomination Committee Report
(continued)

For personal use only

The following fees have been applied:

	1 January 2025 to 31 December 2025 €	1 January 2024 to 31 December 2024 €
Base fees		
Chair	40,817	10,920
Interim Chairman	-	32,683
Other Non-Executive Directors	125,825	130,813
Sub-Total – Base fees	**166,642**	**174,416**
Post employment benefits		
Chair	-	-
Other Non-Executive Directors	-	-
Sub-Total – Post employment benefits	**-**	**-**
Total	**166,642**	**174,416**

iv. Executive Directors
The Executive Directors' pay and reward framework currently has 4 components:
- Base pay and benefits
- Annual discretionary bonus
- Annual and long-term incentives through participation in the Oneview Healthcare PLC RSU Plan (RSU)
- Long-term incentives through participation in the Oneview Healthcare PLC Employee Share Option Plan (ESOP).

The combination of these comprises the Executive Director's total remuneration.

a. Base pay and benefits
Executive Directors are offered a competitive base pay that comprises the fixed component of pay and rewards, plus benefits. Base pay for Executive Directors is reviewed annually to ensure the Executive Director's pay is competitive with the market. An Executive Director's pay is also reviewed on promotion. There are no guaranteed base pay increases included in any Executive Director's contracts. Executive Directors may receive benefits including health insurance or other expense reimbursements.

b. Annual discretionary bonus
The Executive Directors are entitled to receive an annual discretionary bonus of up to 100% of base salary. Bonuses of €300,000 and €50,000 were awarded to the CEO and CFO, respectively, in respect of 2025 (2024: €147,000 and €50,000 respectively).

c. Restricted share unit plan ("RSU")
The Company operates a Restricted Share Unit Plan ("RSU") which was established on 2 July 2019. The scheme was approved by shareholders at the Company's Annual General Meeting on 1 August 2019. The purpose of the Plan is to attract, retain and motivate Directors and employees of Oneview Healthcare PLC, its subsidiaries and affiliates, to provide for competitive compensation opportunities, to encourage long term service, to recognise individual contributions and reward achievement of performance goals and to promote the creation of long-term value for shareholders by aligning the interests of such persons with those of shareholders. Executive Directors, Non-Executive Directors, employees and consultants are eligible to participate in the RSU at the discretion of the Remuneration and Nomination Committee.

d. Employee share option plan ("ESOP")
The Board adopted an Employee Share Option Plan ("ESOP") effective from 1 October 2013. Under the ESOP, options over securities were offered to Executive Directors, Non-Executive Directors, employees and consultants of companies within the Oneview Group. Any offers were made entirely at the discretion of the Remuneration and Nomination Committee. The ESOP expired in October 2023, so no further grants of options were made after this date. There were 773,250 options outstanding at 31 December 2025. No Directors had any outstanding options as at 31 December 2025 (2024: nil).

For personal use only

2. Details of remuneration

Remuneration of Directors

	Short-term benefits							
	Salary & fees	Bonus	Other cash benefits	Sub Total	Post employment benefits	Intrinsic value of share awards[2]	Total 2025	Total 2024
	€		€	€	€	€	€	€
Barbara Nelson	40,817	-	-	40,817	-	85,842	126,659	43,604
Nashina Asaria	40,817	-	-	40,817	-	62,481	103,298	166,303
Mark Cullen	40,817	-	-	40,817	-	84,453	125,270	43,604
Joe Rooney	40,817	-	-	40,817	-	123,454	164,271	43,604
Michael Dowling	3,374	-	-	3,374	-	-	3,374	-
Sub-total – Non-Executive Directors	**166,642**	**-**	**-**	**166,642**	**-**	**356,230**	**522,872**	**297,115**
James Fitter	300,000	300,000	10,474	610,474	11,567	300,447	922,488	475,974
Darragh Lyons	225,000	50,000	1,000	276,000	9,000	50,593	335,593	122,346
Total Executive Directors	**525,000**	**350,000**	**11,474**	**886,474**	**20,567**	**351,040**	**1,258,081**	**598,320**
Total[1]	**691,642**	**350,000**	**11,474**	**1,053,116**	**20,567**	**707,270**	**1,780,953**	**895,435**

1. Excludes employer-based taxes of €21,476 (2024: €12,564).
2. The intrinsic value of share awards is based on the taxable value of RSUs vested during the year.

Options & RSUs

Directors have been awarded restricted stock units under the RSU plan, as highlighted earlier in this report. The fair value charges associated with these awards are as follows:

	2025	2024
	€	€
Barbara Nelson	102,102	71,658
Nashina Asaria	34,570	52,513
Mark Cullen	95,451	82,843
Joe Rooney	54,869	60,170
Michael Dowling	-	-
Subtotal – Non-Executive Directors	**286,992**	**267,184**
James Fitter	575,500	709,336
Darragh Lyons	315,504	75,967
Subtotal – Executive Directors	**891,004**	**785,303**
Total	**1,177,996**	**1,052,487**

Remuneration and Nomination Committee Report
(continued)

For personal use only

3. Service agreements

On appointment to the Board, all Non-Executive Directors enter into a service agreement with the Company in the form of a letter of appointment. The letter summarises the Board policies and terms, including compensation, their roles and responsibilities and Oneview's expectations of them as Non-Executive Directors of the Company.

The terms of employment and remuneration for the Executive Directors are also formalised in service agreements. These agreements provide for the provision of a fixed salary, a discretionary bonus, participation in the Group Restricted Stock Share Plan and other benefits including health insurance.

i. James Fitter, CEO and Executive Director

James Fitter is employed as CEO under an employment contract with a Oneview Group company.

James' remuneration package is comprised of a base salary of €300,000 per annum, an annual discretionary bonus of up to 100% of base salary and participation in the Group Restricted Share Unit Plan (RSU). The terms and conditions of James' bonus and any further awards, including targets and vesting are determined annually by the Remuneration Committee.

James's employment contract may be terminated by Oneview providing at least 6 months' notice in writing. Further, Oneview may terminate the employment of James immediately in certain circumstances for any offence stipulated under Article 120 of the U.A.E. Labour Law including for any act of dishonesty, fraud, wilful disobedience, serious misconduct or serious breach of duty. James may terminate his employment contract by providing at least 6 months' notice in writing before the proposed date of termination. James' employment contract also includes restrictive covenants that operate for a period of 6 months following expiry of the notice period. Enforceability of such restrictions would be subject to all usual legal requirements.

ii. Darragh Lyons, CFO and Executive Director

Darragh Lyons is employed as CFO under an employment contract with Oneview Healthcare Limited.

Darragh's remuneration package is comprised of a base salary of €225,000 per annum, an annual discretionary bonus of up to 100% of base salary and participation in the Group Restricted Share Unit Plan (RSU). The terms and conditions of Darragh's bonus and any further awards, including targets and vesting are determined annually by the CEO and the Remuneration Committee.

Darragh's employment contract may be terminated by Oneview providing at least 3 months' notice in writing. Darragh may terminate his employment contract by providing at least 3 months' notice in writing before the proposed date of termination.

4. Share Based Compensation

a. Employee Share Option Plan (ESOP)

The Board adopted an Employee Share Option Plan (ESOP) effective from 1 October 2013. Under the ESOP, options over shares were offered to Executive Directors, Non-Executive Directors, employees and consultants of companies within the Oneview Group. Any offers were made entirely at the discretion of the Remuneration and Nomination Committee. The ESOP expired in October 2023, so no further grants of options were made after this date. There were 773,250 options outstanding at 31 December 2025. No Director had any outstanding options as at 31 December 2025 (2024: nil).

b. Restricted Stock Share Unit Plan (RSU)

On 2 July 2019, the Company adopted a new Restricted Share Unit Plan (RSU). The scheme was subsequently approved by shareholders at the Company's Annual General Meeting on 1 August 2019. Pursuant to the scheme, the Remuneration and Nominations Committee of the Company's Board of Directors may make an award under the plan to Executive Directors, Non-Executive Directors, employees and consultants. The purpose of the plan is to attract, retain and motivate Directors, employees and consultants of Oneview Healthcare PLC, its subsidiaries and affiliates, to provide for competitive compensation opportunities, to encourage long term service, to recognise individual contributions and reward achievement of performance goals and to promote the creation of long-term value for shareholders by aligning the interests of such persons with those of shareholders.

The RSUs are contracts to issue shares at future vesting periods ranging between 1 year and 3 years, at an award price of €0.001, and are dependent on achievement of performance and service conditions which are set periodically by the Remuneration and Nominations Committee. All awards to Executive Directors and Non-Executive Directors are subject to shareholder approval annually at the Annual General Meeting.

For personal use only

The following movements in RSUs awarded to Directors and Non-Executive Directors occurred:

Award Date	Recipient	No. of RSUs Awarded	Vested During Year	Lapsed During Year	Outstanding At 31 December 2025	Vesting Term	Performance Conditions
26 October 2023	Joe Rooney	470,833	470,833	-	-	1 Year	Continued board appointment
26 October 2023	Nashina Asaria	208,333	208,333	-	-	1 Year	Continued board appointment
26 October 2023	Mark Cullen	312,500	312,500	-	-	1 Year	Continued board appointment
26 October 2023	Barbara Nelson	208,333	208,333	-	-	1 Year	Continued board appointment
26 October 2023	Mark Cullen	869,565	-	-	869,565	3 Years	Continued board appointment
26 October 2023	Barbara Nelson	869,565	-	-	869,565	3 Years	Continued board appointment
26 October 2023	James Fitter	9,000,000	1,000,000	1,000,000	7,000,000	1 - 3 Years	Total Shareholder Return, Contracted Bed Numbers & EBITDA performance targets
31 October 2024	James Fitter	9,000,000	600,000	2,400,000	6,000,000	3 Years	Revenue Targets
31 October 2024	Darragh Lyons	3,000,000	-	-	3,000,000	3 years	Continued Employment
31 October 2024	Darragh Lyons	900,000	300,000	-	600,000	3 years	Revenue Targets
2 December 2024	Joe Rooney	234,375	234,375	-	-	1 Year	Continued board appointment
2 December 2024	Barbara Nelson	312,500	312,500	-	-	1 Year	Continued board appointment
2 December 2024	Mark Cullen	234,375	234,375	-	-	1 Year	Continued board appointment
2 December 2024	Nashina Asaria	156,250	156,250	-	-	1 Year	Continued board appointment
2 December 2025	Joe Rooney	245,901	-	-	245,901	1 Year	Continued board appointment
2 December 2025	Barbara Nelson	327,868	-	-	327,868	1 Year	Continued board appointment
2 December 2025	Mark Cullen	245,901	-	-	245,901	1 Year	Continued board appointment
2 December 2025	Nashina Asaria	163,934	-	-	163,934	1 Year	Continued board appointment
2 December 2025	Darragh Lyons	3,000,000	-	-	3,000,000	3 years	Achievement of key strategic initiatives
Total RSUs awarded to Directors and outstanding at 31 December 2025					22,322,734		

* Chess Unit of Foreign Securities

All RSUs have an award price of €0.001. The RSUs granted to the directors on 2 December 2025 have been approved under ASX Listing Rule 10.14 at Oneview's AGM on 1 December 2025.

On behalf of the Board

Joe Rooney
Chairman of the Remuneration Committee

25 March 2026

Directors' Report

For personal use only

The Directors present their report and the audited consolidated financial statements of Oneview Healthcare PLC and Subsidiaries (the "Group") for the year ended 31 December 2025.

Deeds of access, indemnity and insurance for directors

The Company has entered into agreements to indemnify all Directors of the Company that are listed in page 32 and 33, former Directors of the Company and its controlled entities against all liabilities which arise out of the performance of their normal duties as Directors or Executive Officers, unless the liability relates to conduct involving lack of good faith. The Company has agreed to indemnify the Directors and Executive Officers against all costs and expenses incurred in defending an action that falls within the scope of the indemnity along with any resulting payments, subject to policy limits.

The Directors' and Officers' liability insurance provides cover against costs and expenses, subject to terms and conditions of the policy, involved in defending legal actions and any resulting payments arising from a liability to persons (other than the Company or related entity) incurred in their position as a Director or Executive Officer unless the conduct involves a wilful breach of duty or an improper use of inside information or position to gain advantage.

Political contributions

The Group and Company did not make any disclosable political contributions during the year.

Going concern

Since its inception, the Group has incurred net losses and generated negative cash flows from its operations. To date, it has financed its operations through the sale of equity securities, including its initial public offering of Oneview Healthcare PLC in March 2016 and various equity raisings, the most recent of which occurred in November and December of 2024. As at 31 December 2025, the Group had cash balances of €4.6 million.

Subsequent to year end, in March 2026, the Company announced commitments for a two tranche placement to raise approximately A$19 million (approximately €11.6 million) in gross proceeds through the issuance of 100 million New CDIs at A$0.19 per CDI. Tranche 1 settled on 24 March 2026, raising gross proceeds of A$12 million (approximately €7.3 million). Tranche 2, raising A$7 million (approximately €4.3 million) and involving the Company's largest shareholder, Manderrah Pty Ltd as trustee of the GJJ Family Trust, is subject to shareholder approval at an extraordinary general meeting expected to take place in May 2026. The Company has also launched a security purchase plan (SPP) to raise up to A$2 million (approximately €1.2 million), which will close in April 2026.

The settlement of the first tranche of the placement (net proceeds of approximately A $11.4 million / approximately €7.0 million) increases the Company's cash position to apporximately €10.1m million. The Company will have additional gross proceeds inflows of $9 million (approximately €5.5 million) assuming the Company gains shareholder approval for the second tranche of the placement involving the Company's largest shareholder and if the Company raises A$2 million (approximately €1.2 million) from the SPP.

At the date of signing of the final financial statements, management assessed the Group's ability to continue as a going concern and determined that it expects that its existing cash and other working capital will be sufficient to enable the Group to fund its operating expenses and capital expenditure requirements for a period of at least 12 months from the date of approval of the financial statements. The Group has based this estimate on assumptions that may prove to be wrong, and the Group may use its capital resources sooner than it currently expects.

After making inquiries, including the review of cashflow projections, and considering the uncertainties described above, the Directors have a reasonable expectation that the Company and the Group have adequate resources to continue in operational existence for the foreseeable future. For these reasons, they continue to adopt the going concern basis in preparing the annual financial statements.]

Audit Committee

The Group has established an Audit Committee with responsibility for assisting the board of the Company in fulfilling its corporate governance and oversight responsibilities in relation to the Company's financial reports and financial reporting process and internal control structure, risk management systems (financial and nonfinancial) and the external statutory audit process. The Committee meets on a regular basis to:

- review and approve internal audit and external statutory audit plans;
- review and approve financial reports; and
- review the effectiveness of the Company's compliance and risk management functions.

Statement of directors' responsibilities

The Directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare Group and Company financial statements for each financial year. As required by Australian Securities Exchange Rules, the Directors are required to prepare the Group financial statements in accordance with IFRS as adopted by the EU. The Directors have elected to prepare the Company financial statements in accordance with IFRS as adopted by the EU and as applied in accordance with the Companies Act 2014.

Under company law, the Directors must not approve the Group and Company financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Group and Company and of the Group profit or loss for that year. In preparing each of the Group and Company financial statements, the Directors are required to:

- select suitable accounting policies
- and then apply them consistently;

For personal use only

- make judgements and estimates that are reasonable and prudent;
- state whether applicable Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- assess the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and
- use the going concern basis of accounting unless they either intend to liquidate the Company or to cease operations or have no realistic alternative but to do so.

The Directors are responsible for keeping adequate accounting records which disclose with reasonable accuracy at any time the assets, liabilities, financial position of the Group and Company and the profit and loss of the Group and which enable them to ensure that the financial statements comply with the provision of the Companies Act 2014. The Directors are also responsible for taking all reasonable steps to ensure such records are kept by its subsidiaries which enable them to ensure that the financial statements of the Group comply with the provisions of the Companies Act 2014. They are responsible for such internal controls as they determine are necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have a general responsibility for safeguarding the assets of the Company and the Group, and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The Directors are also responsible for preparing a Directors' report that complies with the requirements of the Companies Act 2014.

Directors' compliance statement

The Directors, in accordance with Section 225(2) of the Companies Act 2014, acknowledge that they are responsible for ensuring the Company's compliance with certain obligations specified in that section arising from the Companies Act 2014, and Tax laws ('relevant obligations'). The Directors confirm that:

- a compliance policy statement has been drawn up setting out the Company's policies with regard to such compliance;
- appropriate arrangements and structures that, in their opinion, are designed to secure material compliance with the Company's relevant obligations, have been put in place; and
- a review has been conducted, during the financial year, of the arrangements and structures that have been put in place to secure the Company's compliance with its relevant obligations.

Relevant audit information

The Directors believe that they have taken all steps necessary to make themselves aware of any relevant audit information and have established that the Group's statutory auditors are aware of that information. In so far as they are aware, there is no relevant audit information of which the Group's statutory auditors are unaware.

Accounting records

To ensure that adequate accounting records are kept in accordance with Sections 281 to 285 of the Companies Act 2014, the Directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the Company's office at Avoca Court, Temple Road, Blackrock, County Dublin, A94 R7W3, Ireland.

Auditor

The auditors, KPMG, were appointed on 31 October 2013. In accordance with Section 383(2) of the Companies Act 2014 the auditors, KPMG, Registered Auditors, will continue in office.

Other Information

Other information relevant to the Directors' Report may be found in the following sections of the annual report:

Information	Location in Annual Report
Board of Directors	Pages 32 to 33
Business review and likely future developments	Chair's Statement & Chief Executive's Reports– Pages 5 to7
Principal Risks and Uncertainties	Risk Management – Pages 25 to 31
Results (including R&D spend)	Financial Statements – Pages 51 to 92; Performance Review – 12 to 16
Corporate Governance Structures	Pages 36 to 38
Directors' Remuneration	Remuneration and Nomination Committee Report – Pages 39 to 43
Interests of the Director and Company Secretary in the share capital of the Company	Financial Statements (note 24) – Pages 90 to 91
Subsidiaries	Financial Statements - Page 92
Events after the Balance Sheet Date	Financial Statements - Page 91

On behalf of the Board



James Fitter
CEO

Darragh Lyons
Chair

25 March 2026

Financial Statements

Independent auditors' report	47
Consolidated statement of total comprehensive income	51
Consolidated statement of financial position	52
Company statement of financial position	53
Consolidated statement of changes in equity	54
Company statement of changes in equity	56
Consolidated statement of cash flows	58
Notes to the consolidated and company financial statements	59
Additional ASX Info	93
Corporate Information	96

For personal use only



Independent Auditor's Report

to the Members of Oneview Healthcare public limited company

For personal use only

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Oneview Healthcare public limited company ('the Company') and its consolidated undertakings ('the Group') for the year ended 31 December 2025 as set out on pages 51 to 92, which comprise the Consolidated statement of total comprehensive income, Consolidated statement of financial position, Company statement of financial position, Consolidated statement of changes in equity, Company statement of changes in equity, Consolidated statement of cash flows and related notes, including the material accounting policies set out in note 1.

The financial reporting framework that has been applied in their preparation is Irish Law and International Financial Reporting Standards (IFRS) as adopted by the European Union and, as regards the Company financial statements, as applied in accordance with the provisions of the Companies Act 2014.

In our opinion:

- the financial statements give a true and fair view of the assets, liabilities and financial position of the Group and Company as at 31 December 2025 and of the Group's loss for the year then ended;
- the Group financial statements have been properly prepared in accordance with IFRS as adopted by the European Union;
- the Company financial statements have been properly prepared in accordance with IFRS as adopted by the European Union, as applied in accordance with the provisions of the Companies Act 2014; and
- the Group and Company financial statements have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We have fulfilled our ethical responsibilities under, and we remained independent of the Group in accordance with ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), as applied to listed entities.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Our evaluation of the director's assessment of the Group's and Company's ability to continue to adopt the going concern basis of accounting included considering the inherent risks to the Group's and Company's business model and analysed how those risks might affect the Group's and Company's financial resources or ability to continue over the going concern period, including assessing the reasonableness of the Group's and Company's revenue targets and expected cash burn.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group or the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Detecting irregularities including fraud

We identified the areas of laws and regulations that could reasonably be expected to have a material effect on the financial statements and risks of material misstatement due to fraud, using our understanding of the entity's industry, regulatory environment and other external factors and inquiry with the directors. In addition, our risk assessment procedures included:

- Inquiring with the directors and other management as to the Group and Company's policies and procedures regarding compliance with laws and regulations, identifying, evaluating and accounting for litigation and claims, as well as whether they have knowledge of non-compliance or instances of litigation or claims.
- Inquiring of directors, the audit committee and other management, and inspection of policy documentation as to the Group and Company's high-level policies and procedures to prevent and detect fraud , including the Group and Company's channel for "whistleblowing", as well as whether they have knowledge of any actual, suspected or alleged fraud.
- Inquiring of directors and other management regarding their assessment of the risk that the financial statements may be materially misstated due to irregularities, including fraud.
- Inspecting the Group and Company's regulatory and legal correspondence.
- Reading Board of director and audit committee minutes.
- Performing planning analytical procedures to identify any unusual or unexpected relationships.

Independent Auditor's Report
to the Members of Oneview Healthcare public limited company (continued)

For personal use only

We discussed identified laws and regulations, fraud risk factors and the need to remain alert among the audit team.

Firstly, the Group and Company are subject to laws and regulations that directly affect the financial statements including companies and financial reporting legislation. We assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items, including assessing the financial statement disclosures and agreeing them to supporting documentation when necessary.

Secondly, the Group and Company are subject to many other laws and regulations where the consequences of non-compliance could have a material effect on amounts or disclosures in the financial statements, for instance through the imposition of fines or litigation. We identified the following areas as those most likely to have such an effect: health and safety, anti-bribery, employment law, environmental law, regulatory capital and liquidity and certain aspects of company legislation recognising the regulated nature of the Group and Company's activities and its legal form.

Auditing standards limit the required audit procedures to identify non-compliance with these non-direct laws and regulations to inquiry of the directors and other management and inspection of regulatory and legal correspondence, if any. These limited procedures did not identify actual or suspected non-compliance.

We assessed events or conditions that could indicate an incentive or pressure to commit fraud or provide an opportunity to commit fraud. As required by auditing standards, we performed procedures to address the risk of management override of controls. On this audit we do not believe there is a fraud risk related to revenue recognition. We did not identify any additional fraud risks.

In response to the fraud risk(s), we also performed procedures including:

- Identifying journal entries and other adjustments to test based on risk criteria and comparing the identified entries to supporting documentation.
- Evaluating the business purpose of significant unusual transactions
- Assessing the disclosures in the financial statements

As the Group and Company is regulated, our assessment of risks involved obtaining an understanding of the legal and regulatory framework that the Group and Company operates and gaining an understanding of the control environment including the entity's procedures for complying with regulatory requirements.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it.

In addition, as with any audit, there remains a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.

Key audit matters: our assessment of risks of material misstatement

Key audit matters are those matters that, in our professional judgement, were of most significance in the audit of the financial statements and include the most significant assessed risks of material misstatement (whether or not due to fraud) identified by us, including those which had the greatest effect on: the overall audit strategy; the allocation of resources in the audit; and directing the efforts of the engagement team. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

In arriving at our audit opinion above, the key audit matters, in decreasing order of audit significance, were as follows (unchanged from 2024):

Group key audit matter

No key audit matters to report for the group.

Company key audit matter

Valuation of Investment in subsidiaries and Intercompany Loans and Receivables €76.5m (2024: €78m).

Refer to page 62 (accounting policy) and pages 72 to 74 (financial disclosures)

For personal use only

The key audit matter	How the matter was addressed in our audit
The Parent Company's investment in subsidiaries and intercompany loans and receivables make up 99% of total assets (by value). We do not consider there to be a significant risk of error related to the Company's investment in subsidiaries and intercompany loans and receivables, or to be subject to a significant level of judgements or estimation due to the Group's market capitalisation at year end. However, due to their materiality in the context of the Company financial statements and as the Group as a whole is currently loss making, they are considered an area of audit focus and of significance to the audit of the financial statements. For the reasons outlined above the engagement team determine this matter to be a key audit matter.	Our audit procedures over the valuation of the investment in subsidiaries and intercompany loans and receivables included, but were not limited to: • obtaining an understanding of the impairment process, including where relevant, the process relating to the development of projected financial information; • assessing the appropriateness of the Company's impairment review, including the consideration of any indicators of impairment, and the assessment of the significant data inputs, such as market capitalisation, against externally derived sources ; • comparing the value of the Parent Company's investment in subsidiaries and intercompany loans and receivables as at 31 December 2025 to the Group's market capitalisation at the same date; • considering the appropriateness of the relevant disclosures in the financial statements, and assessing whether these are in accordance with relevant accounting standards. Based on evidence obtained, we found that management's assessment of the carrying value of the Parent Company investment in subsidiaries and intercompany loans and receivables impairment calculation and related disclosures to be reasonable. In determining the valuation of investment in subsidiaries, intercompany loans and receivables, we found the Company's judgment to be reasonable and the relevant disclosures to be appropriate.

Our application of materiality and an overview of the scope of our audit

Materiality for the Group financial statements and Company financial statements as a whole was set at €0.3m (2024: €0.3m) and €0.3m (2024: €0.3m) respectively, determined with reference to benchmarks of group loss before tax (Group) and net assets of the Company (Company) (of which it represents 3% (2024: 3%) and 0.4% (2024: 0.4%) respectively.

Performance materiality for the Group financial statements and Company financial statements as a whole was set at €0.23m (2024: €0.23m) and €0.23m (2024: €0.23m) respectively, determined with reference to benchmarks of group loss before tax (Group) and net assets of the Company (Company) (of which it represents 3% (2024: 3%) and 0.4% (2024: 0.4%) respectively.

We consider group loss before tax to be the most appropriate benchmark for the Group as it provides a stable measure year on year, given the phase of the Group's development. Net assets are deemed to be the most appropriate benchmark for the parent Company as it is a holding company only that provides financial support to its operating subsidiaries.

We reported to the Audit Committee any corrected or uncorrected identified misstatements exceeding €0.2m (2024: €0.2m), in addition to other identified misstatements that warranted reporting on qualitative grounds.

We applied materiality to assist us to determine what risks were significant risks and the procedures to be performed. Of the group's nine (2024: nine) reporting components, we subjected nine (2024: nine) to full scope audits for group purposes. Our audit procedures covered 100% of Group balances.

Our audit was undertaken to the materiality and performance materiality level specified above and was all performed by a single engagement team in Dublin.

Other information

The directors are responsible for the other information presented in the Annual Report together with the financial statements. The other information comprises the information included in the directors' report and Chairman's Letter, CEO Report, Remuneration Report, Additional ASX Information and Specific Risks (unaudited). The financial statements and our auditor's report thereon do not comprise part of the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except as explicitly stated below, any form of assurance conclusion thereon.

Independent Auditor's Report

to the Members of Oneview Healthcare public limited company (continued)

For personal use only

Our responsibility is to read the other information and, in doing so, consider whether, based on our financial statements audit work, the information therein is materially misstated or inconsistent with the financial statements or our audit knowledge. Based solely on that work we have not identified material misstatements in the other information.

Based solely on our work on the other information undertaken during the course of the audit, we report that:

- we have not identified material misstatements in the directors' report;
- in our opinion, the information given in the directors' report is consistent with the financial statements; and
- in our opinion, those parts of the directors' report specified for our review, which does not include sustainability reporting when required by Part 28 of the Companies Act 2014, have been prepared in accordance with the Companies Act 2014.

Our opinions on other matters prescribed by the Companies Act 2014 are unmodified

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the Company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

We have nothing to report on other matters on which we are required to report by exception

The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by Sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

Respective responsibilities and restrictions on use

Responsibilities of directors for the financial statements

As explained more fully in the directors' responsibilities statement set out on page 42, the directors are responsible for: the preparation of the financial statements including being satisfied that they give a true and fair view; such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error; assessing the Group and Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and using the going concern basis of accounting unless they either intend to liquidate the Group or the Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A fuller description of our responsibilities is provided on IAASA's website at https://iaasa.ie/publications/description-of-the-auditors-responsibilities-for-the-audit-of-the-financial-statements/.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the Company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



John Corrigan
for and on behalf of
KPMG
Chartered Accountants, Statutory Audit Firm
1 Stokes Place
St. Stephen's Green
Dublin 2
D02 DE03

25 March 2026

Consolidated Statement of Total Comprehensive Income

for the year ended 31 December 2025

	Note	2025 €'000	2024 €'000
Continuing Operations			
Revenue	2	**12,001**	9,895
Cost of sales		**(4,327)**	(3,224)
Gross profit		**7,674**	6,671
Other income	5	**37**	-
Sales and marketing expenses		**(3,973)**	(4,034)
Product development and delivery expenses		**(11,466)**	(10,513)
General and administrative expenses		**(3,289)**	(3,482)
Operating loss	3,4	**(11,017)**	(11,358)
Finance charges	6	**(1,546)**	(150)
Finance income	6	**28**	737
Loss before tax		**(12,535)**	(10,771)
Income tax	7	**(53)**	(65)
Loss for the year		**(12,588)**	(10,836)
Attributable to ordinary shareholders		**(12,588)**	(10,836)
Loss per share			
Basic	8	**(0.02)**	(0.02)
Diluted	8	**(0.02)**	(0.02)
Other comprehensive (loss)/gain			
Items that will or may be reclassified to profit or loss			
Foreign currency translation differences on foreign operations (no tax impact)		**564**	(328)
Other comprehensive (loss)/gain, net of tax		**564**	(328)
Total comprehensive loss for the year		**(12,024)**	(11,164)

The total comprehensive loss for the year is entirely attributable to equity holders of the Group.

On behalf of the Board

James Fitter Director

Darragh Lyons Director

25 March 2026

For personal use only

Consolidated Statement of Financial Position
as at 31 December 2025

	Note	2025 €'000	2024 €'000
Non-current assets			
Intangible assets	9	**666**	720
Property, plant and equipment	10	**1,062**	1,132
Research and development tax credit	13	**1,014**	893
		2,742	2,745
Current assets			
Inventories	12	**2,864**	3,147
Trade and other receivables	13	**4,671**	5,291
Contract assets	2	**604**	943
Cash and cash equivalents		**4,602**	13,833
Total current assets		**12,741**	23,214
Total assets		**15,483**	25,959
Equity			
Issued share capital	19	**767**	760
Share premium	19	**147,319**	147,319
Treasury reserve	19	**-**	(3)
Other undenominated capital	19	**4**	4
Translation reserve		**356**	(193)
Reorganisation reserve		**(1,352)**	(1,352)
Share-based payments reserve	18	**2,505**	7,853
Retained earnings		**(145,955)**	(141,139)
Total equity		**3,644**	13,249
Non-current liabilities			
Trade and other payables	15	**1,148**	1,668
Lease liabilities	17	**880**	898
Deferred income	16	**-**	20
Total non-current liabilities		**2,028**	2,586
Current liabilities			
Trade and other payables	14	**9,556**	9,867
Lease liabilities	17	**229**	253
Current income tax liabilities		**26**	4
Total current liabilities		**9,811**	10,124
Total liabilities		**11,839**	12,710
Total equity and liabilities		**15,483**	25,959

On behalf of the Board

James Fitter Director

Darragh Lyons Director

25 March 2026

For personal use only

Company Statement of Financial Position

as at 31 December 2025

	Note	2025 €'000	2024 €'000
Non-current assets			
Financial assets	11	**15,941**	13,859
		15,941	13,859
Current assets			
Trade and other receivables	13	**39,653**	31,833
Loan to group company	13	**21,108**	23,097
Cash and cash equivalents		**312**	11,692
Total current assets		**61,073**	66,622
Total assets		**77,014**	80,481
Equity			
Share capital	19	**767**	760
Share premium	19	**147,319**	147,319
Treasury reserve	19	**-**	(3)
Other undenominated capital	19	**4**	4
Share based payment reserve	18	**2,505**	7,853
Retained earnings		**(75,367)**	(77,899)
Total equity		**75,228**	78,034
Non-current liabilities			
Trade and other payables	15	**167**	237
Total non-current liabilities		**167**	237
Current liabilities			
Trade and other payables	14	**1,619**	2,210
Total current liabilities		**1,619**	2,210
Total liabilities		**1,786**	2,447
Total equity and liabilities		**77,014**	80,481

On behalf of the Board

James Fitter Director

Darragh Lyons Director

25 March 2026

For personal use only

Consolidated Statement of Changes in Equity

for the year ended 31 December 2024

	Share capital €'000	Share premium €'000	Treasury reserve €'000	Other undenominated capital €'000	Reorganisation reserve €'000	Share based payment reserve €'000	Translation reserve €'000	Retained loss €'000	Total equity €'000
As at 1 January 2024	**671**	**134,082**	**(3)**	**4**	**(1,352)**	**7,218**	**172**	**(131,654)**	**9,138**
Loss for the year	-	-	-	-	-	-	-	(10,836)	(10,836)
Foreign currency translation	-	-	-	-	-	-	(365)	37	(328)
Total comprehensive loss	-	-	-	-	-	-	**(365)**	**(10,799)**	**(11,164)**
Transactions with shareholders									
Issue of ordinary shares	79	13,237	-	-	-	-	-	-	13,316
Vesting of restricted share unit awards	10	-	-	-	-	(1,324)	-	1,314	-
Share based compensation to employees	-	-	-	-	-	1,657	-	-	1,657
Share based compensation to non-employees	-	-	-	-	-	302	-	-	302
As at 31 December 2024	**760**	**147,319**	**(3)**	**4**	**(1,352)**	**7,853**	**(193)**	**(141,139)**	**13,249**

For personal use only

Consolidated Statement of Changes in Equity

for the year ended 31 December 2025

	Share capital €'000	Share premium €'000	Treasury reserve €'000	Other undenominated capital €'000	Reorganisation reserve €'000	Share based payment reserve €'000	Translation reserve €'000	Retained earnings €'000	Total equity €'000
As at 1 January 2025	**760**	**147,319**	**(3)**	**4**	**(1,352)**	**7,853**	**(193)**	**(141,139)**	**13,249**
Loss for the year	-	-	-	-	-	-	-	(12,588)	(12,588)
Foreign currency translation	-	-	-	-	-	-	549	15	564
Total comprehensive loss	-	-	-	-	-	-	549	(12,573)	(12,024)
Transactions with shareholders									
Issue of ordinary shares	-	-	-	-	-	-	-	-	-
Exercise of options	0	-	-	-	-	-	-	-	0
Share cancellation	(2)	-	2	-	-	-	-	-	-
Transfer to accumulated losses in respect of expired restricted share unit awards	-	-	1	-	-	(6,182)	-	6,181	-
Share based payment compensation to employees	-	-	-	-	-	2,082	-	-	2,082
Share based payment compensation to non-employees	-	-	-	-	-	337	-	-	337
Vesting of restricted share unit awards	9	-	-	-	-	(1,585)	-	1,576	-
As at 31 December 2025	**767**	**147,319**	**-**	**4**	**(1,352)**	**2,505**	**356**	**(145,955)**	**3,644**

For personal use only

Company Statement of Changes in Equity

for the year ended 31 December 2024

	Share capital €'000	Share premium €'000	Treasury reserve €'000	Other undenominated capital €'000	Share based payment reserve €'000	Retained earnings €'000	Total equity €'000
As at 1 January 2024	**671**	**134,082**	**(3)**	**4**	**7,218**	**(81,152)**	**60,820**
Profit and total comprehensive income for the year	-	-	-	-	-	1,939	1,939
Transactions with shareholders							
Issue of ordinary shares	79	13,237	-	-	-	-	13,316
Issue of ordinary shares as consideration for services	-	-	-	-	-	-	-
Vesting of restricted share unit awards	10	-	-	-	(1,324)	1,314	-
Share based compensation to employees	-	-	-	-	1,657	-	1,657
Share based compensation to non-employees	-	-	-	-	302	-	302
As at 31 December 2024	**760**	**147,319**	**(3)**	**4**	**7,853**	**(77,899)**	**78,034**

For personal use only

Company Statement of Changes in Equity

for the year ended 31 December 2025

	Share capital €'000	Share premium €'000	Treasury reserve €'000	Other undenominated capital €'000	Share based payment reserve €'000	Retained earnings €'000	Total equity €'000
As at 1 January 2025	**760**	**147,319**	**(3)**	**4**	**7,853**	**(77,899)**	**78,034**
Profit and total comprehensive income for the year	-	-	-	-	-	**(5,225)**	**(5,225)**
Transactions with shareholders							
Issue of ordinary shares	-	-	-	-	-	-	-
Exercise of options	**0**	-	-	-	-	-	**0**
Share Cancellation	**(2)**	-	**2**	-	-	-	-
Transfer to retained earnings in respect of expired restricted share units	-	-	**1**	-	**(6,182)**	**6,181**	-
Vesting of restricted share unit awards	**9**	-	-	-	**(1,585)**	**1,576**	-
Share based compensation to employees	-	-	-	-	**2,419**	-	**2,419**
Share based compensation to non-employees	-	-	-	-	-	-	-
As at 31 December 2025	**767**	**147,319**	-	**4**	**2,505**	**(75,367)**	**75,228**

For personal use only

Consolidated Statement of Cash Flows

for the year ended 31 December 2025

	Note	2025 €'000	2024 €'000
Cash flows from operating activities			
Receipts from clients		**12,592**	9,471
Payments to employees and suppliers, net		**(21,421)**	(19,637)
Finance charges paid		**(25)**	(208)
Interest received		**28**	-
Research and development tax credit received		**444**	-
Government grant received		**37**	-
Income tax paid		**(22)**	(91)
Net cash used in operating activities	22	**(8,367)**	(10,465)
Cash flows from investing activities			
Purchase of property, plant and equipment	10	**(58)**	(55)
Acquisition of intangible assets	9	**(59)**	(405)
Net cash used in investing activities		**(117)**	(460)
Cash flows from financing activities			
Proceeds from issue of shares		**-**	13,316
Repayment of lease liabilities	21	**(296)**	(179)
Net cash provided by/(used in) financing activities		**(296)**	13,137
Net increase/(decrease) in cash held		**(8,780)**	2,212
Foreign exchange impact on cash and cash equivalents		**(451)**	72
Cash and cash equivalents at beginning of financial year		**13,833**	11,549
Cash and cash equivalents at end of financial year		**4,602**	13,833

For personal use only

Notes to the Consolidated and Company Financial Statements

1. Accounting policies – Group and Company

Reporting entity

Oneview Healthcare PLC ("OHP" or "the Company") is domiciled in Ireland with its registered office at 2nd Floor, Avoca Court, Temple Road, Blackrock, County Dublin (company registration number 513842). The consolidated financial information of OHP as set out for the year ended 31 December 2025 comprises OHP and its subsidiary undertakings (together the "Group"). OHP was incorporated in 2012 to implement a holding company structure, following which OHP became the parent of Oneview Limited. The 2012 reorganisation has been accounted for on a continuity basis. Any residual balances arising from that reorganisation are disclosed in Note 19.

Statement of compliance

The Group financial statements and the Company financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union (EU) that are effective for the year ended 31 December 2025. The directors have elected to prepare the Company financial statements in accordance with IFRS as adopted by the EU and as applied in accordance with the Companies Act 2014. The Companies Act 2014 permits a company that presents its individual financial statements together with its consolidated financial statements to take an exemption from publishing the Company's income statement, statement of comprehensive income and statement of cash flows which forms part of the Company financial statements prepared and approved in accordance with the Act. The Company reported a loss for the year ended 31 December 2025 of €5.3 million (2024 profit: €1.9 million).

Going concern

Since its inception, the Group has incurred net losses and generated negative cash flows from its operations. To date, it has financed its operations through the sale of equity securities, including its initial public offering of Oneview Healthcare PLC in March 2016 and equity raisings since then. As at 31 December 2025, the Group had cash balances of €4.6 million.

Subsequent to year end, in March 2026, the Company announced commitments for a two tranche placement to raise approximately A$19 million (approximately €11.6 million) in gross proceeds through the issuance of 100 million New CDIs at A$0.19 per CDI. Tranche 1 settled on 24 March 2026, raising gross proceeds of A$12 million (approximately €7.3 million). Tranche 2, raising A$7 million (approximately €4.3 million) and involving the Company's largest shareholder, Manderrah Pty Ltd as trustee of the GJJ Family Trust, is subject to shareholder approval at an extraordinary general meeting expected to take place in May 2026. The Company has also launched a security purchase plan (SPP) to raise up to A$2 million (approximately €1.2 million), which will close in April 2026.

The settlement of the first tranche of the placement (net proceeds of approximately A$11.4 million / approximately €7.0 million) increases the Company's cash position to approximately €10.1 million. The Company will have additional gross proceeds inflows of $9 million (approximately €5.5 million) assuming the Company gains shareholder approval for the second tranche of the placement involving the Company's largest shareholder and if the Company raises A$2 million (approximately €1.2 million) from the SPP.

At the date of signing of the final financial statements, management assessed the Group's ability to continue as a going concern and determined that it expects that its existing cash, the additional proceeds expected to be received from the second tranche of the placement and the SPP, as well as other working capital will be sufficient to enable the Group to fund its operating expenses and capital expenditure requirements for a period of at least 12 months from the date of approval of the financial statements. The Group has based this estimate on assumptions that may prove to be wrong, and the Group may use its capital resources sooner than it currently expects.

After making inquiries, including the review of cashflow projections, and considering the uncertainties described above, the Directors have a reasonable expectation that the Company and the Group have adequate resources to continue in operational existence for the foreseeable future. For these reasons, they continue to adopt the going concern basis in preparing the annual financial statements.

Adoption of IFRS and International Financial Reporting Interpretations Committee (IFRIC) Interpretations

The following new standards, interpretations and standard amendments became effective for the Group as of 1 January 2025:

- Lack of Exchangeability – Amendments to IAS 21 (effective from 1 January 2025)

Standards issued but not yet effective

A number of new standards are effective for annual periods beginning after 1 January 2026 and earlier application is permitted; however, the Group has not early adopted the new or amended standards in preparing these consolidated financial statements. The following amended standards and interpretations are not expected to have a significant impact on the Group's consolidated financial statements:

- Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7 (effective from 1 January 2026)
- Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7 (effective from 1 January 2026)
- Annual Improvements to IFRS Accounting Standards – Volume 11 (effective from 1 January 2026)
- IFRS 18 Presentation and Disclosure in Financial Statements – (effective from 1 January 2027)
- IFRS 19 Subsidiaries without Public Accountability: Disclosures (effective from 1 January 2027)
- Sale or Contribution of Assets between and Investor and its Associate or Joint Venture – Amendments to IFRS 10 and IAS 28 (effective date to be determined)

For personal use only

Notes to the Consolidated and Company Financial Statements (continued)

1. Accounting policies – Group and Company (continued)

Use of estimates and judgements

The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Judgements

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the consolidated financial statements is included in the following note:

- Trade and other receivables (note 13)
- Leases (note 17 and 21)

Assumptions and estimation uncertainties

Information about assumptions and uncertainties as at 31 December 2025 that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities in the next financial year is included in the following notes:

- Financial assets – Company (note 11)
- Parent company asset carrying values (note 13)

(a) Basis of consolidation

The Group financial statements consolidate the financial statements of Oneview Healthcare PLC and its subsidiaries.
Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the power to affect those returns through its power over the entity.

Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases. Financial statements of subsidiaries are prepared for the same reporting year as the Company and where necessary, adjustments are made to the results of subsidiaries to bring their accounting policies into line with those used by the Group.

(b) Transactions eliminated on consolidation

All inter-company balances and transactions, including unrealised profits arising from intra-Group transactions, have been eliminated in full. Unrealised losses are eliminated in the same manner as unrealised gains except to the extent that there is evidence of impairment.

(c) Investments in subsidiaries

In the Company's financial statements, investments in subsidiaries are carried at cost less any provision made for impairment.

(d) Translation of foreign currencies

The presentation currency of the Group and Company is euro (€). The functional currency of the Company is euro. Results of non-euro denominated subsidiaries are translated into euro at the actual exchange rates at the transaction dates or average exchange rates for the year where this is a reasonable approximation. The related statements of financial position are translated at the rates of exchange ruling at the reporting date. Adjustments arising on translation of the results of non-euro subsidiaries at average rates, and on the restatement of the opening net assets at closing rates, are dealt with in a separate translation reserve within equity.

Transactions in currencies different to the functional currencies of operations are recorded at the rate of exchange ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the functional currency at the rate of exchange at the reporting date. All translation differences are taken to the income statement through the finance expense line.

Intercompany loans from the Company to subsidiaries that are denominated in the subsidiary's functional currency but not in the functional currency of the Company are treated as monetary items in the Company's separate financial statements. As a result, these balances are retranslated at each reporting date, with the resulting foreign exchange gains or losses recognised in the consolidated income statement. At the subsidiary level, no foreign exchange differences arise as the balances are denominated in its functional currency.

For personal use only

For personal use only

1. Accounting policies – Group and Company (continued)

(e) Revenue

The Group's revenue consists primarily of revenues from its client contracts with healthcare providers for the provision and support of the Oneview Solution. Revenue comprises the fair value of the consideration received or receivable for the sale of products and services in the ordinary course of the Group's activities. Revenue is shown net of value-added-tax (VAT) and discounts. The Group recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and when specific criteria have been met for each of the Group's activities as described below. Where a performance obligation is satisfied but the client has not yet been billed, this is recognised as a deferred contract asset. When consideration is received in advance of work being performed, or amounts billed to a client are in excess of revenue recognised on the contract, this is recognised as deferred income.

i. Software usage and content

Software usage and content revenue is earned from the use of the Group's solution by its clients. Revenue is earned by charging a fee based on the number of endpoints for which the Oneview solution is installed and is charged on a daily basis. This daily charge may vary depending on the level of functionality and content provided.

Contracts for the use of the Oneview solution are typically three to five years in duration with fees typically billable annually in advance. Software usage and content revenue are recognised on a daily basis.

Revenue is recognised rateably over the life of the contract and commences following completion of user acceptance testing (UAT) by the client.

ii. Support income

Support income relates to email and remote support, bug fixes and unspecified software updates and upgrades released during the maintenance term. Support services for hardware relates to phone and/or onsite support. The level of support varies depending on the contract.

The Group receives an annual fee, payable in advance, for hardware and software support services and is recognised on a daily basis over the term of the contract. The fee is based on the number of devices on which the Oneview solution is installed.

iii. License fees

License fees represent an upfront access license fee, payable in advance. The fee is based on the number of devices for which the Oneview solution is installed. The license fee is recognised over the life of the original contract term, typically three to five years, as the upfront delivery of the license does not have stand-alone value to the client. There is no stand-alone value as the license cannot be used on its own without customisation or implementation. The licence is a right to access and future upgrades are necessary for the client to retain continued functionality of the software.

iv. Hardware

Hardware revenue is earned from fees charged to clients for the hardware supplied to operate the Oneview solution. The Group is deemed to act as the principal to an arrangement when it controls a promised good or service before transferring it to a client. Where the Group acts as the principal in the supply of hardware, hardware revenue is recognised gross upon delivery of the hardware to the client. Where the Group acts as an agent in the supply of hardware, the fee paid to the Group is recognised when earned, per the terms of the contract. Revenue from hardware in the years presented in the financial statements is recognised on a gross basis because the Group has acted as the principal.

v. Services income

Installation and professional services revenue is earned from fees charged to deploy or upgrade the Oneview solution and install hardware at client sites. If the service is on a contracted time and material basis, then the revenue is recognised as and when the services are performed. If it is a fixed fee, then the professional services revenue is recognised by reference to the stage of completion accounting method. The Group measures percentage of completion based on labour hours incurred to date as a proportion of total hours allocated to the contract, or for installation of hardware based on units installed as a proportion of the total units to install. If circumstances arise that may change the original estimates of revenues, costs or extent of progress toward completion, estimates are revised. These revisions may result in increases or decreases in estimated revenues or costs and are reflected in the period in which the circumstances that give rise to the revision become known by management.

Notes to the Consolidated and Company Financial Statements (continued)

1. Accounting policies – Group and Company (continued)

(f) Income tax

Income tax expense in the income statement represents the sum of income tax currently payable and deferred income tax.

Income tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and further excludes items that are not taxable or deductible. The Group's liability for income tax is calculated using rates that have been enacted or substantively enacted at the reporting date. Income tax is recognised in the income statement except to the extent that it relates to items recognised directly in other comprehensive income or equity.

Deferred income tax is provided, using the liability method, on all differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes except those arising from non-deductible goodwill or on initial recognition of an asset or liability which affects neither accounting nor taxable profit.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is expected to be realised or the liability to be settled. Deferred tax assets are recognised for all deductible differences, carry forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilised. The carrying amount of deferred income tax assets is reviewed at each reporting date and derecognised to the extent that it is no longer probable that sufficient taxable profit would be available to allow all or part of the deferred income tax asset to be utilised.

(g) Property, plant and equipment

Property, plant and equipment are stated at cost, less accumulated depreciation and impairment losses.

Depreciation is calculated on a straight line basis over the estimated useful life of the asset and is recognised in the statement of total comprehensive income. Depreciation methods and useful lives are reassessed at each reporting date. The estimated useful lives for additions during the current period are as follows:

Fixtures, fittings and equipment	10% - 33% straight line
Land and buildings	2 – 7 years

Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognised net through profit or loss in the consolidated statement of total comprehensive income.

The carrying values of property, plant and equipment are reviewed for indicators of impairment at each reporting date and are subject to impairment testing when events or changes in circumstances indicate that the carrying values may not be recoverable.

(h) Intangible assets

Computer software

Acquired computer software licenses are capitalised on the basis of the costs incurred to acquire and bring to use the specific software. These costs are amortised over their estimated useful lives of three to five years.

Internally generated intangible assets – research and development

Expenditure on research activities undertaken with the prospect of gaining new technical knowledge and understanding is recognised in the income statement as an expense as incurred. Expenditure on development activities, whereby research findings are applied to a plan or design for new or substantially improved products or processes is capitalised if the product or process is (i) technically and commercially feasible; (ii) future economic benefits are probable; and (iii) the company intends to and has sufficient resources to complete the development. Capitalised expenditure includes direct labour and an appropriate proportion of overheads. Other development expenditure is recognised through profit or loss in the consolidated income statement as an expense as incurred. Capitalised development expenditure is stated at cost less accumulated amortisation and impairment losses.

For personal use only

For personal use only

1. Accounting policies – Group and Company (continued)

Amortisation is recognised through profit or loss in the consolidated statement of comprehensive income on a straight-line basis over the estimated useful lives of intangible assets and amortisation commences in the year of capitalisation, as this best reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows:

Capitalised development costs	5 years	straight line

Amortisation methods, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate.

The carrying values of intangible assets are reviewed for indicators of impairment at each reporting date and are subject to impairment testing when events or changes in circumstances indicate that the carrying values may not be recoverable.

(i) Government grants

The Group recognises government grants related to capitalised development costs in the form of research and development (R&D) tax credits in Ireland and other government grants. Government grants are initially recognised as deferred income at fair value, if there is reasonable assurance that they will be received. They are then recognised through profit or loss as a deduction from wages and salaries costs on a systematic basis over the useful life of the asset. Grants that compensate the Group for expenses incurred are recognised through profit or loss on a systematic basis in the periods in which the expenses are recorded.

(j) Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. Where ordinary shares are repurchased by the company they are cancelled or held as treasury shares and the nominal value of the shares is transferred to an undenominated capital reserve fund within equity.

(k) Cash and cash equivalents

Cash and cash equivalents comprise cash balances and cash deposits with an original maturity of three months or less.

(l) Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is based on the first-in/first-out principle and includes all expenditure incurred in acquiring the inventories and bringing them to their present location and condition.

Net realisable value is the estimated proceeds of sale, less all further costs to completion, and less all costs to be incurred in marketing, selling and distribution. Estimates of realisable value are based on the most reliable evidence available at the time the estimates are made.

(m) Employee Benefits

Defined contribution plans and other long term employee benefits

A defined contribution plan is a post-employment benefit plan under which the company pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution retirement benefit plans are recognised as an expense in the profit and loss account in the periods during which services are rendered by employees.

Share based payments

The grant date fair value of share-based payment awards granted to employees is recognised as an employee expense, with a corresponding increase in equity, over the period in which the performance conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award ('vesting date'). The fair value of the awards granted is measured at grant date based on an observable market price using an option valuation model, taking into account the terms and conditions upon which the awards were granted. The amount recognised as an expense is adjusted to reflect the actual number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognised as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions or market conditions, the grant date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes.

Notes to the Consolidated and Company Financial Statements (continued)

1. Accounting policies – Group and Company (continued)

Restricted stock share unit plan (RSU)
In 2019, the Company adopted a new Restricted Share Unit Plan ('RSU') to replace the existing Restricted Stock Share Plan. The total amount to be expensed over the vesting period is determined by reference to the fair value of the awards granted. At each reporting date, the estimate of the number of awards that are expected to vest is revised. The impact of the revision of original estimates, if any, is recognised in the income statement, with a corresponding adjustment to equity. The total expense is recognised over the vesting period which is the period over which all the specified vesting conditions are satisfied.

(n) Finance income and finance costs
The Group's finance income and finance costs include:
- interest income
- interest expense
- lease interest expense
- foreign currency translation gain/loss
- bank charges

Interest income or expense is recognised using the effective interest method.

(o) Financial instruments
All recognised financial assets that are within the scope of IFRS 9 are required to be subsequently measured at amortised cost or fair value on the basis of the entity's business model for managing the financial assets and the contractual cash flow characteristics of the financial assets.

The Group does not hold any financial assets which meet the criteria for classification at fair value reported in other comprehensive income or fair value reported in profit and loss.

Impairment of financial assets
In relation to the impairment of financial assets, the Group applies an expected credit loss model (ECL). The expected credit loss model requires the Group to account for expected credit losses and changes in those expected credit losses at each reporting date to reflect changes in credit risk since initial recognition of the financial assets. In respect of trade receivables, the Group applies the simplified approach to measuring expected credit losses using a lifetime expected loss allowance.

The Company applies the general approach in calculating ECLs on its intercompany loans. Where the recoverable amount of the investment in subsidiaries is less than the carrying amount, an impairment loss is recognised. As there was an indicator of a significant increase in credit risk as a result of negative cash flows and net liabilities in certain subsidiary undertakings, the Company has provided for impairment losses. No increase in this provision was recognised during 2025 (2024: €Nil).

Financial liabilities
Financial liabilities are classified as either financial liabilities at fair value through profit or loss or other financial liabilities. Financial liabilities are classified as at fair value through profit or loss if the financial liability is either held for trading or it is designated as such upon initial recognition.

(p) Contract assets
Contract assets include accrued revenue and Work in Progress assets. A contract asset is recognised when a performance obligation is satisfied (and revenue recognised), but the payment conditions relate to the Group's fulfilment of other performance obligations in the contract. Accrued revenue is different from trade receivables, because trade receivables represent an unconditional right to receive payment.

(q) Deferred income
Deferred income relates to advance consideration received from clients for which revenue is recognised in line with the Group's accounting policy.

(r) Leases
The Group recognises a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset comprises the initial amount of the lease liability, adjusted for any lease payments made at or before the commencement date, plus any initial direct costs. The right of use asset is subsequently measured at initial cost less any accumulated depreciation and impairment losses and adjusted for any remeasurements of the lease liability.

For personal use only

For personal use only

1. Accounting policies – Group and Company (continued)

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease, or if that rate cannot be readily determined, the Group's incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate. A discount rate of 7% is used for leases entered into before 2023 and a discount rate of 11% is used for leases entered into during and after 2023, which the Group considers to be its incremental borrowing rate, to calculate the present value of lease commitments.

The lease liability is subsequently increased by the interest cost on the lease liability and decreased by lease payments made. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, a change in the estimate of the amount expected to be payable under a residual value guarantee, or as appropriate, changes in the assessment of whether a purchase or extension option is reasonably certain to be exercised or a termination option is reasonably certain not to be exercised.

Lease commitments are recognised as a liability and a right-of-use asset on the Group's consolidated statement of financial position. A right-of-use asset has been capitalised on the Group's consolidated statement of financial position. This right-of-use asset is depreciated over the term of the lease as an operating expense, with an associated finance cost applied annually to the lease liability, in the Group's consolidated statement of comprehensive income.

The Group has applied judgment to determine the lease term for some lease contracts which include renewal options in which it is a lessee. The assessment of whether the Group is reasonably certain to exercise such options impacts the lease term, which significantly affects the amount of lease liabilities and right-of-use assets recognised. The Group has also applied judgment to determine the appropriate discount rate.

2. Segment information

The Group is managed as a single business unit engaged in the provision of interactive patient care and accordingly operates in one reportable segment which provides a patient engagement solution for the healthcare sector.

Our operating segment is reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The CODM has been identified as our executive management team. The executive management team comprises the CEO, CFO, Chief Operating Officer (COO) and Chief Product Officer (CPO). The CODM assess the performance of the business, and allocates resources, based on the consolidated results of the company.

Revenue by type and geographical region is as follows:

	2025 €'000	2024 €'000
Recurring revenue:		
Software usage and content	**5,246**	4,615
Support income	**2,315**	2,391
Licence fees	**90**	170
	7,651	7,176
Non-recurring revenue:		
Hardware	**2,845**	1,558
Services income	**1,505**	1,161
	4,350	2,719
Total revenue	**12,001**	9,895

Notes to the Consolidated and Company Financial Statements
(continued)

2. Segment information (continued)

	2025 €'000	2024 €'000
Revenue attributable to country of domicile and other material countries		
Ireland (country of domicile)	**704**	547
United States	**8,814**	6,243
Australia	**2,040**	2,638
Asia	**443**	430
Middle East	**-**	37
Total revenue	**12,001**	9,895

Major clients
Revenues from client A totalled €2,498k (2024: €1,767k) and represented 21% (2024: 18%) of total revenues. Revenues from Client B totalled €1,856k (2024: €1,373k) and represented 15% (2024: 14%) of total revenue. Revenues from Client C totalled €1,399k (2024: €1,133k) and represented 12% (2024: 11%) of total revenue

Receivables, contract assets and contract liabilities from contracts with clients:	2025 €'000	2024 €'000
Receivables, which are included in 'trade and other receivables'	**3,398**	3,305
Contract assets	**604**	943
Deferred income	**(5,436)**	(5,018)

The contract assets primarily relate to the Group's rights to consideration for work completed but not billed at the reporting date and consists of accrued revenue and Work in Progress assets. The contract assets are located outside of the country of domicile, primarily in the US. Accrued revenues are transferred to receivables and Work in Progress assets are released to the profit and loss when the rights become unconditional. This usually occurs when the Group issues an invoice to the client.

	2025 €'000	2024 €'000
Balance at start of year	**943**	431
Transfers from Accrued Revenue recognised at the beginning of the year to receivables	**(88)**	(102)
Increase in Work in Progress as a result of changes in the measure of progress	**(542)**	526
Increase in Accrued Revenue as a result of additions in the year	**291**	88
Balance at end of year	**604**	943

The deferred income primarily relates to the Group's performance obligations for work billed but not completed at the reporting date.

For personal use only

2. Segment information (continued)

	2025 €'000	2024 €'000
Balance at start of year	**5,018**	4,862
Transfers from deferred income at the beginning of the year to profit or loss	**(3,748)**	(4,850)
Increase as a result of additions in the year	**4,166**	5,006
Balance at end of year	**5,436**	5,018

3. Statutory and other information

Loss before tax for the year has been arrived at after charging / (crediting):

	2025 €'000	2024 €'000
Amortisation of capitalised development costs	**165**	159
Depreciation of property, plant and equipment	**333**	366
Foreign exchange loss / (gain)	**1,409**	(605)

4. Employee numbers and benefits expense

The average number of permanent full-time persons (including executive directors) employed by the Group during the year was 96 (2024: 96).

	2025 Number	2024 Number
Administrative	**12**	10
Product development and delivery	**69**	73
Sales and marketing	**15**	13
	96	96

The staff costs (inclusive of directors' salaries) comprise:	2025 €'000	2024 €'000
Wages and salaries	**9,228**	9,453
Social welfare costs	**980**	972
Share based payments (note 18)	**2,419**	1,959
Defined contribution retirement benefit charge and disability payments	**305**	327
Termination costs	**177**	-
	13,109	12,711

Included within the defined contribution retirement benefit charge and disability payments for 2025 is a provision for a disability payment to a former executive, which the Company will continue to pay until the earlier of his return to work or his retirement.

For personal use only

Notes to the Consolidated and Company Financial Statements (continued)

4. Employee numbers and benefits expense (continued)

Directors' Remuneration

	2025 €'000	2024 €'000
Short-term employee benefits	**1,053**	700
Post-employment benefits	**21**	23
Intrinsic value on vesting	**707**	123
Total compensation	**1,781**	846

The share based payment fair value charge in respect of key management personnel for the year ended 31 December 2025 was €1,377k (2024: €1,117k).

Key management personnel are deemed to be comprised of all board members, the Chief Product Officer and the Chief Operating Officer. Total remuneration for key management personnel in 2025 was €2,323k (2024: €1,742k) which comprised of (i) Short-term employee benefits of €1,494k (2024: €1,216k) (ii) Post-employment benefits of €43k (2024:€80k) and (iii) Share-based payments of €786k (2024: €446k).

5. Other income

The grant income recognised during the year relates to funding provided for the implementation of NIS 2 and SOC 2 compliance measures. The grant has been recognised as income in accordance with applicable accounting standards.

6. Finance (charges) / income

	2025 €'000	2024 €'000
Bank charges	**(25)**	(20)
Foreign exchange loss	**(1,409)**	-
Interest charge on lease liabilities	**(112)**	(130)
Finance charges	**(1,546)**	(150)
Foreign exchange gain	**-**	605
Interest income	**28**	132
Finance income	**28**	737

The foreign exchange loss is comprised of an intercompany foreign currency loss of approximately €1.0 million on the translation of a US dollar-denominated intercompany loan, with the balance attributable to trading foreign currency losses due to the depreciation of both the Australian Dollar and U.S. Dollar against the Euro during 2025.

For personal use only

7. Income tax

The components of the income tax charge for the years ended 31 December 2025, and 2024 were as follows:

	2025 €'000	2024 €'000
Current tax expense		
Foreign tax for the year	**(53)**	(65)
Income tax (charge)/credit in Consolidated statement of total comprehensive income	**(53)**	(65)

Reconciliation of effective tax rate

A reconciliation of the expected tax credit, computed by applying the standard Irish tax rate to loss before tax to the actual tax credit, is as follows:

	2025 €'000	2024 €'000
Loss before tax	**(12,535)**	(10,771)
Irish standard tax rate	**12.5%**	12.5%
Tax at Irish standard tax rate	**(1,567)**	(1,347)
Tax effect of permanent items	**695**	(161)
Losses for which no deferred tax is recognised	**827**	1,391
Effect of foreign tax	**42**	56
Income taxed at higher rate	**62**	123
Non-taxable losses/(profits)	**(6)**	3
Total tax charge/(credit)	**53**	65

No tax charge has been credited or charged directly to other comprehensive income or equity.

The company has an unrecognised deferred tax asset carried forward of €16,821k (31 December 2024: €16,134k). The deferred tax asset relates to Ireland and therefore has no expiry date. As the Company has a history of losses, a deferred tax asset will not be recognised until the company can predict future taxable profits with sufficient certainty.

For personal use only

Notes to the Consolidated and Company Financial Statements (continued)

7. Income tax (continued)

The unrecognised deferred tax asset at 31 December 2025 and 2024 was comprised as follows:

	2025 €'000	2024 €'000
Unrecognised deferred tax asset		
Net operating losses carried forward	**15,990**	14,743
Differences taxable in future periods	**748**	(242)
PPE and intangible assets temporary differences	**(7)**	235
Excess management expenses	**90**	1,398
Total unrecognised deferred taxation asset	**16,821**	16,134

8. Earnings per share

	2025 €'000	2024 €'000
Basic earnings per share		
Loss attributable to ordinary shareholders	**(12,588)**	(10,836)
Weighted average number of ordinary shares outstanding (i)	**765,103**	684,418
Basic loss per share	**(0.02)**	(0.02)

	2025 No. ('000)	2024 No. ('000)
(i) Weighted-average number of ordinary shares (basic)		
Issued ordinary shares at 1 January	**760,495**	671,482
Effect of shares issued	**4,608**	12,936
Weighted average number of ordinary shares at 31 December	**765,103**	684,418

Basic loss per share is calculated by dividing the loss for the year after taxation attributable to ordinary shareholders by the weighted average number of ordinary shares in issue during the year.

For personal use only

8. Earnings per share (continued)

	2025	2024
	€	€
Diluted earnings per share		
Loss attributable to ordinary shareholders	**(12,588)**	(10,836)
Weighted average number of ordinary shares outstanding (i)	**765,103**	684,418
Diluted loss per share	**(0.02)**	(0.02)

	2025	2024
	No. ('000)	No. ('000)
(i) Weighted-average number of ordinary shares (diluted)		
Issued ordinary shares at 1 January	**760,495**	671,482
Effect of shares issued	**4,608**	12,936
Weighted average number of ordinary shares at 31 December	**765,103**	684,418

The calculation of diluted earnings per share has been based on the loss attributable to ordinary shareholders and weighted-average number of ordinary shares outstanding after adjustments for the effects of all dilutive ordinary shares. Potential ordinary shares are treated as dilutive when, and only when, their conversion to ordinary shares would decrease EPS or increase the loss per share from continuing operations. As the company is loss making, there is no difference between the basic and diluted earnings per share. The number of ordinary shares, including potentially dilutive shares at 31 December 2025 is 809,856,555 (2024: 792,503,329). The weighted average number of ordinary shares, including potentially dilutive shares, is 807,729,148 (2024: 716,426,845).

For personal use only

Notes to the Consolidated and Company Financial Statements
(continued)

9. Intangible assets

	Software	Development Costs	Total
	€'000	€'000	€'000
Cost			
At 1 January 2024	239	5,599	5,838
Additions	43	362	405
At 31 December 2024	**282**	**5,961**	**6,243**
At 1 January 2025	282	5,961	6,243
Additions	72	56	128
At 31 December 2025	**354**	**6,017**	**6,371**
Accumulated amortisation and impairment losses			
At 1 January 2024	221	5,125	5,346
Amortisation	18	159	177
At 31 December 2024	**239**	**5,284**	**5,523**
At 1 January 2025	239	5,284	5,523
Amortisation	17	165	182
At 31 December 2025	**256**	**5,449**	**5,705**
Carrying amount			
At 1 January 2024	18	474	492
At 31 December 2024	43	677	720
At 31 December 2025	**98**	**568**	**666**

Amortisation & Impairment losses
Amortisation expense of €182k (2024: €177k) has been charged in product development and delivery expenses in the Consolidated statement of comprehensive income.

For personal use only

For personal use only

10. Property, plant and equipment

	Fixtures fittings and equipment €'000	Land and Buildings* €'000	Total €'000
Cost			
At 1 January 2024	1,667	2,395	4,062
Additions during the year	55	394	449
Foreign exchange translation differences	8	9	17
At 31 December 2024	**1,730**	**2,798**	**4,528**
At 1 January 2025	1,730	2,798	4,528
Additions during the year	58	255	313
Foreign exchange translation differences	(8)	(39)	(47)
At 31 December 2025	**1,780**	**3,014**	**4,794**
Depreciation			
At 1 January 2024	1,454	1,571	3,025
Charge for the year	100	266	366
Foreign exchange translation differences	1	4	5
At 31 December 2024	**1,555**	**1,841**	**3,396**
At 1 January 2025	1,555	1,841	3,396
Charge for the year	78	255	333
Foreign exchange translation differences	-	3	3
At 31 December 2025	**1,633**	**2,099**	**3,732**
Net book value			
At 1 January 2024	213	824	1,037
At 31 December 2024	175	957	1,132
At 31 December 2025	**147**	**915**	**1,062**

*Land and Buildings is comprised of Right of Use assets, held under leases. See note 21.

Notes to the Consolidated and Company Financial Statements (continued)

11. Financial assets - Company

	2025 €'000	2024 €'000
Investment in Group companies – including share based payments:		
At start of year	**13,859**	12,202
Share based payments charge relating to subsidiary entity employees	**2,082**	1,657
At end of year	**15,941**	13,859

Share based payments relating to subsidiary entity employees represent capital contributions made to certain subsidiary undertakings to reflect the amounts expensed by these subsidiary undertakings for share based payment expenses.

The Company's subsidiary companies are listed in Note 27.

12. Inventories

	Group		Company	
	2025 €'000	2024 €'000	2025 €'000	2024 €'000
Finished goods	**2,864**	3,147	**-**	-
	2,864	3,147	**-**	-

The carrying value of inventories are not higher than their realisable value. The cost of inventories charged to cost of sales through profit or loss during the year was €2,434k (2024: €1,378k).

For personal use only

13. Trade and other receivables

	Group		Company	
	2025	2024	2025	2024
	€'000	€'000	€'000	€'000
Amounts falling due within one year:				
Trade receivables	**3,398**	3,305	**-**	-
Prepaid expenses and other current assets	**678**	1,542	**195**	299
Research and development tax credit	**594**	444	**-**	-
Amounts due from group companies[1]	**-**	-	**38,958**	31,034
Loan to group companies[2]	**-**	-	**21,108**	23,097
Amount due from Oneview Limited[3]	**-**	-	**500**	500
VAT recoverable	**1**	-	**-**	-
	4,671	5,291	**60,761**	54,930
Amounts falling due after more than one year:				
Research and development tax credit[4]	**1,014**	893	**-**	-
	5,685	6,184	**60,761**	54,930

1. Amounts due from group companies are interest free and repayable on demand.
2. The loan to the Oneview Healthcare INC bears interest at the US risk free rate plus a margin. This loan is repayable in 2026.
3. Enterprise Ireland acquired convertible shares in Oneview Ltd in 2009 and 2011. These shares had a right to an interest coupon and other conversion features. On 19 December 2013, Oneview Healthcare plc, acquired these shares from Enterprise Ireland. On the same date, Oneview Healthcare plc waived all rights to interest and convertible features. These shares are redeemable. This loan is payable on demand and is not incurring any interest.
4. €444,440 was received in January 2025 from the Irish Revenue Commissioners for prior year R&D Tax Credits.

The fair value of trade receivables approximates to the values shown above. The maximum exposure to credit risk at the reporting date is the carrying value of each class of receivable mentioned above.

For personal use only

Notes to the Consolidated and Company Financial Statements (continued)

13. Trade and other receivables (continued)

Company only – Amounts due from Group Companies

	Total
	€'000
Cost	
At 1 January 2024	**96,697**
Advances to subsidiary undertakings and other movements	**9,348**
At 31 December 2024	**106,045**
At 1 January 2025	**106,045**
Advances to subsidiary undertakings and other movements	**7,924**
At 31 December 2025	**113,969**
Provision for impairment	
At 1 January 2024	**75,011**
Increase in provision	**-**
At 31 December 2024	**75,011**
At 1 January 2025	**75,011**
Increase in provision	**-**
At 31 December 2025	**75,011**
Carrying amount	
At 1 January 2024	21,686
At 31 December 2024	31,034
At 31 December 2025	**38,958**

Provision for impairment
Exposures are segmented by credit risk. An ECL rate is calculated for each risk grade based on the likely ability of the subsidiary undertaking to repay the advance. As there was an indicator of a significant increase in credit risk as a result of negative cash flows and net liabilities in certain subsidiary undertakings in previous years, the Company has provided for impairment losses. The carrying value of the receivables net of impairment reflects management's estimate of the net present value of future cashflows.

The Company assessed the recoverability of the balances due from its subsidiary undertakings at 31 December 2025 and determined that no impairment charge was required (2024: €Nil).

For personal use only

For personal use only

13. Trade and other receivables (continued)

The Group does not hold collateral as security. The aging analysis of past due trade receivables is set out below:

	Less than 30 days	Between 31-60 days	More than 60 days	Credit Impaired	Total
	€'000	€'000	€'000	€'000	€'000
As at December 2025	**2,976**	**300**	**122**	**-**	**3,398**
As at December 2024	2,103	760	442	-	3,305

The Group's clients are primarily state controlled public hospitals in their relevant jurisdictions and have strong credit ratings. Accordingly, any expected credit loss is not material. As at 31 December 2025, a significant portion of the trade receivables related to a limited number of clients as follows: Client A 42% (2024: 46%), Client B 21% (2024: 14%) and Client C 7% (2024: 9%).

The carrying amount of the Group's trade receivables is denominated in the following currencies:

	2025	2024
	€'000	€'000
US Dollar	**3,270**	3,036
Australian Dollar	**56**	94
Euro	**72**	163
Thai Baht	**-**	12
	3,398	3,305

14. Trade and other payables (current)

	Group		Company	
	2025	2024	2025	2024
	€'000	€'000	€'000	€'000
Trade payables	**1,236**	1,319	**122**	227
Payroll related taxes	**415**	685	**71**	77
Superannuation	**59**	69	**-**	-
Other payables and accruals	**2,023**	2,424	**191**	195
VAT payable	**90**	128	**-**	-
Deferred income	**5,436**	4,998	**-**	-
R&D tax credit – deferred grant income	**297**	244	**-**	-
Amounts due to group companies	**-**	-	**1,235**	1,711
	9,556	9,867	**1,619**	2,210

Notes to the Consolidated and Company Financial Statements (continued)

15. Trade and other payables (non-current)

	Group		Company	
	2025	2024	2025	2024
	€'000	€'000	€'000	€'000
Other payables and accruals	**108**	182	**-**	-
Payroll related taxes	**1,040**	1,486	**167**	237
	1,148	1,668	**167**	237

Included within payroll related taxes due at 31 December 2025 is €1,449k (2024: €1,932k) relating to the Irish Revenue Commissioners Debt Warehousing scheme for the period May 2020 to December 2021. An initial 10% "down payment" of €247k was made in April 2024. The remaining balance is being repaid in 60 equal instalments over a 5-year period with a 0% interest rate. €409k (2024: €445k) of the outstanding balance is due within 1 year and presented as a current liability, with the balance of €1,040k (2024: €1,486k) due after more than 1 year and presented as a non-current liability.

16. Deferred income (non-current)

	Group		Company	
	2025	2024	2025	2024
	€'000	€'000	€'000	€'000
Deferred income	**-**	20	**-**	-

17. Lease liabilities

	Group		Company	
	2025	2024	2025	2024
	€'000	€'000	€'000	€'000
Current	**229**	253	**-**	-
Non-current	**880**	898	**-**	-
	1,109	1,151	**-**	-

For personal use only

For personal use only

18. Share-based payments

At 31 December 2025, the Group had the following share based payment arrangements:

(a) Employee Share Option Scheme ("ESOP")

In July 2013, the Group established a share option program that entitles certain employees to purchase shares in the Company. Options vest over a service period and are settled in shares. The key terms and conditions related to grants under this programme are as follows:

Options granted on or after October 2016 have a vesting period of 25% in after one year and 6.25% per quarter thereafter. The ESOP expired in October 2023, so no further grants of options were made after this date. The fair value of services received in return for share options granted is based on the fair value of share options granted, measured using the Black-Scholes model.

	Number of options 2025	Weighted average exercise price 2025	Number of options 2024	Weighted average exercise price 2024
Outstanding at 1 January	**1,091,150**	**€0.142**	1,203,500	€0.091
Forfeited during the year	**(267,900)**	**€0.142**	(112,350)	€0.140
Exercised during the year	**(50,000)**	**€0.001**	-	-
Granted during the year	**-**	**-**	-	-
Outstanding at 31 December	**773,250**	**€0.148**	1,091,150	€0.142
Exercisable at 31 December	**773,250**	**€0.148**	1,091,150	€0.142

The options outstanding at 31 December 2025 had an exercise price in the range of €0.001 to €0.17 (2024: €0.001 to €0.17).

(b) Restricted Stock Share Unit Plan (RSU)

On 2 July 2019, the Company adopted a new Restricted Share Unit Plan ("RSU") to replace the existing Restricted Stock Share Plan ("RSP"). The scheme was subsequently approved by shareholders at the Company's Annual General Meeting on 1 August 2019.

Pursuant to the scheme, the Remuneration and Nominations Committee of the Company's board of directors may make an award under the plan to certain directors, non-executive directors, consultants, senior executives and employees. The purpose of the Plan is to attract, retain, and motivate directors and employees of Oneview Healthcare plc, its subsidiaries and affiliates, to provide for competitive compensation opportunities, to encourage long term service, to recognize individual contributions and reward achievement of performance goals, and to promote the creation of long term value for shareholders by aligning the interests of such persons with those of shareholders.

The RSUs are contracts to issue shares at future vesting periods ranging between 1 year and 3 years, at an award price of €0.001, and are dependent on achievement of performance conditions which are set periodically by the Remuneration and Nominations Committee. All awards to executive directors and non-executive directors are subject to shareholder approval annually at the Annual General Meeting.

	Number of instruments	
	2025	2024
Balance at start of year	**30,917,379**	34,521,145
Granted	**21,773,103**	25,256,334
Vested	**(8,760,831)**	(9,626,861)
Forfeited	**(2,076,237)**	(19,233,239)
Balance at end of year	**41,853,414**	30,917,379

Notes to the Consolidated and Company Financial Statements (continued)

18. Share-based payments (continued)

As at 31 December 2025, 41,853,414 RSU's were outstanding with a vesting term and performance conditions as follows:

Recipients	Number of instruments	Vesting Term	Vesting conditions
Non-Executive Directors	2,722,734	1 - 3 Years	Continued board appointment
Executive Directors/employees	39,130,680	3 Years	Recurring revenue targets/personal milestones/continued employment
	41,853,414		

Operating loss for the year ended 31 December 2025, is stated after charging €2,419k in respect of the Restricted Stock Share Unit plan (2024: €1,959k) for non-cash stock compensation expense. The 2.1 million forfeited RSUs relate to awards held by employees who left employment before vesting or where performance conditions were not achieved.

19. Share capital and other reserves – Group and Company

Authorised Share Capital	2025	2024
Ordinary shares		
No. of shares	**1,000,000**	1,000,000,000
Nominal value	**€0.001**	€0.001
"B" Ordinary shares		
No. of shares	**420,000**	420,000
Nominal value	**€0.01**	€0.01
	€	**€**
Authorised Ordinary Share Capital	**1,000,000**	1,000,000
Authorised "B" Ordinary Share Capital	**4,200**	4,200
Authorised Share Capital	**1,004,200**	1,004,200

For personal use only

19. Share capital and other reserves — Group and Company (continued)

Issued share capital Ordinary Shares	No of ordinary Shares	Par value of units	Share capital	Share premium	Total
			€	€	€
Balance at 1 January 2024	**671,482,227**	**€ 0.001**	**671,482**	**134,082,384**	**134,753,866**
Share issue — 4 Mar 2024	1,422,000	€0.001	1,422	-	1,422
Share issue — 13 Mar 2024	1,308,334	€0.001	1,308	-	1,308
Share issue — 22 Apr 2024	2,154,830	€0.001	2,155	-	2,155
Share issue — 15 May 2024	695,998	€0.001	696	-	696
Share issue — 2 Jul 2024	127,863	€0.001	128	-	128
Share issue — 4 Sept 2024	345,336	€0.001	345	-	345
Share issue — 20 Sept 2024	625,001	€0.001	625	-	625
Share issue — 25 Sept 2024	683,333	€0.001	683	-	683
Share issue — 21 Nov 2024	68,965,518	€0.001	68,967	11,501,107	11,570,074
Share issue — 3 Dec 2024	2,264,166	€0.001	2,264	-	2,264
Share issue — 13 Dec 2024	10,420,194	€0.001	10,420	1,735,422	1,745,842
Balance at 31 December 2024	**760,494,800**	**€ 0.001**	**760,495**	**147,318,913**	**148,079,408**
Share issue - 11 Mar 2025	3,778,728	€0.001	3,779		3,779
Share issue - 16 May 2025	1,232,788	€0.001	1,233		1,233
Share issue - 18 June 2025	421,666	€0.001	422		422
Share issue - 02 Sept 2025	531,000	€0.001	531		531
Share issue - 02 Sept 2025	50,000	€0.001	50		50
Share issue - 01 Oct 2025	905,619	€0.001	905		905
Share issue - 17 Nov 2025	1,891,030	€0.001	1,891		1,891
Share cancellation - 15 Dec 2025	(2,075,740)	€0.001	(2,076)		(2,076)
Balance at 31 December 2025	**767,229,891**	**€ 0.001**	**767,230**	**147,318,913**	**148,086,143**

Oneview's ordinary shares are issued by the Irish parent company, while ASX investors hold corresponding CHESS Depositary Interests ("CDIs"). CDIs are issued by CHESS Depositary Nominees and represent beneficial ownership of the underlying Irish-registered ordinary shares. CDIs mirror the economic and voting rights of the underlying ordinary shares.

8,760,831 ordinary shares (2024: 9,626,861) were issued during the year, in respect of restricted share unit awards which vested during the year and were issued at a price of €0.001 per share. 50,000 ordinary shares (2024: Nil) were issued during the year, in respect of employee share options and were issued at a price of €0.001 per share.

During 2025, 2,075,740 ordinary shares were cancelled. No CDIs were issued in respect of these ordinary shares. The ordinary shares had been issued on 16 March 2016 and held by Goodbody Trustees Ltd as restricted stock units on behalf of certain Directors at that time. The vesting of these restricted stock units were subject to the continued employment of the beneficiaries and certain performance conditions which were not achieved.

For personal use only

Notes to the Consolidated and Company Financial Statements (continued)

19. Share capital and other reserves – Group and Company (continued)

Subsequent to year-end, in March 2026, the Company announced commitments for a two-tranche placement to raise approximately A$19 million approximately (€11.6 million) in gross proceeds through the issuance of 100 million New CDIs at A$0.19 per CDI. Tranche 1 settled on 24 March 2026, raising A$12 million (€7.3 million) through the issuance of 63,157,895 CDIs. Tranche 2, raising A$7 million (€4.3 million) through the issuance of 36,842,105 CDIs and involving the Company's largest shareholder, Manderrah Pty Ltd as trustee of the GJJ Family Trust, is subject to shareholder approval at an extraordinary general meeting expected to take place in May 2026. The Company has also launched a security purchase plan (SPP) to raise up to A$2 million (approximately €1.2 million), which will close in April 2026.

During the prior year the Company successfully conducted a placement ("Placement") and raised A$20 million (equivalent to approximately €12 million), before costs, through the issue of 68,965,518 CDIs over new fully paid ordinary shares, to institutional and sophisticated investors at a price per share of A$0.29. Additionally, A$3 million worth of New CDIs under the security purchase plan (10,420,194 CDIs) were issued at an issue price of A$0.29 per share.

Ordinary shares
The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company. On winding up the holders of ordinary shares shall be entitled to receive the nominal value in respect of each ordinary share held together with any residual value of the entity.

The holders of B ordinary shares are not entitled to receive dividends as declared and are not entitled to vote at meetings of the Company; however, they are entitled to attend all meetings. On winding up the holders of B ordinary shares shall be entitled to receive the nominal value in respect of each B ordinary share held.

Treasury reserve
The reserve for the Company's shares comprises the cost of the Company's shares held by Oneview Healthcare plc. The treasury reserve has been reduced to nil at 31 December 2025 following the cancellation of 2,075,740 ordinary shares held by Goodbody Trustees Ltd.

Undenominated capital
Ordinary shares repurchased by the company are cancelled or held as treasury shares and the nominal value of the shares is transferred to an undenominated capital reserve fund within equity.

Translation reserve
The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.

Reorganisation reserve
During 2012, OHP was incorporated for the purpose of implementing a holding company structure. This resulted in a group re-organisation with OHP becoming the new parent company of Oneview Limited ("OL") by way of share for share swap with the existing shareholders of OL. This has been accounted for as a continuation of the original OL business via the new OHP entity resulting in the creation of a reorganisation reserve in the consolidated financial statements in the amount of €1,347,642, (increased by €4,200, to €1,351,842 in 2013 due to the issue of B shares). No reorganisation reserve was created at OHP company level as the fair value of the net assets of OHP was equal to the carrying value of its net assets on the date of the reorganisation.

For personal use only

For personal use only

20. Capital and other commitments – Group and Company

There are no capital commitments at the current or prior year end.

21. Leases

Leases as lessee (IFRS 16)
The Group leases offices. The leases typically run for a period of 2-7 years, with an option to renew certain leases after that date.

The Group also leases offices on a short term basis for a period of no longer than 12 months. These leases are short term and, as permitted by IFRS 16, the group has elected not to recognise right-of-use assets and lease liabilities for these leases.

Information about leases for which the Group is a lessee is presented below.

(i) Right-of-use assets
Right-of-use assets related to leased properties that do not meet the definition of investment property are presented as property, plant and equipment.

Land and Buildings	2025 €'000	2024 €'000
At start of year	**957**	824
Additions to right-of-use assets	**255**	394
Modification of right-of-use assets	**-**	-
Depreciation of right-of-use assets	**(255)**	(266)
Foreign currency translation differences	**(42)**	5
At end of year	**915**	957

Additions to right of use assets in 2025 is comprised of a lease to 1 office premise. Additions to right of use assets in the prior year are comprised of leases to 1 office premises.

(ii) Amounts recognised in profit or loss:

Leases under IFRS 16	2025 €'000	2024 €'000
Interest on lease liabilities	**112**	130
Expenses relating to short term leases	**56**	4

(iii) Amounts recognised in Consolidated Statement of Cashflows
Right-of-use assets related to leased properties that do not meet the definition of investment property are presented as property, plant and equipment.

Leases under IFRS 16	2025 €'000	2024 €'000
Lease interest payments	**112**	130
Lease liability payments	**296**	179
Total cash outflows for leases	**408**	309

Notes to the Consolidated and Company Financial Statements
(continued)

22. Reconciliation of net cash used in operating activities

Consolidated	2025 €'000	2024 €'000
Loss for the year after income tax	**(12,588)**	(10,836)
Non-cash items		
Depreciation	**333**	371
Amortisation of software and development costs	**182**	177
Research and development credit, net	**(662)**	692
Taxation	**53**	64
Net finance costs	**109**	19
Share based payment expense	**2,419**	1,959
Foreign exchange (gain)/loss	**1,409**	(605)
Changes in assets and liabilities		
Increase in inventories	**283**	(906)
Increase in trade and other receivables	**770**	(600)
(Increase) in contract assets	**339**	(512)
Increase in deferred income	**418**	156
(Decrease)/increase in trade and other payables	**(1,894)**	(334)
Cash used in operating activities	**(8,829)**	(10,355)
Finance charges paid	**(25)**	(150)
Interest received	**28**	132
Research and development tax credit received	**444**	-
Government Grant	**37**	-
Income tax paid	**(22)**	(92)
Net cash used in operating activities	**(8,367)**	(10,465)

For personal use only

22. Reconciliation of net cash used in operating activities (continued)

Reconciliation of movement of liabilities to cash flows arising from financing activities

	Total €'000
At 1 January 2024	**935**
Additions to lease liabilities	**394**
Repayment of lease liabilities	**(179)**
At 1 January 2025	**1,150**
Additions to lease liabilities	**255**
Repayment of lease liabilities	**(296)**
At 31 December 2025	**1,109**

23. Financial instruments

In terms of financial risks, the Group has exposure to credit risk, liquidity risk and foreign currency risk. This note presents information about the Group's exposure to each of the above risks together with the Group's objectives, policies and processes for measuring and managing those risks.

The board of directors has overall responsibility for the establishment and oversight of the Group's risk management framework. The Group's risk management policies are established to identify and analyse the risks faced by the Group, to set appropriate risk limits and controls and to monitor risks and adherence to the limits. Risk management systems and policies are reviewed regularly as the Group expands its activities and resource base to take account of changing conditions.

Credit risk

The Group's and Company's exposure to significant credit risk relates to cash on deposit and trade receivables (note 13). The Group and Company maintained its cash balances with its principal financial institution throughout the periods covered by this financial information.

The Group held cash and cash equivalents of €4.6 million at 31 December 2025 (2024: €13.8 million). The Company held cash and cash equivalents of €312k at 31 December 2025 (2024: €11.7 million). The cash and cash equivalents are held with bank and financial institution counterparties, which are AA- based on Moody's rating agency ratings.

Expected credit loss assessment for clients

The Group and Company allocate each exposure to a credit risk grade based on data that is determined to be predictive of the risk of loss (including but not limited to external ratings, audited financial statements, management accounts and cash flow projections and available press information about clients) and applying experienced credit judgment. Credit risk grades are defined using qualitative and quantitative factors that are indicative of the risk of default and are aligned to external credit rating definitions from credit rating agencies.

Exposures within each credit risk grade are segmented by geographic region and industry classification and an ECL rate is calculated for each segment based on delinquency status and actual credit loss experience over the past seven years.

The Group's clients are primarily state controlled public hospitals in their relevant jurisdictions and have strong credit ratings. Accordingly, any expected credit loss is not material.

For personal use only

Notes to the Consolidated and Company Financial Statements (continued)

23. Financial instruments (continued)

Liquidity risk

The principal operating cash requirements of the Group include payment of salaries, suppliers, office rents and travel expenditures. The Group primarily finances its operations and growth through the issuance of ordinary shares and receipts from clients.

The Group's primary objectives in managing its liquid and capital resources are as follows:

- to maintain adequate resources to fund its continued operations;
- to ensure availability of sufficient resources to sustain future development and growth of the business;
- to maintain sufficient resources to mitigate risks and unforeseen events which may arise.

The Group manages risks associated with liquid and capital resources through ongoing monitoring of actual and forecast cash balances and by reviewing the existing and future cash requirements of the business. The following table sets out details of the maturity of the Group's financial liabilities into the relevant maturity groupings based on the remaining period from the financial year end date to contractual maturity date:

Group

Year ended 31 December 2025

	Carrying amount	Contractual cashflows	6 months or less	6-12 months	1-2 years	2-5 Years	More than 5 years
	€'000	€'000	€'000	€'000	€'000	€'000	€'000
Trade and other payables	**(3,365)**	**(3,365)**	**(3,227)**	**(31)**	**(56)**	**(51)**	**-**
Lease liabilities	**(1,109)**	**(1,487)**	**(175)**	**(171)**	**(300)**	**(617)**	**(224)**
Payroll related taxes	**(1,455)**	**(1,455)**	**(192)**	**(223)**	**(446)**	**(594)**	**-**

Year ended 31 December 2024

	Carrying amount	Contractual cashflows	6 months or less	6-12 months	1-2 years	2-5 Years	More than 5 years
	€'000	€'000	€'000	€'000	€'000	€'000	€'000
Trade and other payables	(3,924)	(3,924)	(3,720)	(34)	(62)	(108)	-
Lease liabilities	(1,150)	(1,542)	(186)	(173)	(291)	(561)	(331)
Payroll related taxes	(2,171)	(2,171)	(462)	(223)	(446)	(1,040)	-

Company

Year ended 31 December 2025

	Carrying amount	Contractual cashflows	6 months or less	6-12 months	1-2 years	2-5 Years	More than 5 years
	€'000	€'000	€'000	€'000	€'000	€'000	€'000
Trade and other payables	**(313)**	**(313)**	**(313)**	**-**	**-**	**-**	**-**
Payroll related taxes	**(238)**	**(238)**	**(37)**	**(36)**	**(71)**	**(94)**	**-**

For personal use only

23. Financial instruments (continued)

Year ended 31 December 2024

	Carrying amount	Contractual cashflows	6 months or less	6-12 months	1-2 years	2-5 Years	More than 5 years
	€'000	€'000	€'000	€'000	€'000	€'000	€'000
Trade and other payables	(422)	(422)	(422)	-	-	-	-
Payroll related taxes	(314)	(314)	(42)	(36)	(71)	(165)	-

Currency risk

Group

Exposure to currency risk

The table below shows the Group's currency exposure. The Group is exposed to currency risk to the extent that there is a mismatch between the currencies in which sales and purchases are denominated and the respective functional currencies of Group companies. The functional currencies of Group companies are primarily euro, US dollars and Australian dollars.

The following table sets out the Group's currency risk in relation to financial assets and liabilities at 31 December 2025. Euro balances are excluded from the below table:

	U.S. Dollar 2025	Australian Dollar 2025	AED 2025	Thai Baht 2025	GBP 2025
	€'000	€'000	€'000	€'000	€'000
Cash and cash equivalents	**1,453**	**1,689**	**15**	**280**	**6**
Trade receivables	**3,270**	**56**	**-**	**-**	**-**
Trade and other payables	**(393)**	**(38)**	**(11)**	**(22)**	**(63)**
Total currency risk	**4,330**	**1,707**	**4**	**258**	**(57)**

Foreign exchange gains and losses recognised on the above balances are recorded in "finance (charges)/income". The total foreign exchange loss reported during the year ending 31 December 2025 amounted to €1,409k (2024: gain of €605k).

The following table sets out the Group's currency risk in relation to financial assets and liabilities at 31 December 2024. Euro balances are excluded from the below table:

	U.S. Dollar 2024	Australian Dollar 2024	AED 2024	Thai Baht 2024	GBP 2024
	€'000	€'000	€'000	€'000	€'000
Cash and cash equivalents	457	11,054	41	266	64
Trade receivables	3,036	93	-	12	-
Trade and other payables	(490)	(3)	-	(7)	(110)
Total currency risk	**3,003**	**11,144**	**41**	**271**	**(46)**

For personal use only

Notes to the Consolidated and Company Financial Statements (continued)

23. Financial instruments (continued)

Company

The following table sets out the Company's transaction risk in relation to financial assets and liabilities at 31 December 2025. Euro balances are excluded from the below table:

	U.S. Dollar 2025 €'000	Australian Dollar 2025 €'000	Pound Sterling 2025 €'000
Cash and cash equivalents	**57**	**207**	**-**
Loan to Group company	**21,108**	**-**	**-**
Trade and other payables	**-**	**(19)**	**(62)**
Total currency risk	**21,165**	**188**	**(62)**

The following table sets out the Company's currency risk in relation to financial assets and liabilities at 31 December 2024. Euro balances are excluded from the below table:

	U.S. Dollar 2024 €'000	Australian Dollar 2024 €'000	Pound Sterling 2024 €'000
Cash and cash equivalents	31	10,423	3
Loan to Group company	23,097	-	-
Trade and other payables	-	(72)	(110)
Total currency risk	**23,128**	**10,351**	**(107)**

The following significant exchange rates applied during the year:

	Average Rate		Closing Rate	
	2025	2024	2025	2024
euro 1: US$	**1.12004**	1.08628	**1.17500**	1.03890
euro 1: A$	**1.74755**	1.63954	**1.75810**	1.67720
euro 1: THB	**37.00617**	38.24825	**37.21800**	35.67600
euro 1: AED	**4.12096**	3.98526	**4.31943**	3.82517

Foreign currency sensitivity analysis

A 10% weakening of the euro against the above currencies at year end would decrease the Group's reported loss for the year and increase the Group's reported equity by approximately €163k (2024: €272k).

A 10% appreciation of the euro against the above currencies at year end would increase the Group's reported loss for the year and decrease the Group's reported equity by approximately €133k (2024: €223k).

For personal use only

For personal use only

23. Financial instruments (continued)

Fair values of financial assets and liabilities

Group

The fair values of financial assets and liabilities by class and category, together with their carrying amounts shown in the statement of financial position, are as follows:

	31 December 2025		31 December 2024	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
	€'000	€'000	€'000	€'000
Financial assets – amortised cost				
Cash and cash equivalents	**4,602**	**4,602**	13,833	13,833
Trade and other receivables	**3,398**	**3,398**	3,305	3,305
	8,000	**8,000**	17,138	17,138
Financial liabilities				
Trade and other payables	**(3,365)**	**(3,365)**	(3,924)	(3,924)
Payroll related taxes	**(1,455)**	**(1,388)**	(2,171)	(2,055)
	(4,820)	**(4,753)**	(6,095)	(5,979)

For cash and cash equivalents, the nominal amount is deemed to reflect fair value. For receivables and payables, the carrying value is deemed to reflect fair value, where appropriate.

Company

	31 December 2025		31 December 2024	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
	€'000	€'000	€'000	€'000
Financial assets – amortised cost				
Cash and cash equivalents	**312**	**312**	11,692	11,692
Loan to Group company	**21,108**	**21,108**	23,097	23,097
	21,420	**21,420**	34,789	34,789

	31 December 2025		31 December 2024	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
	€'000	€'000	€'000	€'000
Financial liabilities				
Trade and other payables	**(313)**	**(313)**	(422)	(422)
Payroll related taxes	**(238)**	**(226)**	(314)	(294)
	(551)	**(539)**	(736)	(716)

For cash, cash equivalents and payables, the carrying value is deemed to reflect fair value, where appropriate. For amounts due from/due to subsidiaries, the carrying value is deemed to be fair value as the amounts are repayable on demand. For amounts due from Oneview Limited the carrying value is deemed to be fair value as the loans are repayable on demand at year end, or shortly thereafter. The loan to Group company has a maturity date of December 2026, however, as the loan was issued in December 2016 and rolled over in 2018, 2021 and 2025, the fair value has been deemed to be the same as the carrying amount.

Notes to the Consolidated and Company Financial Statements
(continued)

24. Related party transactions

The Company considers directors, the COO, the CPO and group undertakings as set out in note 11 as being related parties. Transactions with directors are disclosed in the table below. The current directors are as set out on page 32. The directors held the following interests at:

Name	Name of company	Interest at 31 December 2025* Number of instruments	Interest at 31 December 2024* Number of instruments
Joe Rooney	Oneview Healthcare PLC		
	Ordinary shares €0.001	**4,187,605**	3,849,126
	Restricted Stock Units	**245,901**	705,208
Nashina Asaria	Oneview Healthcare PLC		
	Ordinary shares €0.001	**762,359**	577,984
	Restricted Stock Units	**163,934**	364,583
Mark Cullen	Oneview Healthcare PLC		
	Ordinary shares €0.001**	**11,860,723**	11,587,286
	Restricted Stock Units	**1,115,466**	1,416,440
James Fitter	Oneview Healthcare PLC		
	Ordinary shares €0.001	**16,533,090**	14,933,090
	Restricted Stock Units	**13,000,000**	14,600,000
Barbara Nelson	Oneview Healthcare PLC		
	Ordinary shares €0.001	**510,775**	248,275
	Restricted Stock Units	**1,197,433**	1,390,398
Darragh Lyons	Oneview Healthcare PLC		
	Ordinary shares €0.001	**1,006,104**	788,604
	Restricted Stock Units	**6,600,000**	3,900,000
John Paul Howe	Oneview Healthcare PLC		
	Ordinary shares €0.001	**267,200**	641,943
	Restricted Stock Units	**1,733,214**	180,000
Niall O'Neill	Oneview Healthcare PLC		
	Ordinary shares €0.001	**1,054,404**	905,204
	Restricted Stock Units	**1,733,214**	280,000

** beneficiary of a trust which holds these securities
* or date of appointment/resignation

For personal use only

24. Related party transactions (continued)

The interests of directors include the interests held by the parents or children of directors in accordance with the requirements of the Australian Corporations Act ("ASX"). The table below reconciles those interests back to the Irish Companies Act requirement disclosure:

	31 December 2025		31 December 2024	
	ASX	Irish	ASX	Irish
James Fitter	**29,573,541**	**29,533,090**	29,573,541	29,533,090

In accordance with the Articles of Association at least one third of the directors are required to retire annually by rotation. Babara Nelson and Mark Cullen retired by rotation and were re-elected at the Company's Annual General Meeting on 1st December 2025.

No other members of management, other than those mentioned above, are considered key. Unless otherwise stated all transactions between related parties are carried out on an arm's length basis.

The Company has availed of the exemption available in IAS 24 Related Party Disclosures from the requirement to disclose details of transactions with related party undertakings where those parties are 100 per cent members of the Group.

25. Auditor's remuneration

	Year ended 31 December 2025			Year ended 31 December 2024		
	Group Auditor	Affiliated Firms	Total	Group Auditor	Affiliated Firms	Total
	€'000	€'000	€'000	€'000	€'000	€'000
Audit fees	**130**	**18**	**148**	120	17	137
Tax fees	**105**	**59**	**164**	20	55	75
Other non – audit assurance services	**5**	**-**	**5**	5	-	5
	240	**77**	**317**	145	72	217

Audit fees for the Company for the year are included in the amount above and are set at €10k (2024: €10k).

26. Subsequent events

Subsequent to year-end, in March 2026, the Company announced commitments for a two-tranche placement to raise approximately A$19 million approximately (€11.6 million) in gross proceeds through the issuance of 100 million New CDIs at A$0.19 per CDI. Tranche 1 settled on 24 March 2026, raising A$12 million (€7.3 million) through the issuance of 63,157,895 CDIs. Tranche 2, raising A$7 million (€4.3 million) through the issuance of 36,842,105 CDIs and involving the Company's largest shareholder, Manderrah Pty Ltd as trustee of the GJJ Family Trust, is subject to shareholder approval at an extraordinary general meeting expected to take place in May 2026. The Company has also launched a security purchase plan (SPP) to raise up to A$2 million (approximately €1.2 million), which will close in April 2026.

For personal use only

Notes to the Consolidated and Company Financial Statements (continued)

27. Subsidiaries of the Company

As at 31 December 2025, the Company had the following subsidiary undertakings:

Name	Registered office	Nature of business	Proportion held by group 2025	2024
Oneview Limited	Avoca Court, Temple Road Blackrock, Dublin	Software development, distribution and implementation	**100%**	100%
Oneview KSA Limited	Avoca Court, Temple Road Blackrock, Dublin	Dormant	**100%**	100%
Oneview Healthcare Inc	444 North Michigan Ave Suite 3310 Chicago IL 60611 USA	Software distribution and implementation	**100%**	100%
Oneview Assisted Living Inc	444 North Michigan Ave Suite 3310 Chicago IL 60611 USA	Software distribution and implementation	**100%**	100%
Oneview Middle East DMCC	Unit No: AG-PF-38 AG Tower Plot No: JLT-PH1-I1A Jumeirah Lakes Towers	Software distribution and implementation	**100%**	100%
Oneview Healthcare PTY Limited	Level 7 176 Wellington Parade East Melbourne VIC 3002	Software distribution and implementation	**100%**	100%
Oneview Assisted Living PTY Limited	Level 7 176 Wellington Parade East Melbourne VIC 3002	Software distribution and implementation	**100%**	100%
Oneview Healthcare Company Limited	Empire Tower, 47th Floor 1 South Sathorn Road Bangkok 10120, Thailand	Software distribution and implementation	**100%**	100%

28. Approval of financial statements

The financial statements were approved by the Board on 25 March 2026.

For personal use only

Additional ASX Information

Shareholder Information

The information set out below was current as at 25 March 2026. This date is after securities were issued pursuant to the tranche 1 placement announced by the Company on 16 March 2026, and accordingly the information includes those securities. This information does not include any proposed securities to be issued by the Company pursuant to the tranche 2 placement or the security purchase plan that were also announced by the Company on 16 March 2026. As of 25 March 2026, the issued share capital of Oneview Healthcare PLC consists of 830,387,786 ordinary shares of €0.001 each held by 2,643 security holders. These shares are held by CHESS Depositary Nominees Pty Ltd (CDN), quoted on the ASX in the form of CHESS Depositary Interests (CDIs) and held by 2,643 CDI holders. The top 20 security holders held 679,676,764 CDIs comprising ~82% of the issued capital. The Company's ASX issuer code is ONE.

At a general meeting of the Company, every holder of CDIs is entitled to vote in person or by proxy or attorney, or in the case of a body corporate, its duly authorised representative, and on a poll every person present in person or by proxy or attorney or duly authorise representative has one vote for each CDI held by that person, except that in the case of partly paid CDIs the voting rights a CDI holder are pro rata to the proportion of the total issued price paid up (not credited) on the CDIs.

Distribution of CDI holdings

Range	No of holders	No of CDI's	% of issued capital
1 - 1,000	169	44,107	0.01
1,001 – 5,000	1,006	2,735,630	0.33
5,001 – 10,000	429	3,370,155	0.41
10,001 – 100,000	823	26,708,021	3.22
100,001 and above	216	797,529,873	96.03
Total	**2,643**	**830,387,786**	**100.00**

There were 633 shareholders, with a total of 825,149 shares, holding less than a marketable parcel under the ASX listing rules. The ASX listing rules define a marketable parcel of shares as "a parcel of not less than A$500".

For personal use only

Additional ASX Information
(continued)

Twenty largest holders of CDI securities

Rank	Holder	No of CDI's	% of issued capital
1	Citicorp Nominees Pty Limited	238,160,687	28.68
2	Bell Potter Nominees Ltd <Bb Nominees A/C>	80,014,007	9.64
3	Hsbc Custody Nominees (Australia) Limited	78,097,916	9.40
4	Hsbc Custody Nominees (Australia) Limited-Gsi Eda	42,516,744	5.12
5	Manderrah Pty Limited	34,436,435	4.15
6	Manderrah Pty Ltd Atf <The Gjj Famility Trust>	31,963,565	3.85
7	Cjh Holdings Pty Limited <Cjh Family A/C>	27,174,971	3.27
8	BNP Paribas Noms Pty Ltd	25,246,744	3.04
9	Warbont Nominees Pty Ltd <Settlement Entrepot A/C>	21,052,632	2.54
10	Mr James Nicholas Fitter	16,533,090	1.99
11	HSBC Custody Nominees (Australia) Limited - A/C 2	16,491,259	1.99
12	Longbridge Nominees Pty Limited <Longbridge A/C>	13,335,603	1.61
13	UBS Nominees Pty Ltd	10,051,652	1.21
14	BNP Paribas Noms Pty Ltd <Global Markets>	9,523,113	1.15
15	Top 4 Pty Ltd <The Foundation Inv S/F A/C>	7,386,207	0.89
16	Netwealth Investments Limited <Wrap Services A/C>	6,889,190	0.83
17	Barana Capital Pty Limited <Shand Family A/C>	6,802,956	0.82
18	Aja Investments Pty Ltd <The Oliver Amelia Prop A/C>	5,632,107	0.68
19	Ov No.1 Pty Ltd <The Ov A/C>	4,210,798	0.51
20	William Lempriere	4,157,088	0.50
	Top 20 holders of CDIs	**679,676,764**	**81.85**
	Total remaining holders	**150,711,022**	**18.15**
	Total CDIs on issue	**830,387,786**	**100.0%**

Excludes disclosure of the interests held by parents and children of directors in accordance with the requirements of the Australian Corporations Act. Refer to Note 24 of the Financial Statements

For personal use only

Substantial shareholders

The following table shows the substantial shareholders (within the meaning of the Corporations Act) who, together with their associates, hold 5% or more of the voting rights in the Company, as notified to the Company as at 25 March 2026. A person has a substantial holding if the total votes they or their associates have relevant interests in is 5% or more of the total number of votes.

Range	No of CDI's	% of issued capital	Last date of ASX notification
James William Vicars	312,210,110	40.69%	16th Jan 2026
FIL Investment Management (Hong Kong) Limited/FIL Investments International	62,642,075	8.4%	24th Nov 2024
Christopher White	38,152,973	5.01%	16th Apr 2025

On-market buyback

The Company is not currently conducting an on-market buyback.

Securities purchase on-market

No securities were purchased on-market in the period from 1 January 2024 under or for the purpose of an employee incentive scheme or to satisfy the entitlements of holders of options or other rights to acquire securities granted under an employee incentive scheme.

Shareholder information

The name of the Company Secretary is Toni Pettit. The address of the registered office is in Ireland at 2nd Floor, Avoca Court, Temple Road, Blackrock, Co Dublin, Ireland. Our principal business address in Australia is Level 7, 176 Wellington Parade, East Melbourne, VIC 3002, Australia. The Company is listed on the Australian Securities Exchange. Registers of securities are held by Computershare Investor Services Pty Ltd, Level 4, 60 Carrington Street, Sydney, NSW 2000, Australia. Their local call number is 1300 850 505 with international call number being +61 3 9415 4000.

For personal use only

Corporate Information

Directors
Barbara Nelson (Chair)
Darragh Lyons (CFO)
James Fitter (CEO)
Joe Rooney
Mark Cullen
Michael Dowling
Nashina Asaria

Company Secretary
Toni Pettit

Irish Company Registration Number
513842

Australian Registered Body Number (ARBN)
610 611 768

Registered Offices
2nd Floor
Avoca Court, Temple Road
Blackrock
Co. Dublin
A94 R7W3 Ireland

Level 7
176 Wellington Parade
East Melbourne
VIC 3002
Australia

Website
http://www.oneviewhealthcare.com

Share Identifiers
Ticker: ONE
ISIN: AU000000ONE9

Share Registrar
Computershare Investor Services Pty Limited
6 Hope Street
Ermington, NSW, Australia, 2115
+61 02 8877 3000

Legal Advisors
A&L Goodbody
3 Dublin Landings
N Wall Quay
International Financial Services Centre
Dublin 1, D01 C4E0, Ireland

Herbert Smith Freehills Kramer
ANZ Tower, 161 Castlereagh Street
Sydney
NSW 2000

Auditor
KPMG
1 Stokes Place
St Stephen's Green
Dublin 2 Ireland

For personal use only

For personal use only

sourcedesign.ie

For personal use only

United States
Chicago
+1 312 763 6800

Ireland
Dublin
+353 1 524 1677

Australia
Melbourne
+61 3 9114 2210

Thailand
Bangkok
+353 1 524 1677

Middle East
Dubai
+971 58 568 7680